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Ephesians 3: 20 - 21 
, , , Now to Him who is able to do immeasurably more than all we ask 
or imagine, according to His power that is at work within us, to 
Him be glory in the church and in Christ Jesus throughout all 
generations, for ever and ever! Amen,,, 
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Abstract 
Introduction: Two hypotheses with regard to calcium oxalate (CaOx) renal stone formation 
were tested in this thesis. 
The first hypothesis is that fatty acid (FA) supplementation (n-6 and n-3) and chondroitin 
sulphate (CS) supplementation may reduce the plasma (FA) and urinary (FA and CS) risk 
factors for CaOx renal stone formation , and ultimately serve as therapeutic agents in the 
management of this disease. The notion that FAs may reduce plasma risk factors is based on 
previous studies which have shown that n-6 and n-3 FA supplementation reduces the 
concentrations of arachidonic acid, while the notion of an effect on urinary risk factors is based 
on reports of these supplements decreasing urinary calcium and/or oxalate excretion in animal 
and human studies. The notion of CS playing a role in reducing CaOx stone risk is based on its 
chemical structure which presents potential binding sites for calcium and magnesium. 
The second hypothesis is that black and white healthy South African subjects may respond 
differently to these dietary supplements and that these differences may provide insights which 
could account for the lower stone incidence in the former group compared to the latter. This 
hypothesis is based on the observation in many previous studies of different renal responses in 
the two race groups, to different dietary and supplemental challenges. FA's and CS have not 
been previously investigated in this regard. 
Methods: These hypotheses were tested simultaneously by administering n-6 and n-3 FA 
supplements individually and in combination, and supplemental CS, to different groups of black 
and white healthy male subjects. For the FA studies, blood samples were analyzed for serum 
biomarkers (25-hydroxyvitamin 03 and triglycerides) for CaOx stone formation and FA profiles 
in plasma total phospholipids since arachidonic acid regulates calcium excretion . Urine samples 
were analyzed for individual CaOx stone risk factors, risk indices (Tiselius risk index and 
supersaturation (SS) of calcium oxalate, brushite and uric acid) ; crystallization experiments 
(metastable limit and crystal growth kinetics) were also conducted . 
For the CS studies, thermodynamic binding constants for calcium-CS and magnesium-CS 
complexes were determined by isothermal titration calorimetry. These constants were then used 
to model speciation in different urines using the computer program Joint Expert Speciation 
System (JESS), and to calculate supersaturation values under different urinary conditions. This 
was followed by in vitro crystallization experiments in which the effects of exogeneous CS on 
the CaOx metastable limit and CaOx crystallization kinetics were investigated in artificial and 
real urine samples. Finally, human studies were performed in which CS supplements were 
administered to subjects to test their efficacy on reducing the urinary risk factors for CaOx stone 
formation . Urines were analyzed and crystallization experiments were performed as described 
for the FA supplementation studies. 
Results: In the FA studies, favourable changes in the plasma CaOx stone risk factors were 
achieved by the supplementation of n-3 FA alone. Post-supplementation , the concentration of 
arachidonic acid in plasma total phospholipids was significantly reduced in both groups, thereby 
implying a reduction in urinary calcium excretion . However, FA supplementation had no positive 
effect on the urinary risk factors or on CaOx metastable limits and CaOx crystallization kinetics. 
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In the CS studies, theoretical modelling showed that the reduction of ionized calcium 
concentrations can only be attainable at 100 times physiological concentrations of urinary CS 
and that the formation of the calcium-CS complex does not influence the urinary supersaturation 
of CaOx. The formation of the magnesium-CS complexes was unfavourable because it resulted 
in an increase in the concentrations of ionized oxalate, a risk factor for CaOx stone formation. 
The in vitro crystallization experiments showed that exogeneous CS at physiological and above 
physiological concentrations had no favourable effect on the metastable limit and crystal growth 
kinetics in all the tested urine samples. Finally, the human study showed that CS 
supplementation had no effect on urine chemistry and crystallization kinetics. Speciation 
calculations also showed that the SS values of CaOx and the concentrations of ionized calcium 
were not significantly changed by supplementation . 
Within groups, the effects of FA supplementation on the urinary risk factors were different. n-6 
FA supplementation significantly increased magnesium and significantly decreased urate in the 
black group whereas in whites citrate, oxalate and potassium were significantly increased while 
ionized calcium was significantly reduced. In the n-3 FA study, magnesium was significantly 
increased and SS value of brushite was significantly decreased in whites . In the black group, 
there was no significant difference in the urinary risk factors after supplementation compared to 
baseline values. With regards to n-6 & n-3 FA supplementation , citrate was significantly 
increased while oxalate and SS CaOx were significantly decreased in the black group whereas 
in the white group, magnesium was significant increased. 
With regards to the CS study, SS values for brushite, tribasic calcium phosphate, 
hydroxylapatite and octacalcium phosphate decreased significantly in black subjects after CS 
supplementation , whereas the SS value for hydroxylapatite increased significantly in the white 
group. These effects could not be attributed to complexation of CS with calcium or magnesium. 
However, they are noteworthy because they are different in the two groups. 
Discussion: The results of these studies do not support the hypothesis that supplemental fatty 
acids or chondroitin sulfate have significant beneficial effects for reducing blood and urinary risk 
factors for calcium oxalate stone formation . Although the response to FA and CS 
supplementation was different between the two race groups, these findings did not provide new 
information to explain the difference in the incidence of calcium oxalate stone disease in the two 
population groups. 
The work described in this thesis provides a foundation for future studies in which CaOx stone 
patients, rather than healthy individuals are investigated. 
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Chapter 1 Introduction 
1.1 COMPOSITION OF KIDNEY STONES 
Kidney stones are described as crystals that have gathered together to form a hard solid within 
the kidney. These stones come in different types and are distinguished by the type of chemical 
components that they contain . Nearly 80 % of all stones are made up of calcium oxalate (CaOx) 
and calcium phosphate (CaP) [1 - 6]. CaOx is the most encountered stone and can occur either 
as the monohydrate [Ca0x·H20 , whewellite] or dihydrate [Ca0x·2H 20 , weddellite) [7 - 10]. 
Whewellite (COM) stones are the most thermodynamically stable CaOx stones and are more 
prevalent than weddellite (COD) [11 - 13]. Apatite [Ca5(P04)30H, basic calcium hydrogen 
phosphate] and brushite [CaHP04 ·2H20 , calcium hydrogen phosphate] are types of calcium 
phosphate (CaP) stones and are formed to a lesser extent than CaOx [14 - 16]. Uric acid (UA) 
stones are responsible for about 10 % of all stones [13, 17 - 19]. Both calcium phosphate and 
uric acid crystals are often found in trace amounts as mixtures with CaOx as the main 
component [20 - 24]. Struvite and cysteine are the least common types of kidney stones [25 -
28] . 
Because there is no known cause for idiopathic CaOx stone formation , they are the most 
frequently studied types of kidney stones, thus the following discussion is focused. 
1.2 EPIDEMIOLOGY OF STONE FORMATION 
As far back as the first century, people have been developing stones. Although bladder stones 
were the most common stones found during those periods, nowadays the occurrence of stones 
formed in the kidney are the most documented [29 - 31]. The risk of developing kidney stones 
appears to be more frequent in males than in females. In adults, the stone risk ratio has been 
reported to be about 3.1 times higher in males compared to females [32 - 35]. Recently, an 
increasing trend in stone incidence among women has been observed , and the ratio has been 
lowered to 1.3: 1, male to female [36, 37]. 
Stone incidence begins to rise after the age of 20 in both adult men and women, and reaches its 
peak during middle age and after that declines. Children have been reported to develop kidney 
stones at any age, from premature to newborn babies and teenagers [38 - 40]. Once an 
individual forms a stone, he/she is likely to develop another one. It has been estimated that 
about 10 to 20 % of untreated individuals will form another stone within 1 to 2 years, whereas 
the recurrence rate increases from 35 % to 60 % within 5 to 10 years, respectively [41 - 43]. 
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Changes in environmental climate have been shown to affect the rate of stone formation in 
various populations. For example, the combination of warm temperatures and inadequate fluid 
intakes is associated with increased incidence of stone formation [44 - 48]. 
The tendency of developing stones varies across the world. The highest prevalence, 20 %, of 
stone formation has been found in men living in the United Arab Emirates and Saudi Arabia. In 
Europe, stone formation accounts for about 2 to 8 % of the population whereas in Greece it is 
estimated to be around 15 %. Approximately 12 % of individuals in the United State are 
predicted to form stone at least once in their lifetime. Meanwhile, Asian males have been found 
to have the lowest risk at 5 % [49 - 53] . 
The prevailing trends in kidney stone disease are highly dependent on the socioeconomic 
conditions of the communities. For example, changes in social and financial status over time, 
and the subsequent changes in dietary habits, have affected the incidence of stone formation. 
Dietary intake influences urinary composition, and can therefore modify the urine components 
associated with stone formation. The most common nutrients implicated in stone formation 
include calcium, animal protein, oxalate, sodium, carbohydrates, magnesium, phosphorus, 
vitamins B, C, D and E, etc [54 - 61] . 
Regardless of the location, it has been found that stone occurrence differs among race groups. 
In the USA, the black population has significantly less risk of developing stones compared to the 
white population [62 - 65] . Similarly, in South Africa the risk of stone formation in the black 
population is considerably less (<1 %) compared to the white race group (15 %) [66, 67]. Other 
groups that are known to have less occurrence of stone formation include aboriginal tribes of 
Australia and the Inuit of Greenland [68, 69] . 
1.3 URINARY BIOCHEMICAL RISK FACTORS 
Kidney stones are created as a consequence of changes in the parameters that are present in 
urine which regulate the activity of ions that participate in CaOx salt precipitation . Below is the 
description of the most important urinary determinants that contribute to the process of CaOx 
stone formation. 
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Urine volume 
Low urinary volume leads to greater saturation of stone-forming salts and is therefore a risk 
factor for all types of kidney stones. In situations where water is lost through other means than 
via the kidney, the amount of water that is retained by the kidney increases while the amount 
that is excreted becomes low. For instance, frequent perspiration due to increased physical 
activities such as working outdoors and playing sports in high temperatures leads to decreased 
urinary volume [70 - 74] . Individuals who suffer from long periods of diarrhoea without replacing 
the amounts of water fluids lost are also likely to have low urinary volumes [75, 76] . 
When the total urine volume is low, the stone-forming salts become more concentrated and 
their solubility decreases, which may lead to their being precipitated out of the urine [77 - 80] . In 
contrast, a high urine output (~ 2L per day) has been suggested to have the opposite effect 
where the urinary components become diluted, with subsequent reduction in the saturation of 
salts that form stones [81 - 83]. 
Urinary oxalate 
In urine, oxalate combines with calcium to form CaOx. Precipitation of this salt under favorable 
conditions will result in CaOx stone formation [84 - 87]. Urinary oxalate is obtained from 
absorption of dietary foods that contain oxalate and as an end-product of endogenous 
metabolism [88 - 90]. Increased absorption of foods that have a high content of oxalate has 
been shown to result in hyperoxaluria [91 - 96]. Hyperoxaluria is defined as urinary oxalate 
concentrations greater than 0.45 mol/24h [97] . In addition, certain foods that are precursors to 
oxalate also contribute to urinary oxalate excretion [98 - 103]. 
The other source of hyperoxaluria has been suggested to be due to errors in glycolate 
metabolism. The metabolism of glycolate by the enzymes alanine glyoxylate aminotransferase 
(AGT) and D-glycerate dehydrogenase leads to the formation of glyoxylate, which is the 
immediate precursor of oxalate. Under normal circumstances, glyoxylate is catabolized by 
peroxysomal enzymes into glycine, which is further metabolized to serine. Deficiencies in AGT 
and the D-glycerate dehydrogenase enzymes have been shown to result in increased oxidation 
of glyoxylate to oxalate, which ultimately leads to increased urinary oxalate excretion [104 -
108]. In more than 35 % of stone patients, the occurrence of hyperoxaluria has been shown to 
be due to disorders of glycolate metabolism [109- 114]. 
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Some studies have demonstrated that the absorption of oxalate in the gut is regulated by 
oxalate-degrading bacteria . Oxalobacter formigenes breaks down oxalate to form carbon 
dioxide and formate [115 - 120]. Hyperoxaluric stone patients have been shown to have total 
absence or decreased activity of the Oxalobacter formigenes [ 121 - 125]. The concentration of 
oxalate in urine is considerably lower than the concentration of calcium. As a result, slight 
changes in urinary oxalate have the ability to influence the saturation of CaOx salt [126 - 129]. 
Excess supersaturation of urine with CaOx can be avoided by advising the stone patients to 
reduce the amounts of oxalate-rich foods that they normally eat [130, 131 ]. It has been 
observed that urinary oxalate excretions fall from high levels to low concentrations in rats [132] 
and stone patients after reduced oxalate diet [133, 134]. Increasing dietary intake of calcium is 
another way that is used to lower urinary oxalate concentrations. In the gut, oxalate binds to 
calcium to form a salt that is not easily absorbed in the intestines but passed out with stool [135 
- 139]. 
Urinary calcium 
Hypercalciuria, which is an important risk factor for CaOx stone formation , was defined by 
Nordin as having 24h urinary concentrations of calcium greater than 6.2 mmol in females and 
7.5 mmol in males [140] . These observations were made when individuals were taking their 
normal daily foods or when calcium intake was reduced . Increased urinary calcium excretion is 
generated from excessive intake of calcium foods or when there is a change in the metabolic 
pathways responsible for maintaining calcium balance in the body [141 - 145]. In most stone 
patients, the source of hypercalciuria is unknown [146 - 148]. 
High intakes of calcium can lead to more calcium being absorbed in the intestines. When there 
is more calcium than what is needed by the body, the surplus calcium that has been absorbed 
will be excreted in the urine, prompting the precipitation of CaOx [149 - 154]. Apart from calcium 
obtained from the diet, urinary calcium excretion results from processes that occur in the 
gastrointestinal tract, kidney and bone. Regulation of calcium at these 3 organs occurs through 
the action of 1,25-dihydroxyvitamin D (1 ,25(0Hh D) , a metabolic product of vitamin D [155 -
159]. 
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Calcium absorption in the intestines 
Intestinal calcium absorption is determined by the amount of calcium present in food and by the 
concentrations of 1,25(0H)zD [160 - 162]. Vitamin D is obtained mainly from the skin after 
ultraviolet light exposure and when foods rich in vitamin D are consumed. After entering the 
bloodstream, it is transported to the liver where it undergoes metabolism by the action of the 
enzyme 25-hydroxylase to form 25-hydroxyvitamin D (25(0H)D) [160 - 165]. 25(0H)D is 
considered the most predominant form of vitamin D in human populations, and assessment of 
serum 25(0H)D concentrations are used to determine the vitamin D status of an individual [166 
- 168]. From the liver, 25(0H)D is carried to the kidney where it is metabolized by the enzyme 
1 a-hydroxylase, to form 1,25(0H)zD [160 - 165]. When individuals consume high amounts of 
calcium, the activity of 1,25(0H)zD is increased and this results in hyperabsorption of calcium 
from the gut. In addition to th is, when too much vitamin D is ingested, and the calcium intake is 
normal, the concentration of 1,25(0H)zD increases and the amount of calcium the intestines 
absorbs will also rise [169 - 17 4]. In both cases, increased serum calcium concentration will be 
accompanied by a corresponding elevated urinary calcium concentration [155 - 159]. 
Regulation of calcium in the kidney 
The intestinally absorbed calcium enters the bloodstream and gets transported to the kidney 
where it undergoes filtration at the glomerulus. Once filtered , about 98% of serum calcium is 
reabsorbed along the renal tubules to maintain serum calcium balance. The remainder of the 
filtered calcium is excreted with urine. When the mechanisms responsible for filtering and 
reabsorbing calcium are disrupted, the renal tubules lose the ability to regulate the reabsorption 
of calcium. This disruption results in more calcium released into urine [175 - 180]. 
Release of calcium by bone and the role of parathyroid hormone 
Decreased serum calcium concentrations have been shown to occur in certain individuals 
because of reduced absorption of calcium from the diet [160 - 162]. 25(0H)D concentrations 
that are below the acceptable level decrease intestinal calcium absorption, which lowers serum 
calcium concentrations concentrations [181 - 183]. Another scenario for low serum calcium 
concentrations is when there is decreased reabsorption of filtered calcium from the kidney [175 
- 180]. 
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Under these circumstances, the parathyroid gland is triggered and it secretes the parathyroid 
hormone (PTH). The function of the PTH is to restore serum calcium concentrations to 
acceptable levels and it does this in 3 ways. In the kidney, PTH decreases the amounts of 
calcium concentrations lost into the urine by increasing the reabsorption of calcium by the renal 
tubules. Another way is to enhance the activity if 1 a-hydroxylase to produce 1,25(0HhD from 
25(0H)D. The third way PTH influences serum calcium concentrations is through the release of 
calcium from bone [184 - 187]. 
Bone is composed primarily of calcium, magnesium, phosphorus and type I collagen which 
serves as the organic matrix. Throughout the lifetime of an individual , the bone continually 
undergoes remodeling . Bone remodeling involves the degradation of old bone by osteoclasts 
cells in a process called resorption , and the formation of new bone by osteoblast cells [188 -
191 ]. When low serum calcium concentrations are observed, the PTH hormone stimulates the 
formation of new osteoclasts cells [192 - 196]. During the break down of bone, calcium, 
magnesium, phosphate and the products of collagen degradation are released from bone into 
the bloodstream [197 - 200]. 
When serum calcium concentrations are returned to normal levels, the parathyroid gland stops 
secreting PTH and the kidneys begin to excrete excess calcium into the urine [201 - 204]. Along 
with calcium, hydroxyproline is also released by bone during resorption . Hydroxyproline (HYP) 
is an amino acid and is produced from the breakdown of collagen. Since more than 50% of 
urinary HYP is obtained from the breakdown of collagen , urinary HYP is used as a marker of 
bone resorption [205 - 209] . 
Urinary citrate 
Daily urinary citrate concentrations less that 1. 70 mmol in men and 1.90 mmol in females have 
been shown to be a risk factor for the development of CaOx stones [210, 211]. About 19 to 63 
% of stone formers have been reported to excrete low urinary citrate [212 - 217]. The excretion 
of citrate is dependent on the pH balance of the renal tubular cells where citrate is reabsorbed 
and excreted . When the cells are in an acidic state, almost all of the reabsorbed citrate is 
retained by the cells for neutralization, leading to reduced urinary citrate excretion. In contrast, 
reabsorption of citrate is significantly reduced when a basic pH is observed and almost half of 
the filtered citrate is excreted in urine, thus increasing urinary citrate excretion [218 - 223]. 
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High protein intakes and certain conditions such as renal tubular acidosis, diarrhea, 
hypokalemia and urinary tract infections are the main causes of hypocitraturia [224 - 228]. 
Through various mechanisms, citrate inhibits calcium oxalate stone formation [229 - 234]. Thus 
low urinary citrate concentrations are often associated with increased risk for stone formation . 
Oral administration of citrate supplements has been shown to increase urinary citrate 
concentrations [235 - 240]. 
Urinary uric acid 
Hyperuricosuria results from having uric acid concentrations above 4.8 mmol/24h in men and 
4.5 mmol/24h in women [241, 242]. Uric acid stone formers tend to have acidic urine, low urine 
volume and high urate excretion . The source of uric acid in urine is mainly through the 
metabolism of dietary meats that contain purines [243 - 247]. Acidic urine can occur as a 
result of high intakes of foods that contain proteins or due to increased acid production within 
the body because of a defect in ammonium excretion [248 - 250]. At low urinary pH, 
precipitation of uric acid begins, and the subsequent crystal formation that follows provides 
surfaces for the nucleation and growth of CaOx crystals [251 - 253]. Low urinary volume 
accompanied by acidic urine has been shown to increase the urinary supersaturation of uric 
acid [254, 255] . 
Urinary calcium excretion is also affected by an increase in net acid load. Firstly, the increased 
acid load is neutralization by buffers from the skeleton , thereby increasing bone resorption. The 
released calcium eventually contributes to urinary calcium which may result in hypercalciuria. 
Secondly, the reabsorption of sulfates by the renal tubules is minimal. These compounds form 
complexes with calcium, preventing its tubular reabsorption and further exacerbating any 
existing hypercalciuria [256 - 260] . In addition to the above effects, uric acid also influences 
stone formation by interfering with the compounds that inhibit crystallization. The generated 
extra acid reduces urinary citrate excretion by enhancing citrate reabsorption in the proximal 
renal tubule [261 - 264]. It has been observed that uric acid interacts with macromolecular 
substances in urine such as glycosaminoglycans, thus reducing their concentrations and 
thereby lowering their inhibitory effect on CaOx crystallization [265, 266]. Hyperuricosuria can 
be treated by reducing meat and purine intakes or by the administration of citrate to raise 
urinary pH to safe levels (between 6.0 and 6.5) [267 - 269]. Allopurinol treatment has been 
shown to block uric acid production [270 - 273]. 
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Urinary pH 
Changes in urinary pH can affect stone formation directly by altering the concentrations of 
substances that contribute to crystal formation or indirectly by favoring conditions that can 
promote stone formation [274 - 277] . At pH less than 5.5, the solubility of uric acid in urine 
decreases, leading to crystallization of this salt [278 - 283]. On the other hand, urinary pH above 
6 has a tendency to form CaP crystals which may develop into apatite and brushite stones [284 
- 288]. The formation of CaOx crystals has not been linked to urinary pH because the solubility 
of this salt remains unchanged at normal physiological pH [289, 290]. Adjusting urinary pH to 
values greater than 5.5 and less than 6.0 is recommended for minimizing the crystallization of 
both UA and CaP in urine. 
Urinary magnesium 
Hypomagnesiuria is defined as having urinary magnesium concentrations that are less than 50 
mg/24h [291 , 292]. Chronic diarrhea, low dietary intake and malabsorption are the main causes 
of low urinary magnesium excretions [293, 295]. Several animal studies have demonstrated that 
low urinary magnesium excretion increases the risk of stone formation . Dietary restriction of 
magnesium in hyperoxaluric rats resulted in an increase in CaOx crystal deposition in the renal 
tubes and reversing hypomagnesiuria prevented CaOx crystallization [296, 297]. In humans, 
hypomagnesium may be a risk factor because magnesium competes with calcium for combining 
with oxalate to form a salt that is more soluble than CaOx [298] . 
1.4 CaOx STONE FORMATION AND CO-MORBIDITIES 
Certain diseases such as diabetes mellitus type 2 are associated with the increasing trends in 
kidney stone disease [299 - 301] . Type 2 diabetes mellitus is a condition that affects the 
metabolism of sugar in the body. The movement of sugar across cell membranes is regulated 
by the insulin hormone. Diabetes occurs when there are insufficient amounts of insulin or when 
the effects of this hormone are resisted by the body [302 - 304] . In either case, the disturbances 
in the sugar metabolism may change the urinary composition of an individual by increasing the 
production of ammonium [305 - 307]. The urinary pH of diabetic patients who form kidney 
stones has been reported to be very acidic [308 - 311]. As discussed earlier, a low urinary pH is 
a risk factor for uric acid stone formation and lowers urinary citrate concentrations [251 - 253]. 
9I Page 
Chapter 1 Introduction 
More importantly, studies have demonstrated that the ingestion of fructose may decrease the 
reabsorption of filtered calcium along the renal tubules and as a result, increase the urinary 
excretion of calcium [312] . 
Considering the close relationship between sugar consumption and diabetes mellitus, these 
observations suggest that excessive carbohydrate consumption may be a risk factor for CaOx 
stone formation. In both diabetic and stone patients, dietary intake of fructose affects the 
concentrations of serum triglycerides [313, 314]. Consumption of diets high in carbohydrates 
may be a risk factor for diabetes and kidney stone formation and increased serum triglycerides 
concentrations may be a biomarker that links these two diseases [315, 316] . 
1.5 INHIBITORS OF CaOx STONE FORMATION 
Urinary stone inhibitors can be divided into two broad classes - those that affect the 
thermodynamic factors and those that affect the kinetic factors. The saturation of urinary salts 
falls into the first group while crystallization mechanisms such as crystal nucleation , growth and 
aggregation fall into the second group. 
Supersaturation of stone-forming salts occurs very often in urine. It has been observed that 
even healthy individuals who do not form stones excrete microscopic crystals quite regularly. 
This implies that every individual fulfills the initial step of CaOx crystallization . Despite this 
saturation of stone salts, most humans do not form stones. The ability of urine to resist 
crystallization has been largely credited to the presence of molecules such as citrate, 
magnesium, glycoproteins and glycosaminoglycans (GAGs) that are capable of retarding and 
inhibiting the steps involved in stone formation [317 - 322]. In particular, their chemical nature 
allows them to alter or modify the processes that lead to stone formation by various 
mechanisms [323 - 328] . These compounds have been found in very low concentrations in the 
majority of stone formers and also their protective functions in urine have been somehow 
altered [329 - 334]. The role of glycosaminoglycans will be discussed in section 1.9. 
Citrate 
The source of citrate in the body is normally obtained to a large extent as a by-product of the 
Krebs cycle , while the rest is derived from food intakes [335, 336]. In the liver, citrate is 
metabolized to bicarbonate which has alkaline properties. The unabsorbed citrate is excreted by 
the kidney where it contributes to the inhibitory effect of urine against crystallization [337, 338]. 
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In urine, citrate reduces the probability of CaOx formation by binding to the free calcium ion and 
forming a calcium-citrate complex that is more soluble than CaOx [339 - 342] . In addition to 
reducing the supersaturation of CaOx, citrate has been shown to retard crystallization and 
growth of CaOx crystals [343 - 347] . 
Due to its alkalinization properties, the presence of citrate in urine will raise the urinary pH and 
dissolve any existing uric acid crystals, thus preventing heterogenous nucleation of CaOx on 
uric acid crystals [267 - 269]. 
Magnesium 
Several studies have shown that excretion of urinary magnesium may be effective in preventing 
kidney stone formation . In the gut, magnesium combines with oxalate to form magnesium 
oxalate (MgOx) , a more soluble complex compared to CaOx [348, 349] . The MgOx salt 
reduces the amount of free oxalate that can be absorbed in the gut, thereby successfully 
reduces urinary supersaturation of CaOx. It has been shown that oral administration of 
magnesium oxide salt effectly reduced oxalate absorption from 13.5 to 7.6 % [350]. In another 
study, Berg et al observed that urinary excretion of oxalate becomes significantly reduced after 
magnesium supplementation when healthy subjects ate a diet that contained high amounts of 
spinach [351]. In vitro crystallization studies showed that magnesium can reduce both 
nucleation and growth of crystals [352 - 354]. Furthermore, increasing dietary magnesium intake 
has been shown to lower urinary oxalate excretion [355, 356]. On the other hand, 
supplementation with magnesium in healthy subjects resulted in an increased urinary excretion 
of citrate [357] . 
Glycoproteins 
Various urinary glycoproteins are associated with the development of kidney stone disease. 
These compounds are mainly composed of proteins which carry covalently bound 
carbohydrates [358, 359] . Glycoproteins are mostly produced within the kidney and are 
excreted in urine. For example Tamm Horsfall protein (THP) , inter-alpha-trypsin and 
osteopontin occur on cell surfaces of renal tubules in the ascending loops of Henle [360 - 362]. 
Their presence in the renal tubules prevents stone retention by inhibiting crystal attachment to 
renal cells [363 - 368]. 
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In urine, glycoproteins have been found to modify the processes involved in crystallization of 
CaOx. The inhibitory effects of glycoproteins against stone formation include preventing 
nucleation of CaOx crystals, slowing down or inhibiting the rate of crystal growth and 
aggregation [369 - 373]. The individual effects of the glycoprotein inhibitors are presented on 
Table 1.1 . 
The protection effect of these inhibitors against stone formation also depends on the 
physicochemical conditions of the urine. For example, THP can acts as both an inhibitor and a 
promoter of kidney stone formation. In solutions with high pH, low ionic strengths and low 
concentrations of divalent ions and THP, this glycoprotein inhibits stone formation . However, 
THP becomes a promoter of crystal aggregation in the presence of low urine pH and low THP 
levels, accompanied by high concentrations of calcium, sodium, and hydrogen ions [374]. 
Table 1.1 
Types of inhibitors and their mode of action on CaOx crystallization 
Name of inhibitor Effect on crystallization 
Osteopontin Inhibitor of nucleation , growth and aggregation 
Urinary Prothrombin Fragment 1 (UPTF1) Inhibitor of growth, aggregation and adhesion 
Tamm-Horsfall protein (THP) 
Promoter of nucleation and growth, inhibitor 
of aggregation 
Renal lithostathine (RL) Inhibitor of growth 
Nephrocalcin (NC) Inhibitor of growth and aggregation 
Source: Gupta Met al, 2011 . IJRPC 1 (4): 793-8 {319] 
1.6 PROCESSES INVOLVED IN CaOx STONE FORMATION 
Normally, urine contains numerous ions including calcium, oxalate, urate, phosphate [375 -
378]. These ions interact with each other and form salts such as CaOx, UA, brushite, etc. When 
the amounts of these salts reaches a maximum point where they are no longer able to dissolve 
in urine, the urine is described as being saturated [379 - 381]. As the concentration of these 
salts is increased further in the saturated urine, crystals begin to precipitate out of the urine. 
Supersaturation is defined as the state where the concentration of stone-forming salts exceeds 
the saturation concentration and is the fundamental driving force for crystallization . It is often 
expressed as a ratio of salt concentrations over their solubilities [379 - 384]. 
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In general, supersaturation is higher in stone formers than in individuals who do not form stones 
[385, 386] . At supersaturation ratios above 1, crystals tend to nucleate and grow, promoting 
stone formation whereas they dissolve at ratios below 1 [379- 384]. 
Crystal formation , known as nucleation , is the process by which free ions in solution are 
transformed into loose particles [384] . There are two types of nucleation. The formation of 
crystals in the absence of surfaces is described as homogeneous nucleation. Homogeneous 
nucleation rarely occurs in urine due to the presence of dissolved impurities. Heterogenous 
nucleation is the formation of crystals on the surfaces of substances found in urine [379 - 384]. 
Surfaces of epithelial cells, urinary casts , red blood cells, and other crystals are known to 
promote nucleation and to also reduce the amounts of energy required for nucleation [385 -
390]. 
Secondary nucleation results from the presence of crystals in the supersaturated urine which 
act as catalysts for nucleation [379 - 384] . Both heterogeneous and secondary nucleation 
requires lower supersaturation of salts in urine compared to homogeneous nucleation [391]. 
Crystal growth is the next stage of crystallization where the formed nuclei grow larger by the 
addition of ions from the supersaturated urine onto the crystal [392, 393] . Since the rate of 
crystal growth is quite slow and about 5 to 1 O minutes are required for the tubular fluid to pass 
through the kidney, the process of crystal growth alone is not sufficient to give rise to a crystal 
large enough to be retained inside the kidney [394] . These small crystals are usually passed out 
of the body with urine without forming a stone [395]. 
One way of forming large crystal particles is through a process called aggregation. Aggregation 
is accomplished when crystals come into close contact and bind to each other [396] . Clustered 
particles can be formed when crystal particles use an organic matrix as the binding agent to 
attach to other crystals of the same chemical nature [397 - 404]. The organic matrix has been 
reported to contain proteins, lipids, polysaccharides and other cell derived materials. Pure CaOx 
stones are suggested to be formed via this process [405] . Alternatively, aggregation may be 
achieved when pre-formed crystals settle and nucleate on the surfaces of other crystals. For 
example, CaOx crystals can aggregate on surfaces of both CaP [406] and UA crystals [407, 
408] resulting in a mixed CaOx-CaP or CaOx-UA stone, respectively. Compared to crystal 
growth , aggregation is a rapid process and crystals grow into appreciable sizes during the 
transit time in the urine [394]. 
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Free- vs fixed-particle theory 
Stone development occurs when the formed particles are retained inside the kidney. This 
process is suggested to occur via 3 mechanisms. In cases where the crystals have aggregated 
to a substantial size and the urine flow is poor, crystals may become trapped inside the renal 
tubules. Further crystal growth and aggregation may lead to the formation of large particles that 
may block the renal tubules. Alternatively, retention of particles inside the kidney can be 
achieved when particles attach to tubular cell surfaces [409- 414]. 
When the particles are confined inside the kidneys due to their large size, the retention process 
is defined as the free particle mechanism [415]. This mechanism is not favored because the 
crystal particles can never grow or aggregate into appreciable sizes while travelling through the 
renal tubules for them to become trapped inside the kidney. These observations were based on 
calculations made by Finlayson and Reid who calculated the rates of crystal precipitation growth 
under favorable CaOx supersaturation conditions, while taking into account the kidney 
structures and nephron dimensions [416] . 
However, when the major processes involved in stone are dominated by the attachment of 
crystals to cell surface, the mechanism of stone retention is known as the fixed particle 
mechanism [417]. Oxidative stress, contact with crystals and bacteria usually causes damage to 
epithelial cells lining the renal tubules [418] . The exposed cell fragments provide a suitable 
surface for the attachment of crystals [417] . Proteins and glycosaminoglycans that are found at 
the renal cell surfaces have been implicated as the sites at which CaOx attach to renal cells. 
Once on the surface of the cells , the crystals can either be endocytosed [418] or they may 
increase in size leading to further crystal aggregation [419] . The crystals that are engulfed by 
the cells slowly disintegrate without increase in growth or forming a stone [420] . Meanwhile, 
further crystal growth can occur for long periods as long as the urine is supersaturated and 
there is aggregation of new crystals. Although debris from the damaged cells usually forms the 
surface upon which crystals attach to renal tubules, crystal attachment may also occur on 
calcium deposits found on the renal papilla [421] . Both brushite and apatite crystallization 
mainly occurs in the loop of Henle, resulting into deposits that may grow extensively to form a 
plaque known as Randall 's plaque [422] . This theory was supported by a study conducted by 
Aspin et al [423] where he found out that the loop of Henle is supersaturated with respect to 
calcium-phosphate salts. Stones formed in these plaques are largely composed of CaOx and 
CaP [424]. 
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1.7 DIETARY FACTORS 
The types of foods that an individual consume can modify the composition of urine. As a result, 
certain foods are suggested to affect the saturation of stone-forming salts and are associated 
kidney stone development [425 - 430] . On the other hand, the consumption of other types of 
foods is recommended for people who form stone because they are capable of minimizing or 
preventing the risk of stone formation [431 - 436]. 
Fluid intake 
Several studies have demonstrated that drinking large amounts of fluids reduces the 
concentrations of calcium, oxalate, and phosphate in urine, leading to a reduction in the 
supersaturations of salts such as CaOx and CaP and urate [437 - 440]. In addition, it has been 
shown that the likelihood of forming another stone can be reduced by 12 % after increasing the 
amounts of fluid that an individual drinks. However, stone patients who maintain their normal 
fluid intake are reported to have an average recurrence rate of 27 % [441 - 443]. 
A high urine volume can be achieved by consuming adequate amounts of various fluids. Water 
is the most preferred type of fluid to drink because it is easily accessible [443 - 448]. In addition 
to water, drinking adequate amounts of green teas, coffee, beer and wine [449 - 453] has been 
found to be useful in increasing urinary volume. An added benefit may be obtained from other 
types of fluids because of ingredients that they contain which protect against stone formation. 
Drinking lemon and orange juices increases urinary concentrations of citrate [454 - 456], an 
inhibitor of stone formation . Cola, grape-, cranberry and blackcurrant juice consumption have a 
negative impact on stone formation due to the high levels of oxalate found in these drinks [457 -
459]. 
Oxalate 
Ingestion of foods that have high oxalate content can increase the concentrations of oxalate in 
urine [460 - 463] . Intestinal hyperabsorption of oxalate from green leafy vegetables (spinach 
and rhubarb) , nuts, tea, chocolate, etc increases the risk of stone formation [464, 465] . It has 
been shown that as much as 10 - 20 % of oxalate excretion per day is derived from dietary 
oxalate [466] . However, in a study conducted by Holmes, it was found that almost 50 % of 
urinary oxalate originates from dietary intakes of foods that contain oxalate [467] . 
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When vitamin C, xylitol and amino acids such as hydroxyproline and glycine are ingested in 
great amounts, a corresponding increase in urinary oxalate is observed [468 - 473]. This is 
because the metabolism of these nutrients produces glyoxylate, which is converted to oxalate 
and excreted as a waste product. CaOx stone formers are normally advised to restrict their daily 
intakes of foods rich in oxalate since oxalate has a more powerful effect on CaOx saturation 
than calcium [474, 475]. 
Calcium 
In most hypercalciuric stone patients, consumption of foods that contain high amounts of 
calcium is directly associated with increased calcium excretion [476 - 479]. Van Unruh et al 
[480] demonstrated that urinary calcium increased by 8 % and 20 % in healthy controls and 
stone formers, respectively after ingesting similar calcium intakes. 
Normally stone formers will try to minimize the risk of stone formation by decreasing the 
amounts of calcium in the diet [481 - 484]. This route is not advisable because dietary calcium 
binds to oxalate in the gut to form a non-absorbable salt [136, 485 - 486]. The benefit of this is 
that oxalate obtained from foods is eliminated from the body with faeces without increasing the 
risk of stone formation. In addition , reduced calcium intake is connected to the low calcium 
content of bone, and can lead to diseases such as osteoporosis [487, 488]. 
Sodium 
Increased salt consumption may promote stone risk by reducing calcium reabsorption , leading 
to increased urinary calcium excretion [489 - 492] . In the kidney, sodium is reabsorbed along 
the renal tubules at the same sites responsible for calcium reabsorption [493, 494]. As a result, 
excretion of one ion may interfere with the excretion of the other [143]. 
Dietary intake of salts, particularly sodium chloride (NaCl) , provides the necessary sodium 
needed by the body. Nordin et al [495] estimated that about 2 g of NaCl intake will result in 1 
mmol increase of urinary calcium excretion in healthy subjects whereas if the stone formers 
consumed the same amount, 2 mmol of calcium will be lost in urine. Also, high sodium intakes 
have been associated with a significant decrease in urinary citrate [496]. 
Since reducing calcium intake may promote the stone incidence, limiting dietary sodium is the 
most preferred way to lower stone risk [497 - 499] in hypercalciuric stone patients. 
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Protein 
Ingestion of high amounts of foods that contain proteins is considered to increase the risk of 
developing kidney stones. Animal protein foods are a rich source of sulfur-containing amino 
acids. Metabolism of these amino acids generates sulfuric acid, which influences the overall 
acid excretion [248 - 250]. Low urinary pH favors the formation of uric acid stones [251 - 253]. 
Also, the increased excretion of acid affects the renal reabsorption of citrate and results in 
decreased urinary citrate excretion [500, 501 ]. 
With regards to calcium excretion , high intakes of animal proteins enhance bone resoprtion 
which may lead to hypercalciuria [500, 502 - 503]. In a study conducted in healthy subjects, 
Kerstell et al [504] demonstrated that 25 g of protein intake will raise urinary calcium excretion 
by 0.8 mmol. In addition , Robertson et al observed a 23 % significant increase in urinary 
calcium excretion after 34 g intakes of proteins per day [505]. Low intakes of dietary proteins 
are normally recommended for hypercalciuric stone patients [506, 507]. 
1.8 ROLE OF FATTY ACIDS 
Nomenclature 
Fatty acids (FAs) are straight chain hydrocarbons possessing a carboxyl group at one end [508, 
509] . The most common dietary fatty acids are divided into three classes, namely: saturated 
fatty acids (SFAs), monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids 
(PUFAs) [510 - 514]. SFAs contain no carbon double bonds between the carbons in the main 
carbon chain . MUFAs have one carbon double bond while PUFAs have two or more double 
bonds. According to the International Union of Pure and Applied Chemistry system, FAs are 
named on the basis of the number of carbon atoms, and the number and position of 
unsaturated fatty acids relative to the carboxyl group [515] . 
For example, the chemical formula C18:4 n-3 or C18:4 n-6 indicates that there are 18 carbons 
in the chain with 4 double carbon bonds. The number 3 or 6 preceded by n, indicates the 
distance of first double bond, in carbon atoms, from the methyl end (n-end) of the chain. The 
most encountered dietary fatty acids are shown in Table 1.2. 
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Action and metabolism 
Stone formers have been found to consume higher intakes of dietary fats compared to normal 
subjects [516, 517]. In two separate studies, evaluation of food questionnaires demonstrated 
that fat intake correlates positively with urinary oxalate excretion [518, 519] . In animal models, 
rats fed a fat-rich diet, which was primarily composed of excess cholesterol and neutral fat, 
resulted in an increase in urinary saturation of CaOx [520] . 
Recently, fatty acids have been shown to influence the urinary excretion of calcium and oxalate. 
After analyzing dietary fatty acid intakes of hypercalciuric stone patients, Naya et al reported 
that arachidonic acid was directly correlated with urinary oxalate excretion in these patients 
[521] . However, in a study conducted by Taylor et al , there was no association of dietary fatty 
acid intake with increased risk of stone formation [522] . 
rTable 1.2 
~bbreviated chemical formulae and common names of major fatty acids 
Chemical formulae Common name Chemical name 
C18:3 n-3 ALA Alpha-linolenic acid 9, 12, 15-octadecatrienoic acid 
C20:5 n-3 EPA Eicosapentaenoic acid 5,8, 11 , 14, 17-eicosapentaenoic acid 
C22:5 n-3 DPA Docosapentaenoic acid 7, 10, 13, 16, 19-docosapentaenoic acid 
C22:6 n-3 DHA Docosahexaenoic acid 4,7, 10, 13, 16, 19-docosahexaenoic acid 
C18:2 n-6 LA Linoleic acid 9, 12-octadecadienoic acid 
C18:3 n-6 GLA Gamma-linolenic acid 6, 9, 12-octadecatrienoic acid 
C20:2 n-6 EDA Eicosadienoic acid 11 , 14-eicosadienoic acid 
C20:3 n-6 DGLA Dihomo-gamma-l inolenic acid 8, 11 , 14-eicosatrienoic acid 
C20:4 n-6 AA Arachidonic acid 5,8, 11 , 14-eicosatetraenoic acid 
C22:4 n-6 ADRA Adrenic acid 7, 10, 13, 16-docosatetraenoic acid 
C22:5 n-6 DPA Docosapentaenoic acid 4,7, 10, 13, 16-docosapentaenoic acid 
C16:1 n-7 PTA Palmitoleic acid 9-Hexadecenoic acid 
C18:1 n-7 VA Vaccenic acid 11-0ctadecenoic acid 
C18:1 n-9 OA Oleic acid 9-octadecenoic acid 
C20:1 n-9 GA Gadoleic acid 11-eicosenoic acid 
C24:1 n-9 NA Nervonic acid 15-tetracosenoic acid 
C14:0 MA Myristic acid Tetradecanoic acid 
C16:0 PA Palmitic acid Hexadecanoic acid 
C18:0 SA Stearic acid Octadecanoic acid 
C20:0ARA Arachidic acid lcosanoic acid 
C22:0 BA Behenic acid Docosanoic acid 
C24:0 LGA Lignoceric acid T etracosanoic acid 
(Source: Hon GM et al, 2012. http://www. mtechopen.com!bookslgas-chromatography-b10chem1cals [515]) 
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Other investigators have proposed that fatty acids may influence stone formation via their 
composition in phospholipids. In hypercalciuric stone patients, Baggio et al observed a 
discrepancy in the composition of n-6 fatty acids in both the plasma and red blood cells (RSC) 
membrane phospholipids [523, 524]. Abnormally increased phospholipid concentrations of 
arachidonic acid (AA, 20:4 n-6) compared to the lower content of linoleic acid (LA, 18:2 n-6), its 
precursor, have been shown to create anomalies in the transport mechanisms that regulate 
calcium and oxalate balance in the body. The other fatty acid composition in plasma and RSC 
were found to be within the normal ranges. 
The oxalate transport mechanism across the RSC membranes in the gut and kidney are 
regulated by AA [525]. Band-3 and band-3-related proteins are the major carriers of oxalate at 
these sites and through anion exchange mechanisms, are able to move oxalate across different 
cell membranes [526] . Baggio et al reported that the band-3 phosphorylation is an important 
step of the oxalate cell flux [523]. AA acts a second cell messenger and activates casein kinase 
CK1 , the enzyme responsible for band-3 protein phosphorylation. Increased AA concentration 
may results in enhanced activity of this enzyme, leading to high intestinal absorbance and renal 
clearance of oxalate [527, 528]. 
AA has been shown to exert its effect on calcium excretion via prostaglandin E2 (PGE2), its 
major metabolic product [529] . It has been suggested that PGE2 may promote hypercalciuria in 
the gut by stimulating the activity of 1 a-hydroxylase, which leads to the increased production of 
1,25(0H)D [528]. In particular, increased serum PGE2 and 1,25(0H)2D concentrations have 
been observed in hypercalciuric stone patients [530]. In the kidney, PGE2 is suggested to 
influence calcium balance by reducing the amounts of calcium that are reabsorbed in the thick 
ascending loop of Henle [528] . It has been demonstrated that PGE2 is involved in the bone 
resorption process where PGE2 regulates the activity of osteoclastic cells while inhibiting 
osteoblastic bone formation [531]. Along with high PGE2 concentrations, Pilbeam et al found 
increased concentrations of several bone resorption markers in patients with osteoporosis [531]. 
These observations imply that when PGE2 concentrations are high , increased activity of PGE2 
at these organs will be increased, leading to hypercalciuria. 
The role of PGE2 in calcium excretion was first investigated by Buck et al in animal models and 
stone patients [532] . After injecting rats and monkeys with indomethacin , an anti-inflammatory 
drug known to inhibit the production of PGE2, decreased urinary calcium concentrations were 
observed . Following PGE2 administration , the decreased calcium concentrations rose and 
returned to acceptable levels. 
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Similarly, a reduction in urinary calcium was observed in a group of hypercalciuric patients after 
they were given indomethacin [532] . These observations were later confirmed in a study 
conducted in stone patients by Hirayama et al [533] . 
AA is an n-6 FA that is obtained directly from dietary sources or indirectly from conversion of LA 
[534]. Hypercalciuric stone patients have been shown to have a significantly higher 
concentration of AA than normocalciuric stone patients [523] . Baggio et al hypothesized that this 
abnormality may be as a result of an abnormal change in the metabolism of these fatty acids 
rather than malabsorption [520] . 
Ingestion of n-3 FAs such as eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid 
(DHA, 22:6 n-3) have been suggested to reduce the risk of stone formation [535, 536] . It has 
been observed that the incidence of stone formation in the Inuit group of Greenland is almost 
absent due to the diet that is mainly comprised of fish , which is a rich source of EPA and DHA 
[69] . 
Dietary n-3 FAs lower AA concentrations in plasma and RBC membrane phospholipids and, 
therefore, can inhibit the synthesis of PGE2 and modify its effects [537]. Several studies have 
reported decreased urinary calcium and/or oxalate excretion in stone patients with 
hypercalciuria after supplementation with these n-3 FAs [538 - 540]. EPA and DHA are obtained 
directly from the dietary intake of fish and seafood or as a product of the metabolism of alpha-
linoleic acid (ALA, 18:3 n-3) [508 - 51 O]. 
Metabolic pathways of PUFAs 
Both ALA and LA are essential fatty acids because they cannot be produced by the human 
body, and yet are required for proper physiological functioning [508, 509]. ALA is obtained 
directly from eating nuts and seed whereas plant oils are rich sources of LA [510] . Once 
ingested, they can undergo elongation and desaturation reactions to form long-chain 
polyunsaturated fatty acids. 
LA is converted in a variety of tissues by b-6-desaturase to form y-linolenic acid (GLA, 18:3 n-
6). GLA in turn is rapidly elongated to dihomo-gamma-linolenic acid (DGLA, 20:3 n-6) which is 
desaturated to AA by a b-5-desaturase. In turn , ALA is converted to EPA and DHA by the same 
set of desaturase and elongation enzymes responsible for synthesizing AA [541 - 543]. 
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Although the metabolic pathways of n-3 and n-6 fatty acids use the same enzymes, the major 
products of each pathway are structurally unique and have different physiological functions [544 
- 547] . For example, AA is a precursor of eicosanoids which are involved in inflammatory 
responses. In contrast, EPA and DHA give rise to eicosanoids that have anti-inflammatory 
properties and which are inflammatory resolving [547] . 
Nonetheless, a competition exists between these two families for metabolism [541 - 543] . An 
abundance of one family of fatty acids overwhelms the enzymes, causing a significant decrease 
in the conversion of the other [541 - 543] . The metabolic pathway that converts LA to AA and 
ALA to DHA occurs very slowly in humans and so these FAs are mainly obtained directly from 
the diet [508 - 51 O]. 
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1.9 ROLE OF MACROMOLECULES 
Glycosaminoglycans (GAGs) are large polysaccharides that are found in numerous cells in the 
human body, often as part of the epithelial cells in renal tubules. They are linear in structure and 
are built by repeating units of disaccharides containing one uronic acid (D-glucuronic acid or L-
iduronic acid) and an amino sugar (N-acetylgalactosamine GalNAc) or N-acetylglucosamine 
(GlcNAc)) . GAGs are negatively charged macromolecules as a result of the carboxylate content 
of the uronate monomer and the sulfate content of the galactosamine or glucosamine sugar. 
The number of the repeat units of the uronic acid and sugar monomers varies with each GAG 
but has been reported to reach an average of about 600 units, which correlates to molecular 
weights between 10 - 100 kDa. GAGs are not usually found as free-chain polymers. They have 
been reported to exist as proteoglycans, which are proteins attached to glycosaminoglycan 
chains by covalent bonds [548 - 553]. 
There are 7 types of GAGs, namely: heparin , heparan sulfate, chondroitin-4-sulfate (CSA), 
chondroitin-6-sulfate (CSC), dermatan sulfate, hyaluronic acid , and keratan sulfate [554, 555]. 
These GAGs differ from each other according to the structure of the disaccharide unit, 
molecular weight and distribution in the body. In urine, the most abundant GAG is chondroitin 
sulfate (A and C) , 55 %, followed by heparin sulfate (20 %). Heparan sulfate has been reported 
to contribute about 11 % of all GAGs in urine while the percentage for hyaluronic acid is 
between 4-10 % [556, 557] . 
Several in vitro experiments have demonstrated that urinary GAGs protect individuals from 
stone formation by interfering with the crystallization processes of stone formation . The 
proposed mechanisms by which GAGs have been shown to inhibit stone formation include 
retarding crystallization, preventing stone retention inside the kidney, decreasing urinary oxalate 
excretion and reducing the availability of free calcium in urine [558 - 563]. The latter mechanism 
is of interest in the context of the present study. 
It has been suggested that due to their overall negative charge, GAGs inhibit stone formation by 
blocking the growth sites of the crystals and thereby prevent or delay crystal development [564 -
566]. Several in vitro studies have shown that chondrotin sulfate, heparin sulfate and heparin 
inhibit nucleation , crystal growth and aggregation of CaOx crystals [567 - 572] . However, further 
studies in urine samples and rat models did not show that exogenous GAGs have an inhibitory 
effect on stone formation. 
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It has been shown that dosing urine samples of stone patients with chondroitin sulfate [565] and 
heparan sulfate [573] had no effect on the metastable limit and mass deposition. In another 
study, it was reported that chondroitin sulfate promoted nucleation in urines of stone formers 
whereas heparan sulfate enhanced nucleation [574]. In rat models, chondroitin sulfate had no 
effect on the CaOx deposition in kidneys [575] and instead promoted large particle formation 
[576]. 
In the renal tubules, GAGs have been suggested to lower the risk of stone formation by lining 
the surface of epithelial cells and preventing the confinement of crystals in the kidney [577 -
580]. Experiments conducted in primary cultures of renal epithelial cells demonstrated that the 
attachment of COM crystals to the surface of epithelial cells was significantly reduced in the 
presence of hyaluronic acid and other GAGs [581 - 583]. 
In idiopathic calcium stone patients, the GAG content in red blood cells has been reported to be 
decreased compared to normal controls [584]. Baggio et al suggested that the indirect 
relationship observed between the level of phosphorylation and the transmembrane oxalate flow 
may be due to a link between the erythrocyte deficiency of GAGs and the high concentrations of 
urinary oxalate associated with idiopathic calcium nephrolithiasis [585, 586]. However, 
supplementation with GAGs such as heparin, heparin sulfate and CSA was shown to normalize 
the oxalate self-exchange and the membrane protein phosphorylation mechanisms [586, 587]. 
In addition , GAG supplementation also significantly reduced urinary oxalate excretion [587] . 
Another mechanism by which GAGs reduce stone formation has been suggested to be due to 
the ability of GAGs to directly bind calcium in urine. Since GAGs have an anionic character due 
to the sulfated disaccharide units, they compete with oxalate ions and form a complex with 
calcium, thus reducing CaOx precipitation [578 - 590]. Techniques such as equilibrium dialysis 
[588], ion selective electrodes [589], micropotentiometric titration and ion exchange [590] have 
been applied to study the mechanisms of calcium-GAG complex formation. For example, the 
binding constants (K) for the calcium-GAG complex formation have been suggested to increase 
with the concentration of GAGs when calcium was assumed to bind to one site of the GAG 
chain [588 - 591] . In addition, the binding between calcium and GAGs has been found to be 
reduced in the presence of other ions such as sodium or urate, and that binding is also 
dependent on ionic strength [592, 593]. 
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In principle, these effects can be theoretically investigated by speciation modeling. However, 
accurate thermodynamic constants for the equilibria between calcium and various GAGs, which 
are required for such calculations, are not readily available. The same lack of data exists for 
similar constants involving magnesium. This deficiency in kidney stone literature will be 
addressed in the present thesis. 
With regards to urinary excretion of GAGs, several authors have reported that the urinary 
excretion of GAGs is significantly lower in stone patients compared to healthy subjects [594 -
598] . However, other investigators found no significant differences in the urinary excretion of 
GAGs between stone formers and healthy subjects [599 - 602]. 
The role of GAGs in stone formation therefore remains worthy of further exploration . 
1.10 UROLITHIASIS IN SOUTH AFRICA 
In South Africa , the incidence of stone formation has been reported to be lower (<1 %) in the 
black population compared to the white population (15 %) [603] . Over the years , this 
phenomenon has generated interests in several investigators to determine the cause of this 
abnormality between these two groups [604 - 606] . 
In the Kidney Stone Research Laboratory - University of Cape Town , South Africa , differences 
in CaOx risk factors such as diet [607, 608] , genetics [609] and metabolic disorders [610, 611] 
between blacks and whites have been investigated to further gain insights as to the 
explanations for the racial differences in the incidence of kidney stone disease between these 
two groups. 
Intervention studies have shown that these two groups have different renal handling 
mechanisms when it comes to dietary supplement challenges [607 - 612]. In a study conducted 
by Lewandowski et al [61 O] , it was shown that supplementation with calcium, vitamin 86, L-
glutamine and L-cystein had no effect on the urinary risk factors in the black group whereas in 
whites favourable results were observed. For example, calcium supplementation reduced the 
Tiselius risk index (TRI) while vitamin 86 significantly decreased the saturation of calcium 
oxalate and brushite salts. Meanwhile, L-glutamine lowered the relative saturation of calcium 
oxalate and L-cysteine decreased urinary calcium and the TRI. 
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In another study, supplementation with a high oxalate and low calcium diet had no effect on 
urinary risk factors in blacks whereas in whites urinary oxalate was increased [607] . Further 
studies showed that low calcium and lacto vegetarian diets and vitamin C supplementation were 
not associated with changes in urinary risk factors in the white population [608]. In the black 
group several responses were reported . In the low oxalate diet protocol , urinary oxalate and the 
relative supersaturation (RS) of brushite were increased while RS CaOx was decreased. 
However, an increase in urinary pH and TRI were obseNed in the lacto vegetarian and vitamin 
C studies, respectively. Ingestion of high oxalate diets, however, increased urinary citrate in 
blacks whereas urinary pH, potassium and RS brushite were increased in whites [608] . Lastly, 
glucose and xylitol supplementation in the black population decreased urinary phosphate and 
increased urinary oxalate, respectively [612] . In contrast, these supplements had no effect on 
the urinary risk factors in the white group. 
The differences in responses to dietary inteNentions suggest that the renal handling 
mechanisms of supplement challenges may account for the black and white dissimilarities in the 
incidence of kidney stone disease. Thus, insights gained from studies examining the effects of 
supplement challenges in urinary risk factors of black and white subjects are of particular 
importance to research efforts aimed at reducing the prevalence of kidney stone disease. 
1.11 MOTIVATION FOR THE PRESENT PROJECT 
Despite much research , no single cause for kidney stone disease has been identified. As such, 
it is not surprising that effective conseNative therapeutic protocols are still being explored. 
Among these are polyunsaturated fatty acids and GAGs. There is a need to further interrogate 
their potential roles in treating stone disease by investigating the basic science mechanisms by 
which they may exert their respective influences. 
In addition, the anomaly of the different stone prevalence rates in South Africa 's black and white 
population groups remains unresolved. It is well established that the two groups respond 
differently to different dietary and supplemental inteNentions. The possibility exists that n-6 and 
n-3 FAs and GAGs also may elicit different responses in the two groups. The present thesis will 
attempt to integrate these themes in the hope of casting light on stone pathogenesis on the one 
hand and stone formation on the other. 
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1.12 AIMS AND OBJECTIVES 
There are two main aims of the studies undertaken for this thesis. 
The primary aim of the project is to investigate the potential beneficial effects of supplemental 
polyunsaturated fatty acids (PUFAs) and supplemental chondroitin sulfate (CS) on the risk 
factors for calcium oxalate kidney stone formation using theoretical , experimental and human 
models wherever it is feasible and meaningful to do so. 
The secondary aim of the project is to investigate whether black and white South Africans 
respond differently to these supplements and if so, whether such differences provide insights 
into understanding the anomaly of the different stone incidence rates in the two race groups, 
and whether these in turn , provide insights into understanding stone pathogenesis and 
management in general. 
In order to achieve these aims, the following objectives were established: 
• to administer and analyze 24h dietary recall questionnaires in healthy black and white 
subjects 
• to administer n-6 FA (GLA) and n-3 FAs (EPA and DHA) , and a combination thereof, in 
both groups of subjects 
• to administer chondroitin sulfate in another cohort of healthy black and white South 
African subjects 
• to determine urinary risk factors for CaOx stone formation in both cohorts, at baseline 
and at various times during the test period 
• to determine blood risk factors at baseline and at various times in the PUFA cohort 
• to determine the total concentration of urinary GAGs (and other urinary components) in 
both groups of subjects, at baseline and at various times during the test period in the CS 
cohort 
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• to test the effect of chondroitin sulfate on calcium oxalate crystallization processes in 
synthetic, 24h and pooled urine samples 
• to experimentally determine the thermodynamic binding constants for the formation of 
calcium and magnesium complexes with the most commonly occurring urinary GAG, 
chondroitin sulfate 
• to use these constants to calculate the chemical speciation and the urinary 
supersaturation of various calcium salts in 24h urines of healthy subjects, and to model 
the effect of varying the concentration of chondroitin sulfate 
• to calculate and compare the chemical speciation and the relative supersaturation of 
various calcium salts in 24h urines obtained at baseline with those collected post 
supplementation using physiological concentrations of chondroitin sulfate 
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2.1 INTRODUCTION 
As previously described in Chapter 1, the abnormal composition of FAs in plasma phospholipids 
of idiopathic calcium stone patients has been directly linked to CaOx stone formation. 
Compared to other n-6 FAs, AA has been reported to be the most abundant one in plasma 
phospholipids of such patients [1]. High AA concentrations have been shown to lead to 
increased production of PGE2, a major metabolite of AA which is associated with excess 
calcium and oxalate excretion [2]. The unbalanced FA content in phospholipids can be 
corrected by administering different essential fatty acids that are precursors to AA. For example, 
dietary intakes enriched with LA have the potential to normalize the concentrations of n-6 FAs 
[3]. This route is unfavorable because the conversion of LA to GLA and DGLA occurs very 
slowly in humans [4]. On the other hand, dietary supplementation with GLA has been reported 
to change the FA profile in various lipid fractions and the subsequent metabolite production in 
humans [5] . 
The present study was designed to examine the effects of GLA supplementation on the 
composition of FAs in plasma total phospholipids of healthy black and white South African male 
subjects. A second objective was to assess whether the risk factors for CaOx stone formation 
would be affected by GLA supplementation. This was achieved by measuring the changes in 
both serum biomarkers and urinary physicochemical parameters before and after 
supplementation. In view of the reported differences between black and white subjects in terms 
of their renal handling of different lithogenic agents [6] , the study was also undertaken to 
compare the responses of the two groups to GLA supplementation. Finally, the present study 
aimed to investigate the effect of GLA supplementation on the crystallization kinetics of CaOx in 
urine. 
2.2 STUDY DESIGN 
Before the commencement of the study, approval (HREC REF: 366/2011) was obtained from 
the Human Research Ethics Committee at the University of Cape Town, South Africa (Appendix 
2.1) . Volunteers were told about the research goals and all aspects of the study; if they were 
interested in participating, they signed informed consent forms (Appendix 2.2) . Subjects 
provided information on their general background characteristics and health history by means of 
a questionnaire (Appendix 2.3) . 
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Age, weight and height were obtained from the questionnaire and the body mass index (BMI) 
was calculated . Subjects also provided information on their use of medication ; none were taking 
any form of medication or supplements during the course of the study. 
A total of 20 healthy males (10 blacks (B) and 10 whites (vV)) , aged between 19 - 60 years old , 
participated in the study. This sample size was calculated using the statistical package 
GraphPad /nStat 2. In order to compute the sample size required to achieve statistical power, 
the package requires that a key parameter be identified and that the expected standard 
deviation for this parameter be provided. In the present study, urinary oxalate and urinary 
calcium are both key parameters that are likely to be influenced by the ingestion of GLA 
supplements. Expected standard deviations for both calcium and oxalate were obtained from 
the Kidney Stone Research Laboratory's database (University of Cape Town - South Africa , 
where the present study was undertaken) of over 700 urines collected from healthy and stone-
forming males. At the desired statistical power of 80 %, calcium and oxalate each yielded a 
required sample size of n = 10. The sample size was assessed at a significance level of p-value 
= 0.05, two-tailed. 
At baseline, subjects collected blood and 24h urine samples that were used as control samples. 
Instructions on how to collect 24h urine samples were provided (Appendix 2.4) . During the 24h 
urine collection period, they recorded in a food diary the types and amounts of food that they 
consumed (Appendix 2.5) . Subjects consumed their normal diet but were instructed to avoid 
foods with high oxalate content (Appendix 2.6). GLA supplements were obtained from Solgar, 
UK (Solgar One-A-Day GLA 150 mg). Each softgel capsule contained 225 mg LA, 150 mg GLA 
and 250 mg of other fatty acids. Subjects took 2 capsules per day, one capsule with breakfast 
and one with lunch, for 30 days. 
In a previous study conducted at the Kidney Stone Research Laboratory (University of Cape 
Town , South Africa) supplementation with 80 mg GLA (Natrodale, Kuils River, South Africa) in 
healthy black and white South African male subjects for 20 days changed some of the urinary 
risk factors associated with CaOx stone formation favourably. In both groups, it was shown that 
urinary calcium excretion was significantly reduced after supplementation . Although urinary 
oxalate also decreased, it did not reach statistical significance at day 20 [7] . The present study, 
which was conducted at the same laboratory, was undertaken to further elucidate the effects of 
GLA supplementation on these and other risk factors for CaOx stone formation when a higher 
dose of GLA was given to the same group of subjects for a longer period . 
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Several studies have demonstrated that there are no health risks associated with GLA 
supplementation when doses ranging from 30 to 640 mg are given to healthy subjects [8 - 1 O] . 
24h urine samples were collected during the supplementation period on day 15 and on the last 
day of supplementation at day 30. Blood samples were also obtained on day 30. A washout 
period of 5 days was observed , after which additional 24h urine samples were collected (day 
35) to determine possible carry over effects after supplementation. Copies of the food diaries 
recorded at baseline were given to subjects prior to sample collection during the 
supplementation and washout periods so that they could follow the same dietary intake on 
those days when blood and urine samples were collected. 
2.3 EXPERIMENTAL ANALYSIS 
2.3.1 Nutrient intake assessment 
The recorded food data were translated into nutrient intake values using the Foodfinder II 
program based on South African Medical Research Council (Cape Town, South Africa) Food 
Consumption Tables [11]. 
2.3.2 Blood analysis 
Sample collection 
Before donating blood samples, subjects observed a 12-hour fast the night before which 
consisted of not eating any kinds of foods or drinking any fluids after 8 pm. At 8 am the next 
morning , blood samples were collected into 10 ml evacuated tubes (Vacutainer, USA) by a 
trained nurse. Serum separating tubes (SST) were used for collecting blood samples that were 
going to be used for the determination of serum 25(0H)D and serum TAGs. For plasma and 
RBC membrane total phospholipid analysis, blood samples were collected into tubes containing 
ethylene diamine tetraacetic acid (EDTA) as an anticoagulant. Tubes were continually mixed by 
gentle inversion and were separated into different fractions within an hour of blood collection. 
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Analysis of serum samples 
The SST tubes were centrifuged at 3000 rpm on a Heraeus Labofuge 200 centrifuge with 
Sepatech 3760 rotor (Heraeus, Germany) for 10 minutes at room temperature. The serum 
obtained was separated into 2 aliquots and immediately frozen at -20 °C for the analysis of 
25(0H)D and TAGs. 
Serum 25-hydroxyvitamin 03 analysis 
Serum 25(0H)D samples were analyzed at Pathcare Laboratories (Cape Town , South Africa). 
The measurements were performed with a DiaSorin® chemiluminescent immunoassay kit 
(DiaSorin, USA) using an automated chemistry analyzer (Modular E170 - Roche Diagnostics®, 
Germany) [12] . The first step in the assay involved the incubation of samples for 10 minutes at 
25 °C where 25(0H)D was dissociated from its binding protein and became bound to the 
specific antibody on the solid phase. The tracer, vitamin D linked to an isoluminol derivative, 
was added to the samples. This was followed by incubation of the samples at 25 °C for 10 
minutes. The unbound material was removed with a wash cycle. The starter reagents were then 
added to initiate a flash chemiluminescent reaction . The light signal , which is inversely 
proportional to 25(0H)D concentrations in the serum samples, controls and calibrators, was 
measured by the automated analyzer. 
Serum 25(0H)D concentrations above 30 ng/mL are usually regarded as normal levels in 
healthy populations [13] . In addition , when individuals have 25(0H)D concentrations between 
21 -30 ng/mL, they are regarded as vitamin D insufficient, whereas populations with 
concentrations below 20 ng/mL are considered to be vitamin D deficient. 
Serum triglycerides 
Fasting serum samples were taken to the South African Medical Research Council Laboratory 
(Tygerberg Hospital - Parow, Cape Town) for the analysis of TAGs. The concentration of TAGs 
in serum samples was determined using the Liquicolor triglyceride assay (Human, Germany) 
[14]. According to the principle of the assay, TAGs are first incubated with lipoprotein lipase to 
release glycerol and free fatty acids. This is followed by the conversion of glycerol by glycerol 
kinase (GK) and adenosine triphosphate (ATP) to form glycerol-3-phosphate (G3P) and 
adenosine-5-diphosphate (ADP). 
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G3P is then oxidized by glycerol phosphate dehydrogenase (GPO) to dihydroxyacetone 
phosphate and hydrogen peroxide (H20 2). The hydrogen peroxide further reacts with 4-
aminoantipyrine in the presence of peroxidase (POD) to give a red colored dye. The intensity of 
the color formed is proportional to the triglyceride concentration in the sample. 
Triglycerides 
Lipase ---------t•• glycerol + fatty acids 
Glycerol+ ATP 
GK ------t•- glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + 0 2 GPO .... dihydroxyacetone phosphate+ H20 2 
H20 2 + 4-aminoantipyrine POD .... quinoneimine + HCI + H20 + 4-chlorophenol 
Figure 2.1: Schematic representation for serum TAG analysis 
For the analysis of TAGs in serum, samples and blank were mixed with RGT (kit supplied 
reagent) . The resultant mixture was left for 10 minutes at 20 °C. The absorbance of the red 
complex was read at 500 nm. The concentration of serum triglycerides was calculated as: 
sample absorbance 
Concentration (mmol/L) = d d b b x standard concentration 
stan ar a sor ance 
Total phospholipid fatty acid analysis 
Sample preparation 
Red blood cells (RBCs) were separated from the plasma by centrifugation of the EDTA tubes at 
2500 rpm for 1 O minutes at room temperature. The plasma (upper phase) was removed and 
transferred into 1.5 ml safe-lock tubes (Eppendorf, Germany) and stored at -80 °C. The buffy 
coat (small white layer between the plasma and RBC) was aspirated and discarded. The RBCs 
were washed three times with saline solution (0.9 % NaCl in distilled water) by resuspension 
and centrifugation at 2500 rpm for 10 minutes; supernatant and remaining buffy coat were 
discarded after each centrifugation step. After the last wash , the packed RBCs were transferred 
into 1.5 ml safe-lock Eppendorf tubes and stored at -80 °C [15] . 
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Extraction of lipids from plasma and RBC membranes 
On the days of analysis, the stored plasma and RBC samples were thawed at room 
temperature. Total lipids were extracted from the plasma and RBC samples according to a 
modified method described by Folch et al [16]. 
Plasma (200 µL) and red blood cells (300 µL + 300 µL distilled water) were placed in 15 ml 
glass tubes with screw caps (KiMax, SA) and mixed with 3 ml of methanol by shaking with a 
vortex (BOECO Vortex Mixer V1 Plus - Optima Scientific, South Africa) for 30 s. Then 6 ml of 
chloroform was added and mixed for another 30 s on the vortex. Both methanol and chloroform 
solvents contained 0.01 % butylated hydroxytoluene as an antioxidant. The red blood cell lipid 
extract was filtered (glass funnel lined with 110 mm filter paper (Advantec, Japan)) and the clear 
filtrate collected into a clean glass tube. To the plasma and red blood cell lipid extracts, 1/5 
volume (1 .8 ml) of saline saturated with CMS (chloroform:methanol :saline, 86:14:1 , v/v/v) was 
added and the contents mixed for 20 s using a vortex and then centrifuged (Beckman ® J-6B 
Centrifuge - Soma Technology Inc, USA) at 2500 rpm for 10 min at 4 °C. The top layer was 
aspirated and discarded and the bottom layer transferred into a clean glass tube and sealed 
under nitrogen gas for storage at 4 °C until the next day or to proceed the same day. The 
extracts were dried under nitrogen in a water bath (Ecobath 207 - Labotec, South Africa) at 37 
°C until dry. The dried lipid sample was concentrated by rinsing the inside surface of the tubes 
with 1 ml CMS three times, evaporating the CMS under nitrogen in the water bath after each 
addition . The tubes containing the completely dried lipid samples were put onto ice before 
continuing with thin-layer chromatography. 
Isolation of the total phospholipid fraction 
The total phospholipid (TPL) fraction was separated from neutral lipids using the thin-layer 
chromatography (TLC) technique [15]. A solution containing petroleum ether (boiling point 40-60 
°C), diethyl ether (peroxide free) and acetic acid (90:30:1 - by volume) was prepared as the 
developing solvent. TLC pre-coated silica gel 60 plates (1 O x 1 O cm) without a fluorescent 
indicator (No. 1.05721 ; Merck, SA) were activated by drying in an oven (Heraeus, Thermo 
Scientific, South Africa) at 100 °C for 30 min and then allowed to cool to room temperature. The 
dried lipid extracts were redissolved in 1 ml ice-cold CMS, an aliquot was applied to the TLC 
plate and developed in a chromatography tank containing 30 ml of the developing solvent. 
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The developed plates were dried in a closed tank under nitrogen gas and then sprayed with 
chloroform:methanol (1 :1, by volume) containing 2,5-bis-(5'-tert.-butylbenzoxazolyl-
[2 '])thiophene (5 mg/100 ml; Sigma-Aldrich). The separated lipid bands (total phospholipid 
remaining at the origin of application) were visualized under long-wave ultraviolet light (Ultra-
violet products Inc, UK). The total phospholipid bands (origin) were scraped off into a glass 
tube, mixed with internal standard (C17:0, 54 mg /50 ml; 20 µl for plasma and RBC samples) 
and 2 ml of transmethylating reagent (TMR, 5 % sulphuric acid-methanol). The tubes were 
heated at 70 °C for 2 hours to produce FA methyl esters (FAMEs), which were recovered for 
gas chromatography (GC) analysis after cooling . 
The FAMEs were extracted by adding 4 ml n-hexane and 1 ml distilled water and shaking on a 
vortex-mixer for 30 s. The upper hexane phase was recovered and evaporated to dryness 
under a stream of nitrogen gas in a water bath at 37 °C. The FAMEs were redissolved in carbon 
disulfide (CS2 , Riedel-de Haen - BDH Chemicals, South Africa) , 20 µl for the plasma and 15 µl 
for the RBC TPl-FAMEs; 1 µl was injected in the GC for separation of the individual FAMEs 
[15] . 
Analysis of fatty acid methyl esters 
Gas chromatography was performed on a Finnigan Focus GC equipped with a flame ionization 
detector (Thermo Electron Corporation , TX, USA), using a 30 m x 0.32 mm internal diameter 
BPX 70 0.25 µm capillary column (SGE International Pty Ltd , Victoria , Australia) . Gas flow rates 
were: N2 (make up gas) , 25 mUmin; air, 250 mUmin; H2 (carrier gas) , 25 mUmin, with a split 
ratio of 20:1. Temperature programming was linear at 5 °C/min, initial temperature 140 °C, final 
temperature 220 °C, injector temperature 220 °C, and detector temperature 250 °C. The 
separated FAMEs were identified by comparing the peak retention times with those of a known 
standard FAME mixture (Nu-Check Prep Inc. MN, USA). 
For the relative total phospholipid fatty acid composition profiles the amount of each fatty acid 
was calculated as a percentage of the total sum of all identified fatty acids. Individual fatty acids 
were quantified against the internal standard peak area (C17:0) and expressed as µg/ml 
plasma and µg/ml packed RBC. When plasma or RBC TPl-FA were below the limits of 
detection (no peak integration), they were reported as "trace amount" and as nondetectable 
when no corresponding peak was observed [15]. 
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2.3.3 Urine analyses 
Urinary risk factors 
24h urine samples were collected in 2.5 l polyethylene plastic bottles without any preservatives. 
The total volume of each collected urine sample was measured using a plastic measuring 
cylinder. After measuring the volume, the urine samples were tested for bacterial infection. This 
was done by placing approximately 50 ml of the urine sample in a 100 ml glass beaker (United 
Scientific, South Africa) . Medi-test Combi 10 nitrite test strips (Macherey-Nagel , Germany) were 
dipped in the urine sample. The color changes of the test strips were compared to the color 
scale on the container of the test strips after dipping in the urine sample. A pink color was 
credited to the presence of increased bacterial concentration. None of the collected urine 
samples tested positive for bacterial infection. 
The pH of each 24h urine sample was measured using a pH meter (model pH 221 - Hanna, UK) 
at room temperature. On each day of measurement, the pH meter was calibrated with pH 7.00 
and 4.00 buffer solutions (Merck, SA). Calcium, magnesium, potassium and sodium 
concentrations in urine were determined using a flame atomic absorption spectrophotometer 
(Model 1275 - Varian Techtron AA-5, Australia) [17 - 19]. Chloride measurements were 
determined using an ion selective electrode (Metrohm, USA). 
Creatinine concentrations are measured to assess the completeness of collection in 24h urine 
samples [20] . Creatinine was estimated by the Jaffe rate method using the Synchron lX assay 
kits (Beckman Coulter Inc., UK) [21]. The assay is based on the reaction where creatinine 
combines with picrate in an alkaline solution to form a red color creatinine-picrate complex. 
Absorbance readings were taken at 520 nm and were proportional to the concentration of 
creatinine in urine. In healthy individuals, urinary creatinine concentrations are normally 
between 9 - 19 mmol/24h [20] . 
Urinary oxalate was determined using a commercial oxalate kit (Sigma Diagnostics, USA). The 
principle of the assay is based on the enzymatic conversion of oxalate by oxalate oxidase to 
carbon dioxide and hydrogen peroxide. The hydrogen peroxide reacts with 3-methyl-2-
benzothiazolinine acid and 3-(dimethylamino)benzoic acid in the presence of peroxidase to yield 
an indamine dye which has an absorbance at 590 nm. The intensity of the color produced is 
directly proportional to the concentration of oxalate in the sample. 
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Citrate was analyzed using assay kits from Boehringer Mannheim, Germany. During the first 
reaction , conversion of citric acid to oxaloacetate and acetate is catalyzed by the citrate lyase 
enzyme. In the presence of the enzymes L-malate dehydrogenase and L-lactate 
dehydrogenase, oxaloacetate and its decarboxylation product pyruvate are reduced to L-malate 
and L-lactate, respectively, by nicotinamide-adenine dinucleotide (NADH). The amount of 
NADH oxidized in the above reactions is stoichiometric to the amounts of citrate. The optical 
density of NADH was determined spectrophotometrically at 340 nm. 
The concentrations of urate and phosphorus in 24h urine samples were determined using 
commercially Synchron LX® System kits (Beckman Coulter Inc., UK). The uric acid reagent was 
used to measure the uric acid concentration by a timed-endpoint method. Uric acid was 
oxidized by uricase to produce allantoin and hydrogen peroxide. The hydrogen peroxide reacted 
with 4-aminoantipyrine and 3,5-dichloro-2-hydrobenzene sulfonate in a reaction catalyzed by 
peroxidase to produce a coloured product which was read at 520 nm. For the analysis of 
phosphate, the phosphorus reagent was used to measure phosphorus concentrations by a 
timed rate method. In the reaction , inorganic phosphorus reacted with ammonium molybdate in 
an acidic solution to form a coloured phosphomolybdate complex that had an optical density at 
365 nm. 
Ionized calcium measurements 
The concentration of unbound calcium in unfiltered urine samples was measured using a 
calcium ion-selective electrode (Metrohm 794 Basic Titrino, Germany) with KCI as a reference 
electrode [22] . The electrode was calibrated by measuring the electrode potentials of calcium 
standard solutions; and these were used to plot a calibration curve against known standard 
concentrations. The concentration of ionized calcium in urine was measured in millivolts, and 
the true value extrapolated from the calibration curve. 
Urinary PGE2 assay 
The concentration of PGE2 was determined using an enzyme-linked immunoassay (ELISA) kit 
(R&D System, USA) [23] . The assay is based on the forward sequential competitive binding 
technique in which PGE2 present in a sample competes with horseradish peroxidise (HRP)-
labeled PGE2 for a limited number of binding sites on a mouse monoclonal antibody. PGE2 in 
the sample is allowed to bind to the antibody in the first incubation. 
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During the second incubation , HRP-labeled PGE2 binds to the remaining antibody sites. 
Following a wash to remove unbound materials, a substrate solution is added to the wells to 
determine the bound enzyme activity. After color development is stopped , the absorbance is 
read at 450 nm. The intensity of the color produced is inversely proportional to the concentration 
of PGE2 in the sample. 
All the standards and samples for the assay were prepared according to the kit manufactures' 
instructions. The urine samples were prepared with a 3-fold dilution (150 µl sample + 300 µl of 
cal ibrator diluent RD5-56) . A series of standard solutions (2 500, 1 250, 625, 313, 156, 78 and 
39 pg/ml) were prepared by diluting the PGE2 standard stock solution (25,000 pg/ml) with 
calibrator diluent RD5-56. These were used to generate a standard curve for the assay with 
GraphPad Prism 6 as shown in Figure 2.2. A 500 ml wash buffer solution was prepared by 
diluting 20 ml of wash buffer concentrate with distilled water. The substrate solution was 
prepared by mixing together the color reagents A and B in equal volumes 15 minutes before 
use. 
A 96-well plate coated with a goat anti-mouse polyclonal antibody was included in the kit 
supplied . The diluted urine samples, blanks and standard solutions (150 µl) were first added to 
the microplate. For the assay, each plate contained 2 blanks, 2 non-specific binding wells 
(NSB) , 2 maximum binding wells (Bo) and an 8 point standard curve run in duplicate. Each 
urine sample was run once. 
The plate was incubated with 50 µl of the antibody for 1 hour at room temperature on a 
horizontal orbital shaker (Genie 2 vortex, Scientific Industries Inc. , South Africa). 50 µl of the 
PGE2 conjugate was added to all the wells, and the plate was further incubated for 2 hours at 
room temperature on the shaker. All the unbound materials were removed by aspirating and 
washing the wells with the wash buffer, and this was done four times. After the last wash, the 
plate was dried by blotting with a clean paper towel. Color development was generated by 
adding 200 µl of the substrate solution to the wells , followed by 30 minute incubation at room 
temperature. The reaction was stopped by adding 100 µl of the stop solution to the wells. The 
intensity of the generated color was read on a microplate reader (SpectraMax 340 PC 384, 
USA) at 450 nm and 540nm. To correct for optical imperfections in the plate, absorbance 
readings at 540 nm were subtracted from the readings at 450 nm. After making corrections for 
the dilution of the samples (dividing by the dilution factor) , the concentrations of the PGE2 in the 
samples were extrapolated from the prepared calibration curve. 
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Figure 2.2: PGE2 calibration curve prepared using standard solutions 
Urinary hydroxyproline assay 
Aliquots of urine samples from randomly selected subjects (5 blacks and 5 whites) that were 
collected at baseline and day 30 were sent to National Health Laboratories (Red Cross Hospital , 
Cape Town) for the analysis of hydroxyproline (HYP). HYP was quantified in urine samples 
using the gas chromatography mass spectrometry (GCMS) technique. Amino acids were 
extracted from 100 µL of acidified urine samples by solid phase extraction onto a cation 
exchange column before being washed , eluted and derivatised to their corresponding alkyl 
chloroformates using a commercial kit (EZ:faast, Phenomenex, Torrance CA, USA) [24] . After 
derivatisation , the amino acids were extracted into solvent and 2 µL injected into an Agilent 
7890A/5975C GCMS system fitted with a Zebron ZB AAA 10 m x 0.25 mm capillary GC column. 
The samples were injected at 1: 10 split and 250 °C. Helium was used as the carrier gas at 1.65 
ml/min , and the column heated from 110 °C to 320 °C at 30 °C per minute. 
The amino acids were quantified using a norvaline internal standard against a standard curve 
generated from a traceable calibrator using the following ions and (qualifier ions): 
hydroxyproline - mz 172 (86.1 ), and norvaline - mz 158 (72, 116). Urine creatinine 
concentrations were used to adjust for variation in bone mass within groups and urinary HYP 
concentrations are reported as a ratio with creatinine (HYP:Creatinine - nmol/mg creatinine) 
[25] . 
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2.3.4 Crystallization experiments 
CaOx metastable limit determination 
The CaOx metastable limit (MSL) of each urine sample was determined according to the 
method described by Ryall et al [26] . MSL is defined as the lowest oxalate concentration 
required to produce microscopically detectable crystals in urine. Na20x standard solutions 
needed for the experiment were prepared according to the procedure described in the paper 
[26]. For each collected 24h urine sample, a 200 ml aliquot was filtered through 0.75 mm filter 
paper (Macherey-Nigel , Germany) followed by 0.45 µm cellulose nitrate filters (Sartorius Stedim 
Biotech , Germany). 10 mls of the filtered urine were transferred into 13 coulter cups and 
warmed at 37 °C in an oven (Memmert, Germany) for 1 O minutes. 
To initiate CaOx precipitation, 100 µL of the Na20x standard solutions were added to each cup 
1 minute apart, at increasing concentrations from 15 to 195 mM (in increments of 15 mM) to 
give final concentrations of 0.15 to 1.95 mM. The samples were further warmed at 37 °C. After 
30 minutes, absorbance was measured with an ultraviolet/visible (UV) spectrophotometer 
(Specord 40 Analytik Jena, UK) at a wavelength of 620 nm. The measured absorbance was 
plotted against the final concentration of the dosed urine samples, and the metastable limit was 
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Figure 2.3: A typical CaOx metastable limit plot 
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CaOx crystallization kinetics 
Once the metastable limit was determined, the rate of CaOx crystallization in the urine samples 
was studied . Approximately 50 ml of the filtered urines were transferred into a 150 ml soda 
lime bottle (United Scientific, South Africa). The urine samples were then dosed with 0.50 ml 
Na20x using a concentration of 15 mM above the previously determined MSl, and incubated at 
37 °C in a shaking water bath (labex, South Africa) at 100 rpm for 2 hours. In the black 
subjects, particle number was measured by a Coulter Multisizer (Coulter Electronic Ltd - serial 
no 030288, UK) using a 100 µM orifice aperture every 30 minutes. However, this instrument 
broke down irreparably after measurements in the black group were completed. As such, it was 
not possible to use it to measure the rate of CaOx crystallization in the white group. Thus, the 
formation rate of particles in the white group was determined by measuring absorbance at 620 
nm every 30 minutes using a spectrophotometer (Specord 40 Analytik Jena, UK) . Plots of 
absorbance, and where appropriate particle number, versus time were constructed; and the 
slope of the linear portion in these plots was taken as the measure of the rate of crystallization. 
Thus, although different instruments were used to measure crystallization kinetics in the two 
groups, the effects (if any) of GlA ingestion , within each group, could be routinely determined. 
2.3.5 Risk indices 
To evaluate the possible effect of GlA supplementation on urinary supersaturation of stone 
salts, risk indices, based on lithogenic components, were calculated. 
The Tiselius risk index (TRI) predicts the risk of CaOx stone formation [27] and was determined 
by the mathematical formula : 
(Ca/Cr)0·71 x (Ox/Cr) 
TRI=~~~~~~~~­
(Mg/Cr)o.14 x (Cit/ Cr)o.10 
where Ca (calcium), Ox (oxalate), Mg (magnesium) and Cit (citrate) were expressed in mmol and Cr (creatinine) in 
mo/L. 
Urinary concentrations of calcium, oxalate, phosphate, citrate, urate, magnesium, sodium and 
potassium were used as input for the speciation program EQUll 2 [28] to calculate the 
supersaturation (SS) of various salts including calcium oxalate monohydrate (COM), calcium 
hydrogen phosphate dihydrate (brushite) and uric acid (UA). 
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2.3.6 Statistical analysis 
All data are presented as mean ± SE (standard error) . The lnstat GraphPad3 software program 
was used to test for statistical significance. For both study groups, student's paired t-test was 
applied to assess the outcomes of measurements during the supplementation period ( days 15 & 
30) and at day 35 compared to baseline values. The differences between groups at each 
sample collection period were determined using the unpaired t-test. Two sets of data were 
considered significantly different from each other when the p-value:::; 0.05. Microsoft Excel 2010 
was used for the preparation of graphs with standard error bars. Urine collections were 
excluded from statistical analyses if the creatinine concentrations were < 9 mmol/24h [20]. 
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2.4 RESULTS 
2.4.1 Subject characteristics 
The mean age of black and white subjects at baseline are shown in Table 2.1. Raw data 
showing the age, height, weight and BMI for each individual are presented in Appendix 2.7. 
There were no significant differences observed with regards to age and BMI between the 
groups. 
~able 2.1 
Subject's characteristics at baseline - n-6 FA study 
Parameter Blacks Whites p-value 
Age 21.8±1.47 23.6 ± 3.32 0.6257 
BMI 23.5 ± 1.15 24.8 ± 0.82 0.3795 
2.4.2 Nutrient intakes 
Raw data showing the nutrient intakes for each individual are shown in Appendix 2.8. The 
results for the calculated nutrient intakes of black and white subjects recorded at baseline will 
be discussed in Chapter 8 because normal dietary intake of the two groups is not the main 
focus of the present study. 
2.4.3 Supplement compliance test 
The fatty acid composition of cell membranes has been shown to be dependent on both dietary 
fatty acid intakes and metabolic pathways [29 - 31]. Since subjects were given capsules that 
contained GLA, changes in the concentration of GLA in RBCs total phospholipids were used to 
test for compliance after supplementation. RBCs were chosen because they have a lifespan of 
120 days and the FA profile in these cells has been shown to reflect the amounts of dietary fatty 
acid intakes [32, 33] . Five subjects from each study group were randomly selected for the test. 
Changes in the concentrations of fatty acids in RBC membranes were calculated as follows 
[15]: 
final concentration - baseline concentration 
% Change = x 100 
baseline concentration 
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Table 2.2 shows the percentage changes in the concentrations of GLA and DGLA after 
supplementation for the subjects that were selected for the compliance test. Raw data showing 
the FA composition (as concentration (µg/ml)) in RBC total phospholipids for each individual 
are presented in Appendix 2.9. 
In both study groups, the concentrations of GLA were extremely low for most subjects that were 
selected and could not be quantified as shown in Table 2.2. In the present study, the 
concentrations of GLA in RBCs total phospholipids were expected to increase in response to 
dietary supplementation [32 , 33] . These results imply that the observed FA composition in RBC 
total phospholipids is not due to GLA supplementation . The absence of change in GLA 
concentrations in plasma total phospholipids after supplementation may be explained by two 
hypotheses. 
rTable 2.2 
Concentrations (1,.19/ml) of GLA and DGLA in RBC total phospholipids 
after n-6 FA supplementation 
GLA DGLA 
Subject 
Day O Day 30 % Change Day O Day 30 % Change 
8-1 trace 1.35 ND 14.0 18.3 30.9 
8-2 trace trace ND 13.1 13.4 1.64 
8-3 1.30 1.34 3.65 22.9 19.5 -15.0 
8-4 0.71 trace ND 29.5 31 .7 7.51 
8-5 trace trace ND 20.5 16.3 -20.8 
W-1 trace trace ND 17.4 15.8 -9.28 
W-2 trace trace ND 12.4 10.0 -19.4 
W-3 trace trace ND 14.5 7.52 -48.2 
W-4 trace trace ND 11 .9 15.4 28.9 
W-5 trace trace ND 11 .6 6.10 -47.6 
ND = not determined 
B = blacks and W = whites 
Firstly, it was assumed that the steps involved in the pathways of fatty acid synthesis and 
metabolism occurred very quickly, and that GLA was rapidly converted into DGLA. Fan et al 
reported that the step for the conversion of GLA into DGLA occurs very quickly in humans [34] . 
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Therefore, the percentage changes in the concentration of DGLA in RBC total phospholipid 
were calculated to determine supplement compliance because it was assumed that the DGLA 
concentrations after supplementation were partly due to the metabolism of GLA to DGLA. The 
concentrations of DGLA in RBC total phospholipids for each subject that was selected for the 
compliance test are shown in Table 2.2. 
The mean percentage change for DGLA was 0.86 (p-value = 0.9716) in blacks and -19.1 (p-
value = 0.2855) in whites. The negative value for the mean percentage change of DGLA in the 
white group indicates that mean concentrations of DGLA at day 30 were lower than at day 0, 
hence the non-significant increase in the percentage change that was observed. These results 
suggest that there was no significant increase in DGLA concentrations after supplementation 
and that the fatty acid composition of DGLA in RBCs does not reflect the metabolism of GLA. It 
has been reported that RBCs are not efficient in synthesizing and metabolizing fatty acids [31) ; 
which might explain why there is no significant change in the concentrations of DGLA in the 
present study. The non-significant changes in both GLA and DGLA concentrations have been 
observed in RBC phospholipids of older subjects after GLA supplementation for 3 months with a 
dose similar to the one used in the present study [35) . 
Therefore, it is suggested that the FA composition of RBC total phospholipids after 
supplementation in the present study does not reflect the amounts of GLA given during the 
supplementation period and that GLA was not metabolized to form DGLA. Therefore, 
supplement compliance could not be determined by measuring the changes in GLA or DGLA 
concentrations. 
The second hypothesis is that instead of being incorporated into phospholipids, GLA becomes 
incorporated into other lipid fractions. It has been shown that the FA composition of cholesterol 
ester is closely associated with the amounts of dietary fatty acid intakes [36) . In other studies, 
van Rooyen et al [37] and Brouwer et al [38] reported a significant increase in GLA 
concentrations in the FA profile of cholesterol ester and triglycerides after GLA supplements 
were given to animals and healthy subjects. Unfortunately, due to financial constraints, the 
changes in GLA concentrations in cholesterol ester and triglycerides could not be determined as 
a measure of supplement compliance in the present study. Overall , supplement compliance was 
not confirmed by calculating the changes in the fatty acid composition of GLA in RBCs after 
supplementation. As a result, supplement compliance was determined using another technique, 
as described in the paragraph below. 
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In addition to measuring the changes in FA composition after supplementation , supplement 
compliance can also be determined by counting the number of capsules returned after the end 
of a study [39, 40]. Compliance is considered to be complete if more than 85 % of the capsules 
given to subjects are consumed during the entire supplementation period [41, 42]. In the 
present study, compliance was monitored by instructing the subjects to come to the laboratory 
where the study was undertaken every 10 days to collect the next supply of supplements and 
also to keep all the supplements that they missed taking. At each laboratory visit, they reported 
on side effects that they experienced while taking the supplements and also answered 
questions about supplement compliance. None of the participants returned GLA capsules on 
completing the study and also there were no side effects observed. Since > 85 % of the 
capsules given to subjects were consumed , it was concluded that the subjects had complied 
with the supplement protocol. 
2.4.4 Serum biomarkers and FA profiles in plasma total phospholipids 
It should be noted that in the following discussion , the results for the measurement of fatty acids 
are presented as both absolute amounts (where concentration is expressed as µg/ml plasma) 
and as relative percentages (where the amount of each fatty acid was calculated as a 
percentage of the total sum of all identified fatty acids) . In certain diseases, the fatty acid 
compositions in various lipid fractions of subjects are usually reported as the percentage 
composition of all identified FAs [29 - 33; 35 - 38]. Hence, when the results of the present study 
are compared to literature data, only the percentage composition of fatty acids in plasma will be 
compared. However, absolute amounts are also important because they have been shown to 
reflect their possible availability for metabolite synthesis [43] . In addition, the fatty acids that are 
of particular interest to the present study are n-6 FAs such as GLA, DGLA, AA and n-3 FAs 
such as EPA and DHA. These fatty acids have been directly linked to stone formation [1- 2, 4] , 
and they will be the main focus for this study. 
Baseline 
Concentrations of serum biomarkers and plasma FA profile in black and white subjects are 
shown in Table 2.3. Raw data showing the concentrations of serum 25(0H)D and TAGs for 
each subject are presented in Appendices 2.10 and 2.11 , respectively. Raw data showing the 
concentrations of FAs in plasma phospholipids for each individual are presented in Appendix 
2.12. 
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il"able 2.3 




Day O Day 30 p-value DayO 
Serum biomarkers 
25(0H)D (ng/ml) 13.6 ± 1.45 13.5 ± 1.26 0.9587 33.7 ± 3.71 
TAGs (mmol/L) 0.71 ± 0.10 0.84 ± 0.09 0.3348 1.14±0.14 
SFAs (µg/mL) 
C14:0 MA 3.36 ± 0.89 2.79 ± 0.59 0.6001 4.23 ± 0.64 
C16:0 PA 246 ± 13.2 248 ± 10.5 0.9152 262 ± 21 .0 
C18:0 SA 134 ± 6.56 132 ± 7.80 0.8405 113 ± 9.50 
20:0 ARA 5.18±1.07 4.60 ± 0.36 0.6121 3.57 ± 0.33 
22:0 BA 13.7±1 .16 14.1 ± 0.90 0.7993 7.73 ± 0.88 
24:0 LGA 12.7 ± 1.21 13.3 ± 0.96 0.7110 7.35 ± 1.16 
MUFAs (µg/mL) 
C16:1 n-7 PTA 2.64 ± 0.28 3.21 ± 0.71 0.4658 5.15±1.09 
C18:1 n-9 OA 62.8 ± 4.51 73.8 ± 8.90 0.2852 79.3 ± 8.50 
C18:1 n-7 VA 10.3 ± 0.41 8.86 ± 0.50 0.0426* 8.32 ± 1.03 
20:1 n-9 GA 1.78 ± 0.38 1.17±0.09 0.0962 ND 
24:1 n-9 14.9 ± 0.97 16.5±1 .17 0.2945 8.07±1.15 
n-6 FAs (µg/mL) 
C18:2 n-6 LA 203 ± 10.6 202 ± 10.7 0.9431 187 ± 12.7 
C18:3 n-6 GLA ND ND ND ND 
C20:2 n-6 EDA 3.59 ± 0.18 3.44 ± 0.21 0.5971 2.78 ± 0.42 
C20:3 n-6 DGLA 29.7 ± 4.50 34.9 ± 3.64 0.3805 22.2 ± 2.36 
C20:4 n-6 AA 109 ± 5.62 104 ± 4.71 0.4880 85.1 ± 10.4 
C22:4 n-6 ADRA 4.60 ± 0.17 5.23 ± 0.60 0.3210 3.46 ± 0.34 
C22:5 n-6 DPA 3.55 ± 0.30 3.33 ± 0.32 0.6228 2.38 ± 0.18 
n-3 FAs (µg/mL) 
C18:3 n-3 ALA ND ND ND 3.48 ± 1.31 
C20:5 n-3 EPA 3.13 ± 0.42 3.20 ± 0.69 0.9370 5.13 ± 0.86 
22:5 n-3 DPA 6.74 ± 0.56 6.44 ± 0.62 0.7246 5.83 ± 0.73 
C22:6 n-3 DHA 37.6 ± 3.84 31 .0 ± 1.81 0.1353 28.2 ± 3.69 
* : p-value s 0.05 compared to baseline (intragroup comparison) 
*: p-va/ue s 0.05 (intergroup comparison) 
Whites B vs W (p-values) 
Day 30 p-value Day O Day 30 
28.8 ± 2.67 0.2975 <0.0001 * <0.0001 * 
1.02±0.13 0.5293 0.0250* 0.2869 
4.59 ± 0.87 0.7422 0.4380 0.1032 
282 ± 29.7 0.5947 0.5317 0.2994 
131±11.4 0.2481 0.0881 0.9401 
4.68 ± 0.38 0.0435* 0.1859 0.8832 
10.9 ± 1.12 0.0375* 0.0007* 0.0404* 
9.76 ± 1.21 0.1659 0.0048* 0.0335* 
4.15±0.74 0.4434 0.0250* 0.3712 
93.6 ± 8.30 0.2458 0.1037 0.1220 
10.1 ± 1.26 0.2901 0.0962 0.3748 
ND ND ND 0.1908 
12.2 ± 1.56 0.0461 * 0.0003* 0.0404* 
212±12.8 0.1777 0.3342 0.5580 
ND ND ND ND 
3.18 ± 0.33 0.4656 0.0605 0.5004 
30.7 ± 2.21 0.0173* 0.1612 0.3410 
105 ± 9.93 0.1908 0.0583 0.9413 
4.37 ± 0.48 0.1649 0.0049* 0.2795 
3.10 ± 0.56 0.3720 0.0316* 0.7196 
3.80 ± 1.93 0.9046 ND ND 
5.58 ± 1.23 0.7723 0.0479* 0.1009 
7.18 ± 0.87 0.2560 0.3331 0.4963 
32.5 ± 3.95 0.4355 0.0931 0.7337 
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Serum concentrations of 25(0H)D and TAGs were found to be significantly lower in the black 
subjects compared to the white subjects. These results are in agreement with previous 
studies where lower 25(0H)D concentrations (range 6.00 ± 1.00 to 19.6 ± 10.0, ng/ml) were 
observed in black subjects compared to white subjects (range 20.0 ± 2.00 to 34.8 ± 13.2, 
ng/ml) [44 - 49]. Several studies have also reported on the significantly lower serum 
triglyceride concentrations in the black population compared to the white population [50 -
54]. In these studies, the TAG ranges in the black group were reported as 0.43 ± 0.10 to 1.12 
± 0.64 mmol/L whereas in whites, the TAG concentrations were in the range of 0.79 ± 0.37 to 
1.46 ± 1.03 mmol/L. 
The differences in the concentrations of FAs in plasma total phospholipids between the 
groups at baseline are shown in Table 2.3 and are summarized in Table 2.4. 
Table 2.4 
Summary of significant differences in concentrations 
of FAs (µg/ml) between groups at day O - n-6 FA study 
FA class Type of FA BvsW 
SFA BA, LGA B >W+ 
PTA B<W+ 
MUFA 
24:1 n-9 B>W+ 
ADRA, DPA (n-6 FA) B>W+ 
PUFA 
EPA B<W+ 
:i: . . p-va/ue :5 0.05 (intergroup companson) 
The percentage compositions of FAs in plasma total phospholipids between the two groups 
were compared and are shown in Table 2.5. Raw data showing the percentage composition 
of FAs in plasma phospholipids for each individual are presented in Appendix 2.13. 
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!Table 2.5 
Percentage composition of FAs in plasma total phospholipids after n-6 FA supplementation 
Blacks 
Parameter 
DayO Day 30 p-value Day O 
SF As 
C14:0 MA 0.36 ± 0.09 0.30 ± 0.05 0.5485 0.51 ± 0.07 
C16:0 PA 27.0 ± 0.55 27.2 ± 0.44 0.7118 31.4 ± 0.85 
C18:0 SA 14.7 ± 0.32 14.4 ± 0.29 0.5239 13.5 ± 0.44 
20:0ARA 0.55 ± 0.08 0.50 ± 0.03 0.6252 0.41 ±0.03 
22:0 BA 1.50 ± 0.10 1.56 ± 0.10 0.6509 0.92 ± 0.07 
24:0 LGA 1.39±0.10 1.47 ± 0.10 0.5893 0.86 ± 0.09 
MUFAs 
C16:1 n-7 PTA 0.29 ± 0.03 0.34 ± 0.06 0.5004 0.56 ± 0.11 
C18:1 n-9 OA 6.88 ± 0.37 7.88 ± 0.61 0.1781 9.28 ± 0.35 
C18:1 n-7 VA 1.14±0.06 0.99 ± 0.07 0.1197 0.99 ± 0.09 
120:1 n-9 GA 0.19 ± 0.04 0.12 ± 0.01 0.1172 0.29 ± 0.02 
124:1 n-9 1.64 ± 0.08 1.84±0.15 0.2481 0.95 ± 0.11 
n-6 FAs 
C18:2 n-6 LA 22.3 ± 0.84 22.2 ± 0.71 0.9043 22.6 ± 0.79 
C18:3 n-6 GLA ND ND ND ND 
C20:2 n-6 EDA 0.40 ± 0.02 0.38 ± 0.02 0.5222 ND 
C20:3 n-6 DGLA 3.26 ± 0.46 3.81 ± 0.37 0.3663 2.63 ± 0.14 
C20:4 n-6 AA 12.1 ± 0.74 11 .5 ± 0.52 0.4814 9.91 ± 0.60 
C22:4 n-6 ADRA 0.51 ± 0.03 0.57 ± 0.05 0.3945 0.37 ± 0.02 
C22:5 n-6 DPA 0.39 ± 0.03 0.36 ± 0.03 0.4889 0.26 ± 0.03 
n-3 FAs 
C18:3 n-3 ALA ND ND ND 0.53 ± 0.21 
C20:5 n-3 EPA 0.35 ± 0.04 0.33 ± 0.05 0.7620 0.56 ± 0.07 
122:5 n-3 DPA 0.75 ± 0.06 0.70 ± 0.04 0.5015 0.65 ± 0.04 
C22:6 n-3 DHA 4.10 ± 0.32 3.49 ± 0.29 0.1780 3.45 ± 0.59 
* : p-va/ue :S 0.05 compared to baseline (intragroup comparison) 
:1: : p-value :S 0.05 (intergroup comparison) 
Whites B vs W (p-values) 
Day 30 p-value DayO Day 30 
0.45 ± 0.05 0.4760 0.1976 0.0441* 
28.8 ± 0.96 0.0602 0.0004* 0.1511 
13.5 ± 0.40 0.9604 0.0459* 0.0950 
0.48 ± 0.03 0.1037 0.1538 0.5688 
1.12±0.09 0.0895 0.0001 * 0.0057* 
1.01 ±0.10 0.2451 0.0009* 0.0042* 
0.41 ± 0.05 0.1781 0.0169* 0.3711 
9.71 ± 0.35 0.4006 0.0002* 0.0171 * 
1.04 ± 0.11 0.7278 0.1980 0.6838 
0.33 ± 0.03 0.3751 ND 0.1286 
1.24 ± 0.10 0.0697 0.0001 * 0.0033* 
22.4±1 .10 0.9188 0.8163 0.8392 
ND ND ND 0.6274 
ND ND 0.0054* 0.2401 
3.22 ± 0.16 0.0123* 0.2032 0.1599 
10.8 ± 0.46 0.2682 0.0310* 0.3154 
0.45 ± 0.03 0.0724 0.0056* 0.0667 
0.31 ± 0.04 0.4526 0.0146* 0.2465 
0.35 ± 0.14 0.4743 0.8109 ND 
0.53 ± 0.07 0.7948 0.0234* 0.0378* 
0.73 ± 0.06 0.2984 0.2109 0.6499 
3.33 ± 0.29 0.8575 0.3485 0.7113 
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The differences between groups that were observed at baseline are summarized in Table 
2.6. 
Table 2.6 
Summary of significant differences in the % compositions 
of FAs between groups at baseline - n-6 FA study 
FA class Type of FA BvsW 
PA B<W:t. 
SFA 
SA, BA, LGA B>W:t. 
MUFA PTA, OA, 24:1 n-9 B<W:t. 
EDA, AA, ADRA, DPA (n-6 FA) B>W:t. 
PUFA 
EPA (n-3 FA) B<W:t. 
*: p-value :5 0.05 (intergroup comparison) 
Post supplementation 
The effects of supplementation on the concentrations of serum biomarkers and FAs in 
plasma phospholipids within groups are shown in Table 2.3. In both study groups, 
supplementation with GLA did not result in significant changes in the concentrations of 
serum 25(0H)D and TAGs. Within the black group, VA concentrations decreased 
significantly after supplementation at day 30. No significant changes in the concentrations of 
SFAs and FAs were observed. In the white group, GLA supplementation resulted in a 
significant increase in ARA, BA and 24:1 n-9 concentrations. More importantly, the 
concentration of DGLA (n-6 FA) was increased significantly compared to baseline 
concentrations. 
The effects of supplementation on the percentage compositions of FAs in plasma 
phospholipids within groups are shown in Table 2.5. The changes in the percentage 
composition of FAs relevant to the present study are illustrated in Figures 2.4 and 2.5. The 
percentage composition of n-3 and n-6 FAs in plasma total phospholipids did not show any 
significant change in the black group (Figure 2.4) whereas in whites, the percentage 
composition of DGLA was significantly increased after supplementation as shown in Figure 
2.5. There were no significant changes in the percentage composition of the other FAs 
(Table 2.5) . 
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Figure 2.5: Percentage composition of PUFAs in whites after n-6 FA supplementation 
After supplementation, there were no significant differences in the concentrations and 
percentage compositions of FAs in plasma phospholipids between the two groups (Table 2.3 
and 2.5) . The only major difference was a lower percent composition of MA in blacks 
compared to whites (Table 2.5) . It was noted that although the concentrations of serum 
25(0H)D, SFAs (BA and LGA) and MUFAs (24:1 n-9) were significantly different between 
groups at day 30, these differences were not attributed to the effect of supplementation since 
they were also present at baseline. 
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Similarly, the percentage composition of SFAs (BA and LGA), MUFAs (OA and 24:1 n-9) 
and n-3 FA in the form of EPA remained significantly different between groups at day 30. 
2.4.5 Urinary risk factors 
Baseline 
Baseline urine parameters in blacks and whites are shown in Table 2.7. Raw data showing 
the urinary composition of each subject are presented in Appendix 2.14. At baseline, oxalate 
was significantly higher in blacks, whereas phosphate and the SS brushite were lower. The 
concentrations of phosphate remained significantly lower in blacks throughout the study on 
days 15, 30 and 35. 
Post-supplementation 
Urine values in blacks and whites post supplementation are given in Table 2.8. In blacks, the 
significant increases in the magnesium concentration and in TRI at day 30 relative to 
baseline are in conflict with each other since the former effect should have caused a 
decrease in TRI. An explanation for this anomaly is not obvious, but may be due to subtle, 
non-significant changes in the other urinary parameters which are used to determine TRI , 
such as the concentrations of calcium, oxalate and citrate. 
In whites, different parameters were affected at day 30, but TRI also increased as in blacks. 
The significant increases in citrate and oxalate might have been expected to cancel with 
respect to their effects on TRI, but it is clear that the increase in oxalate dominated, together 
with subtle other changes, as alluded to in the black group. The decrease in the 
concentration of ionized Ca2+ in whites at day 30 is interesting, but surprisingly, this did not 
affect SS values of the calcium-containing salts, Ca Ox and brushite. 
Changes in urinary parameters appeared to occur earlier (i.e. day 15) in whites than in 
blacks, but the latter group showed a greater sensitivity towards "carry-over" effects. 
Ultimately, when the risk ratios TRI and SS changed significantly, they did so unfavourably, 
thereby indicating that GLA has a negative effect on this important risk indicator. 
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rTable 2.7 
Comparison of urinary risk factors between groups a1 
baseline- n-6 FA study 
Parameter Blacks Whites p-values 
pH 6.45 ± 0.14 6.20 ± 0.08 0.1355 
Volume (ml/24h) 1370±149 983 ± 118 0.0559 
Calcium (mmol/24h) 1.71 ± 0.17 2.03 ± 0.23 0.2839 
Chloride (mmol/24h) 133 ± 13.2 113±16.5 0.3577 
Citrate (mmol/24h) 2.18 ± 0.33 1.83±0.18 0.3727 
Creatinine (mmol/24h) 18.3 ± 1.06 17.2 ± 1.40 0.5282 
Magnesium (mmol/24h) 1.36 ± 0.14 1.92 ± 0.28 0.0944 
Oxalate (mmol/24h) 0.26 ± 0.02 0.20 ± 0.02 0.0358; 
Phosphate (mmol/24h) 22.6 ± 1.50 32 .5 ± 2.77 0.0057; 
Potassium (mmol/24h) 26.9 ± 1.52 27.3 ± 1.58 0.8643 
Sodium (mmol/24h) 99.5 ± 7.43 96.0 ± 5.30 0.7081 
Urate (mmol/24h) 3.47 ± 0.23 3.31 ± 0.28 0.6607 
Ionized Ca.1+ (mmol/L) 0.37 ± 0.08 0.48 ± 0.09 0.3737 
PGE2 (ng/24h) 711 ± 84.2 534 ± 39.0 0.0725 
HYP (nmol/mg creatinine) 1.46 ± 0.32 1.11 ± 0.19 0.3789 
MSL (mM) 1.03±0.16 0.90 ± 0.14 0.5524 
TRI 120 ± 8.05 115±13.4 0.7189 
SS CaOx 2.80 ± 0.30 3.64 ± 0.31 0.0686 
SS Brushite 0.77 ± 0.17 1.43 ± 0.25 0.0391 ; 
SS Uric acid 1.04 ± 0.38 1.84 ± 0.34 0.1315 
; : p-value :5 0.05 (intergroup comparison) 

























































































































































































































































































































































































































































































































































































































































Chapter 2 Results 
Intergroup comparisons 
Comparison of urine parameters between blacks and whites on each day of the experiment 
are shown in Table 2.9. Significant differences between the black and white groups for any 
urinary parameter on any particular day (days 15, 30 or 35) can only be attributed to GLA 
ingestion if the same difference did not occur in baseline urines. Thus the significantly lower 
phosphate concentration in blacks relative to whites on days 15, 30 and 35 can be ignored. 
However, the significantly lower citrate and higher ionized Ca2+ in blacks relative to whites on 
day 30 may be tentatively attributed to the ingestion of GLA, for reasons which are not 
apparent. Finally, the significantly higher calcium and significantly higher TRI in blacks 
relative to whites in the carry-over period may be similarly attributed to GLA ingestion. While 
the explanations for these effects are not obvious, an important point is that black and white 
subjects have responded differently to GLA, thereby yet again drawing attention to the 
possibility of different handling mechanisms in the two race groups. 
2.4.6 CaOx MSL and crystallization kinetics studies 
The average CaOx MSL for black and white subjects observed on days 15, 30 and 35 are 
shown in Table 2.10. The p-values are shown in Table 2.11 . In both groups, there were no 
significant differences observed in the CaOx MSL values during the supplementation period 
on days 15 and 30 compared to baseline. At day 35, a significant increase in the CaOx MSL 
(p-value = 0.0221) was observed in the black group whereas in whites the MSL was not 
statistically significant (Table 2.11 ). 
The p-values for the CaOx MSL intergroup comparisons on each day of the experiment are 
shown in Table 2.11 . The CaOx MSL between groups was not statistically significant. 
The rates of particle formation during the supplementation and washout periods compared to 
baseline are shown in Figures 2.6 and 2.7 for blacks and whites, respectively. Each curve is 
the mean of two experiments. The mean values for each group are shown in Table 2.10 and 
the p-values are shown in Table 2.11 . Raw data for each experiment are presented in 
Appendix 2.16. 
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Chapter 2 Results 
In the black group, non-significant increases in particle formation kinetics were observed 
during the supplementation and washout periods compared to baseline. Within the white 
group, the rate of particle formation during the supplementation and washout periods was 
higher than that in baseline samples, but differences were not statistically different. 
Differences in crystallization rates between blacks and whites were not compared since they 
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Figure 2.6: Rates of particle formation in blacks after n-6 FA supplementation 
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Figure 2.7: Rates of particle formation in whites after n-6 FA supplementation 
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2.5 DISCUSSION 
Risk factors for CaOx stone disease can be broadly divided into two classes - those 
associated with blood (serum and plasma) biochemistry and those associated with urine 
physical chemistry. As mentioned in Chapter 1 - page 15, diet influences stone formation by 
altering urine chemistry, and will be discussed in Chapter 8. In the present study, the effects 
of dietary supplementation with GLA on serum, plasma and urinary risk factors for CaOx 
stone formation in healthy subjects were evaluated. 
2.5.1 Serum biomarkers 
Supplementation did not show any effect on the serum concentrations of 25(0H)D and 
TAGs in both population groups. Comparison of these results with other studies is not 
possible because the effect of GLA supplementation on these serum biomarkers has not 
been previously reported. In the USA, individuals with dark skin have been shown to have 
significantly lower serum 25(0H)D concentrations compared to individuals who are lighter 
skinned [44 - 46]. This is mainly attributed to melanin , a pigment on the surface of the skin, 
which protects the skin against ultraviolet light [44, 49]. As a result, the darker pigmentation 
of black subjects reduced the ability of the skin to convert vitamin D from the sun to 25(0H)D 
[49]. As such, the results of the present study are important, albeit that no supplementation 
effects were observed . 
2.5.2 Plasma total phospholipids 
Baseline 
Comparison of the percentage composition of FAs in plasma phospholipids at baseline 
showed that there were several differences between the two race groups (Table 2.5). Similar 
to the present study, Steffen et al found a significantly higher percentage composition of AA 
in plasma phospholipids of black subjects compared to the white subjects from the USA [55] . 
Although several studies have investigated the percentage compositions of FAs in plasma 
phospholipids of both black and white subjects, the differences that were observed in these 
latter studies [56 - 58] were not confirmed in the present study. 
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It is suggested that the differences between blacks and whites observed in the present study 
are caused by the different dietary habits of the two groups since fatty acid composition in 
plasma total phospholipids reflects dietary intakes of fatty acids [30 - 31 , 59]. However, the 
percentage compositions of FAs in plasma total phospholipids of both groups were found to 
be in agreement with those reported by other investigators in healthy populations [60- 64]. 
Post-supplementation 
In both groups, only trace concentrations of GLA in plasma total phospholipids before and 
after supplementation were detected (Appendices 2.9 and 2.10). These results are similar to 
observations made by Yoshimoto-Furuiel et al [65] where change in the percentage 
composition of GLA in plasma total phospholipids was not observed after a protocol in which 
subjects were given 2 g GLA per day for 6 weeks. In the same study, the percentage 
composition of GLA in plasma cholesterol ester and triglycerides was reported to have 
increased significantly compared to baseline concentrations. It is suggested that the trace 
amounts of GLA detected in the present study are due to the limited incorporation of GLA in 
plasma phospholipids. Since the compositions of fatty acids in cholesterol ester and 
triglycerides were not determined because of financial constraints, the changes in GLA after 
supplementation could not be confirmed. However, the concentrations and percentage 
compositions of GLA in these lipid fractions are expected to increase since the fatty acid 
compositions in various lipid fractions reflects dietary intakes of fatty acids [30 - 31 ]. 
Despite these results, GLA supplementation increased the concentrations and the 
percentage composition of DGLA in plasma phospholipids of black and white subjects {Table 
2.3 and 2.5) . Of particular importance is that this increase became statistically significant in 
the white group at day 30. Hornych et al. reported a non-significant increase in the 
percentage composition of DGLA in plasma phospholipids after giving a dose of 320 mg 
GLA to subjects for 30 days [35]. The direct comparison of the significant increase in the 
percentage composition of DGLA in plasma phospholipids of white subjects with previous 
results tended to be difficult because of the varying doses of GLA that were used and also 
because of the different durations of the supplementation periods. 
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In a study conducted by Khan et al in healthy subjects, supplementation with 400 mg GLA 
for 8 months was reported to have significantly increased the percentage composition of 
DGLA in plasma phospholipids [66] . In addition, significant increases in the percentage 
composition of DGLA in plasma total phospholipids have been reported when 1 g of GLA 
was given to subjects for 6 weeks [67]. Yoshimoto-Furuiel et al reported similar results after 
administering 2 g GLA to subjects for 6 weeks [65]. The findings of the present study 
demonstrate that GLA supplementation does increase the percentage compositions of DGLA 
in membrane phospholipids, as was expected. 
On the other hand, supplementation appears not to have caused any significant changes in 
the concentrations and percentage compositions of AA in plasma phospholipids in both 
groups (Table 2.3 and 2.5). These results are in agreement with the observations made by 
other investigators [35, 65 and 67]. In humans, DGLA is converted to AA by the 11-5-
desaturase enzyme (Chapter 1 - page 20) . However, it has been shown that the conversion 
of DGLA to AA is particularly slow in humans [4]. Thus, supplementation with GLA is 
expected to increase the percentage composition of DGLA in plasma phospholipids without 
significantly changing the percentage composition of AA in plasma total phospholipids, as 
observed in the present study. 
DGLA can also undergo metabolism and produce prostaglandin E1 (PGE1 ). PGE1 is an 
inflammatory agent and has functions that are reported to be different from those of PGE2 
[68] . Thus, high amounts of DGLA in membrane phospholipids may be beneficial for 
reducing urinary calcium and oxalate excretion since the formation of PGE1 will be higher 
than the formation of PGE2. In the present study, urinary PGE1 excretion was not measured. 
However, it has been reported that supplementation with GLA increases PGE1 synthesis in 
normal subjects. Therefore, an increase in the production of PGE1 in the present study is 
possible as well [69] . 
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Intergroup comparison 
When comparing the effects of supplementation between the two groups, it was observed 
that although supplementation resulted in an increase in the concentrations and percentage 
compositions of DGLA in both groups, this increase was significant in the white subjects only 
(Table 2.3). However, these amounts were found not to be significantly different when they 
were compared (Table 2.5). There are no studies which have investigated the changes in 
fatty acid composition between black and white subjects after GLA supplementation. As a 
result , the observed changes between these groups could not be compared with literature 
data. The absence of a significant increase in the black group suggests that the rate of 
DGLA incorporation in membrane phospholipids in this group may have occurred very slowly 
compared to the white subjects since the concentration and the percentage composition of 
DGLA in plasma phospholipids were similar at baseline (Table 2.3 and 2.5) . 
2.5.3 Urinary risk factors 
Baseline 
The observed differences in urinary oxalate and phosphate (Table 2.7) excretion between 
the two groups are similar to those reported for the same population groups by Whalley et al. 
[70]. High urinary concentrations of phosphate will increase the saturation of brushite, as 
observed in the white group [71) . Differences in the metabolic characteristics between black 
and white South African populations have been suggested as contributing to the unequal 
prevalence of stone formation in these groups [70]. The discussion for these metabolic 
characteristics will be addressed in Chapter 8. 
Post-supplementation 
In both study groups, GLA supplementation resulted in a significant increase in the TRI at 
day 30 (Table 2.8) . The comparison of these changes with other published data proved 
difficult because there is only one study in which the effects of GLA supplementation on 
urinary CaOx risk factors were investigated [7] . After administering 80 mg GLA for 20 days, 
Rodgers et al. reported a significant decrease in the TRI in the black population after 
supplementation whereas in white subjects, the decrease in TRI was not significant [7] . 
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Thus, the findings in the present study are in contrast to those observed by Rodgers et al 
probably due to the administration of a different dose of GLA and different durations of the 
supplementation periods. As shown Chapter 2 - page 81 , calculation of TRI is based on 
lithogenic components. 
As a result, the changes that occurred in urinary parameters within groups during 
supplementation may account for the observed significant difference in TRI that was 
observed. After supplementation , urinary calcium excretion was not statistically different 
when compared to baseline concentrations in both groups (Table 2.8). These results are in 
contrast to those reported by Rodgers et al [7] who observed a significant decrease in 
urinary calcium excretion in black and white South African subjects after supplementation. 
However, the present results are consistent with the finding in the present study that after 
supplementation , the composition of AA in plasma phospholipids and the concentrations of 
urinary PGE2 (Table 2.8) were not affected by the increased intakes of GLA. As such, an 
increase in urinary calcium was not expected . 
With regards to urinary oxalate, supplementation had different effects within groups. In the 
black group, the concentration of oxalate after supplementation was similar to baseline 
concentrations, whereas in whites, a significant increase was observed at day 30. The 
urinary oxalate results observed in the black group are similar to those reported by Rodgers 
et al [7]. Since the composition of AA in plasma phospholipids and the concentration of 
PGE2 were unaffected by supplementation , urinary oxalate concentrations were also 
expected to be unchanged. Thus, other metabolic processes must have been the cause of 
an increase in urinary oxalate in whites. 
It is noted, however, that there were significant differences in the urinary risk factors within 
groups at day 15 compared to baseline values. In Table 2.8, it is shown that urinary 
magnesium was significantly higher than baseline in blacks whereas in whites, potassium 
and the TRI were significantly higher than baseline while ionized Ca 2+ was significantly 
lower. Importantly, these changes were also observed at day 30. These results are 
promising. Supplementation for longer time periods may be required for other effects to 
occur. 
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Intergroup comparisons 
As previously mentioned in Chapter 1 - page 24, black and white South African populations 
are suggested to have different renal handling mechanisms in response to different 
lithogenic agents (6] . This was confirmed in the present study, in which the two groups 
responded differently with respect to urinary parameters after GLA supplementation (Table 
2.8). 
The differences in the urinary risk factors after supplementation suggest that the pathways 
for GLA metabolism are not similar between groups. Thus, the hypothesis that blacks and 
whites have different renal handling mechanisms with respect to different supplemental 
challenges was confirmed in the present study. 
With regards to the increased urinary citrate in whites, similar observations have been 
reported when GLA supplements were given to healthy white South African subjects [7]. 
Rodgers et al. suggested that the increase in urinary citrate may be due to increased 
filtration of plasma citrate by the glomerulus due to the inhibited lipogenesis which decreases 
citrate consumption . Because kidney stone disease is a multifactorial disease [72 - 75] , other 
factors such as genetics and environmental factors may be associated with the observed 
changes in other urinary risk factors after supplementation in the two race groups. 
Washout period 
A washout period is defined as a period in a trial during which the effect of a treatment given 
previously is believed to disappear (76] . The main purpose for a washout period is to allow 
for the entire administered drug or supplement to be eliminated from the body and to 
determine the length of time for the measured parameters to return to baseline values. 
These observations may be beneficial for future trials in which these values may be used to 
assess the absolute effects of the trial medication with other similar trials. In addition, 
washout periods are necessary to prevent harmful effects from interactions between trial 
drugs or supplements and previous medications [77] . 
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The duration of the washout period usually depends on the half-life of the drug within the 
population of interest [78] . Nonetheless, washout periods ranging from 1 day to 8 weeks 
have been reported in studies where fatty acid supplements were given to healthy subjects 
[79 - 81]. In the present study, a 5 day washout period was chosen because a washout 
period of 4 days was found to be insufficient for urinary parameters to return to baseline 
values after 80 mg of GLA supplements were given to healthy subjects [7]. 
In the present study, several urinary risk factors were found to be significantly increased 
during the washout period compared to baseline values in both race groups (Table 2.8) . In 
the black group, magnesium and TRI remained significantly higher than baseline whereas in 
whites, significantly higher urinary oxalate and the TRI were observed .These findings could 
not be compared with the study by Rodgers et al [7] , since they were not similar during the 
supplementation period . In addition , a significant increase in urinary calcium, MSL and SS 
CaOx was observed at day 35 in the black population. This is of particular interest since 
these observations were not observed during the supplementation period itself. These 
(mainly unfavourable) findings imply that that the effects of GLA supplementation on urinary 
risk factors were delayed during the initial stages of supplementation. Thus, it can be 
concluded that a washout period of 5 days is not sufficient for restoring the amounts of fatty 
acids in plasma phospholipids during the supplementation period to baseline levels. 
Summary 
In conclusion , the results of the present study have demonstrated that n-6 FA 
supplementation did not significantly reduce blood and urinary risk factors associated with 
CaOx stone formation in healthy subjects. Firstly, the percentage composition of AA in 
plasma total phospholipids was not affected by GLA supplementation. Secondly, the 
increase in the TRI that was observed in both population groups during the supplementation 
period suggests that GLA may promote CaOx stone formation . Lastly, supplementation had 
no effect on the CaOx MSL and crystallization kinetics of subjects. However, an increase in 
the percentage composition of DGLA was observed in both population groups, although it 
was only significant in the white group. This finding is favourable since it implies that n-6 FAs 
may exert their effects on CaOx stone formation via other pathways. This potential effect of 
GLA supplementation on CaOx stone formation will be explored in Chapter 4. 
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3.1 INTRODUCTION 
The incidence of cardiovascular diseases in the Greenland Inuit tribes is reported to be lower 
than that for Western populations [1-4]. The lower incidence of heart diseases in this tribe is 
largely credited to their dietary habits. Sinclair reported that the Inuit population consumes 
diets that are high in fats and rich in n-3 FAs such as EPA and DHA [5]. Based on this 
information, the potential effects of these fatty acids as alleviating agents for CaOx stone 
formation have been investigated in several studies. In a study conducted by Buck et al [6] , 
dietary supplementation with 1 O g fish oil for 8 weeks decreased urinary calcium and oxalate 
excretion in hypercalciuric patients. In another study, Baggio et al. [7] reported that urinary 
calcium and oxalate were significantly reduced in hypercalciuric stone patients after 
providing them with 2.31 g n-3 FAs (1.313 g EPA and 0.997 g DHA) for 30 days. Recently, 
Ortiz-Alvarado et al reported a decrease in urinary calcium and oxalate excretion after giving 
1.2 g per day of EPA and DHA to hypercalciuric stone patients for 10 months [8]. These 
results show that supplementation with EPA and DHA may be beneficial for stone formation 
since the major urinary risk factors for CaOx stone formation are reduced . 
However, not all studies have shown that both urinary calcium and oxalate are 
simultaneously decreased after EPA and DHA supplementation. Rothwell et al reported a 
significant decrease in urinary calcium after giving 5 g of 2.7 g EPA and 1.8 g of DHA for 4 
weeks in hypercalciuric recurrent stone patients but no decrease in urinary oxalate [9] . In 
another study, Konya et al demonstrated that supplementation with 1.8 g EPA, as ethyl 
icosapentate, per day for 6 months had no effect on the urinary excretion of calcium and 
oxalate in hypercalciuric stone patients [1 O] . After administering 1.8 g EPA, in a pure form , 
per day for 3 months to hypercalciuric stone patients, Yasui et al reported a significant 
decrease in the urinary excretion of calcium in these patients but no decrease in the urinary 
excretion of oxalate [11 ]. 
Thus, the outcomes of EPA and DHA supplementation on the urinary risk factors for CaOx 
stone formation are not consistent. Differences in urinary calcium and oxalate excretion after 
supplementation are suggested to be due to the type of supplement used, varying doses of 
EPA and DHA and to the different durations of the supplementation periods. 
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The research goal of the study described in the present chapter is to investigate the effects 
of administering n-3 FAs (EPA and DHA) supplements to black and white South African 
subjects as outlined in Chapter 1 - page 26. 
As such, the current study aims to address further the effects of n-3 FA supplementation on 
the urinary risk factors associated with CaOx stone formation . Since there is only one study 
that has investigated other CaOx risk factors (such as fatty acid composition in plasma total 
phospholipids and serum 25(0H)D) besides urinary risk factors [7] , the present study also 
aimed to evaluate the effects of n-3 FA supplementation on serum and plasma risk 
biomarkers for CaOx stone formation . In addition, the effects of EPA and DHA 
supplementation on CaOx risk factors in the black and white South African populations were 
also compared. 
3.2 STUDY PROTOCOL 
The study was undertaken at the University of Cape Town after approval (HREC REF: 
249/2010) was obtained from the Human Research Ethics Committee - Cape Town , South 
Africa (Appendix 3.1 ). All participants provided written informed consent (Appendix 2.2). 
Subjects had no family history of renal or kidney stone disease and they were not allowed to 
participate in the study if they had diseases such as diabetes, bleeding or blood clotting 
disorders that affect lipid metabolism. None of the participants were taking any medication or 
supplements during the course of the study. 
12 Black and 12 white healthy South African males, aged between 18 - 32 years old, were 
initially recruited from the University of Cape Town to participate in the study. The chosen 
number of participants was based on sample size calculations to achieve a statistical power 
of 80 % as described in Chapter 2 - page 69. One subject from the white group dropped out 
of the study due to personal commitments. Thus, the total number of white subjects who 
were enrolled in the study was 11 . 
A 30 day supplementation period was observed by subjects where they were required to 
take encapsulated fish oils, Omega-3 "700", purchased from Solgar - UK. The capsules 
provided 1.92 g of EPA and DHA per day. Each capsule contained 0.38 g of EPA, 0.26 g of 
DHA and 0.06 g of other omega-3 fatty acids. Participants were given instructions to take 1 
capsule 3 times per day. 
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The supplements that were used in the present study contained EPA and DHA as the major 
components. These supplements were chosen because the diet of Inuit is mainly composed 
of fish and these fatty acids are reported to be natural components of fishoil [5]. Several 
studies have reported that consumption of 0.4 to 2 g of n-3 FAs per day, as a combination of 
EPA and DHA, from food or supplements is recommended for healthy individuals to increase 
the EPA and DHA content in various lipid fractions [12 - 14]. Supplementation with doses 
greater than 2 g per day is suggested to cause health complications such as increased risk 
of bleeding , upset stomach and elevated levels of LDL cholesterol ester in healthy 
individuals [15 - 17]. Thus, the supplement dose of 1.92 g EPA and DHA was chosen 
because it was regarded as effective in increasing the EPA and DHA content in plasma lipid 
fractions without imposing health risks. In addition , previous studies have shown that EPA 
and DHA supplementation for four weeks is sufficient to significantly increase the EPA and 
DHA content in various lipid fractions [18 - 21]. Thus, 30 days of EPA and DHA 
supplementation were chosen for the present study because it was expected that moderate 
changes in the percentage composition of these FAs can be achieve within this time period . 
3.3 EXPERIMENTAL ANALYSIS 
3.3.1 Sam pie collection 
In the present study, blood and 24h urine samples were collected prior to the administration 
of n-3 FA supplements at day 0. Additional blood and 24h urine samples were collected 
during the supplementation period at both days 15 and 30. Final blood and 24h urine 
samples were collected at day 35 during the washout period after the subjects had stopped 
taking the supplements. Food intakes were recorded on a food diary (Appendix 2.5) at 
baseline; and subjects followed the same diet on blood and urine sample collecting days. 
3.3.2 Nutrient intake assessment 
Dietary assessment was carried out using the Foodfinder II computer program as described 
in Chapter 2 - page 71 . The nutrient intakes were only measured on the food diaries 
recorded at baseline. 
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3.3.3 Blood analysis 
The collected blood samples were collected and divided into different fractions as previously 
described in Chapter 2 - pages 71 . Serum samples collected at days O and 30 were taken to 
the Pathcare Laboratories and to the South African Medical Research Council Laboratories 
for the analysis of 25(0H)D and TAGs, respectively. The concentrations of serum 25(0H)D 
and TAGs were measured according the procedures described in Chapter 2 - pages 72. The 
FA profiles in plasma and RBC total phospholipids were measured at the South African 
Medical Research Council using the method described in Chapter 2 - pages 72. 
3.3.4 Urine analyses 
Urinary risk factors 
The collected 24h urine samples were analyzed for urinary risk factors as previously 
discussed in Chapter 2 - page 76. Ionized calcium was not measured due to technical 
problems with the calcium electrode. 
3.3.5 Crystallization experiments 
CaOx metastable limit 
The CaOx metastable limit was determined according to the method described in Chapter 2-
page 80. For both groups, the particle number was determined using the Coulter Counter. 
CaOx crystallization kinetics experiment 
In the present study, the results for the rates of particle formation were not included due to 
instrument malfunction. During the course of the study, the particle sensor inside the Coulter 
Counter was not functioning properly. This caused a false count of particles while conducting 
experiments. Furthermore, the instrument broke down before all the experiments could be 
completed. 
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3.3.6 Risk indices 
The TRI and the SS values of COM, brushite and UA were determined as previously 
described in Chapter 2 - page 81 . 
3.3. 7 STATISTICAL ANALYSES 
Statistical analysis was carried out using GraphPad lnstat 3 program. All data are expressed 
as mean ± SE and were considered significant if p-value ~ 0.05. Graphs were prepared with 
Microsoft Excel 201 O with standard error bars. 
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3.4 RESULTS 
3.4.1 Subject's characteristics 
The mean age and BMI of subjects at baseline are shown in Table 3.1 . Raw data showing 
each subject's age, height, weight and BMI are presented in Appendix 3.2. There were no 
significant differences observed between the groups with regard to age and BMI at baseline. 
rTable 3.1 
!Subject's characteristics at baseline - n-3 FA study 
Parameter Blacks Whites p-value 
~ge (years) 24.5 ± 1.11 22.2 ± 0.63 0.0912 
BMI (kg/m2) 25.0 ± 1.18 23.3 ± 0.98 0.2886 
3.5.2 Nutrient intakes 
Raw data showing the calculated nutrient intakes for each subject are presented in Appendix 
3.3. The results for the mean intakes of nutrients, minerals and fatty acids of black and white 
subjects recorded at baseline will be discussed in Chapter 8. 
3.4.3 Compliance test 
In the present study, supplement compliance was determined using two techniques. Firstly, 
compliance was determined by counting the number of capsules remaining after the 
supplementation period, as described in Chapter 2 - page 83. Only two subjects returned 
capsules after the supplementation period; one black subject returned 3 capsules and one 
white subject returned 2 capsules. It was then concluded that > 85 % of the capsules given 
to subjects were consumed during the course of the study. 
Secondly, compliance was assessed by comparing the changes in the concentrations of 
EPA and DHA in RBC total phospholipids during the supplementation period, on days 15 
and 30, with the concentrations at baseline. The changes in these FAs were calculated 
because the capsules that were given to subjects contained EPA and DHA as the major 
components. 
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As previously described in Chapter 2 - page 83, RBCs were chosen because of their 120 
day lifespan and because they reflect dietary intakes of FAs. In each race group, 5 subjects 
were randomly selected for the compliance test. The percentage changes in the 
concentrations of EPA and DHA in RBC total phospholipids for each group were calculated 
as previously described in Chapter 2 - page 83. 
Raw data showing the FA composition (as concentration (µg/ml)) in RBC total phospholipids 
for each individual are presented in Appendix 3.4. The percentage changes in the 
concentrations of EPA and DHA for each subject are shown in Table 3.2. At day 15, the 
black subjects had a 300 % mean percentage change for EPA (p-value < 0.0001) whereas in 
whites, the mean percent change was 185 % (p-value = 0.0003). The mean percentage 
changes in EPA were further increased at day 30 (p-value < 0.0001) in both groups and 
reached mean percentage changes of 482 % and 253 % for blacks and whites, respectively. 
On the other hand, at each sampling point, the percentage changes for DHA increased to a 
smaller extent compared to baseline concentrations in both race groups. In the black group, 
the mean percentage change for DHA at day 15 was 11 % (p-value = 0.2988) . This was 
further increased to 22 % (p-value = 0.0581) at day 30. The mean percentage changes for 
DHA in the white subjects were 12 % (p-value = 0.0551) at day 15 and 20 % (p-value = 
0.0067) at day 30. It has been reported that the rate of DHA incorporation into membrane 
phospholipids occurs at a slower rate as compared to that of EPA [22] . In addition , it has 
been observed that DHA can be converted back to EPA, thus increasing the amounts of 
EPA in membrane phospholipids [22]. These two findings are suggested to be the cause of 
the lower DHA percentage composition in RBC membrane phospholipids that was observed 
after supplementation in the present study. 
The changes in EPA and DHA concentrations that were observed at day 30 are in 
agreement with the results obtained by other investigators after administering fish oil 
supplements to healthy subjects for 4 weeks with EPA and DHA doses similar to the one 
used in the present study [23 - 25]. 
Overall , the results from the capsule counting technique and the changes in the 
concentrations of EPA and DHA in RBC membrane total phospholipids indicate that the 
subjects adhered to the supplement protocol. 
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Chapter 3 Results 
3.4.4 Serum biomarkers and FA profile in plasma total phospholipids 
As mentioned in Chapter 2 - page 86, attention is drawn toward n-6 PUFAs such as GLA, 
DGLA, AA and n-3 PUFAs such as EPA and DHA since they are of most importance with 
respect to modulatory risk factors for kidney stone formation . Also, only the percentage 
compositions of fatty acids in plasma total phospholipids will be compared with other studies. 
Baseline 
The differences in the concentrations of serum biomarkers and fatty acids in plasma total 
phospholipids between groups observed at baseline are presented in Table 3.3. Raw data 
showing the concentrations of serum 25(0H)D and TAGs for each subject are presented in 
Appendices 3.5 and 3.6, respectively. Raw data showing the concentrations of FAs in 
plasma phospholipids for each individual are presented in Appendix 3.7. The comparison of 
serum 25(0H)D concentrations between the two groups showed that the black group had 
significantly lower 25(0H)D concentrations compared to the white subjects. These 
differences are similar to those observed in the previous study (Chapter 2 - page 86) and 
also to those reported by other investigators [26 - 31]. 
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Chapter 3 Results 
The differences in the concentrations of FAs in plasma total phospholipids between the two 
groups at baseline are summarized in Table 3.4. 
iTable 3.4 
Summary of significant differences in concentrations 
~f FAs (1-1g/ml) between groups at day O - n-3 FA study 
FA class Type of FA BvsW 
SF As MA, PA, SA and ARA B <W* 
MUFAs PTA, OA, VA and 24:1 n-9 B <W* 
PUFAs DGLA, EPA, DPA (n-3) B<W* 
*: p-value ~ 0.05 (intergroup comparison) 
The comparison of the percentage compositions of FAs in plasma phospholipids between 
the two groups are shown in Table 3.5. Raw data showing the percentage composition of 
FAs in plasma phospholipids for each individual are presented in Appendix 3.8. 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results 
Table 3.6 shows the summary of the differences between groups that were observed at 
baseline. 
rrable 3.6 
Summary of significant differences in the % compositions 
of FAs between groups at baseline - n-3 FA study 
FA class Type of FA BvsW 
MUFA PTA and OA B<Wt. 
PUFA EPA B<Wt. 
i _. p-va/ue :5 0.05 (intergroup comparison) 
Post-supplementation 
The effects of supplementation on the concentrations of serum biomarkers and FAs in 
plasma phospholipids during the supplementation period are summarized in Table 3.3. The 
p-values are presented in Appendix 3.9. In both groups, there were no significant changes in 
the concentrations of serum 25(0H)D and TAGs observed at day 30. 
With regards to the FA composition in plasma phospholipids, there were several changes 
that occurred in both groups at day 30. Within the black group, 24: 1 n-9 concentrations 
significantly increased after supplementation . In addition , a significant decrease in the 
concentrations of n-6 FAs such as DGLA, ADRA and DPA was observed. As expected, 
supplementation significantly increased the concentrations of n-3 FAs such as EPA, DPA 
and DHA. In the white subjects, the concentration of OA was significantly decreased 
compared to baseline. For n-6 FAs; LA, DGLA, AA and ADRA were significantly decreased 
at day 30. Increases in EPA, DPA and DHA (n-3 FAs) were statistically significant compared 
to baseline concentrations after supplementation, as expected . 
During the supplementation period at day 15, the concentrations of certain fatty acids were 
significantly different compared to baseline values in both groups. In the black group, the 
concentration of 24: 1 n-9 was significantly increased at day 15. In addition, the 
concentrations of n-6 FAs such as DGLA, ADRA and DPA were significantly decreased. 
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On the other hand, the concentrations of n-3 FAs such as EPA, DPA and DHA were 
significantly increased compared to baseline. Within the white population, PTA 
concentrations were significantly decreased at day 15. For PUFAs; DGLA and ADRA (n-6 
FAs) were significantly decreased compared to baseline whereas EPA, DPA and DHA (n-3 
FAs) were significantly increased. 
The changes in the percentage composition of FAs during the supplementation periods 
compared to baseline within groups are shown in Table 3.5. The p-values are presented in 
Appendix 3.10. The percentage compositions of n-6 and n-3 PUFAs relevant to this study 
are illustrated in Figures 3.1 and 3.2. Within the black group, the percentage composition of 
24:1 n-9 was significantly increased after supplementation at day 30. n-6 FAs such as 
DGLA, AA, ADRA and DPA were significantly decreased at day 30 whereas the percentage 
compositions of n-3 FAs such as EPA, DPA and DHA were significantly increased. 
In whites, the percentage compositions of SFAs such as BA and LGA were significantly 
increased after supplementation . With regards to MUFAs, OA was significantly lower at day 
30 compared to baseline. The percentage compositions of DGLA, AA and ADRA (n-6 FAs) 
were significantly decreased at day 30 whereas the percentage compositions of n-3 FAs 
such as EPA, DPA and DHA were significantly increased.Significant changes in the 
percentage compositions of certain FAs also occurred at day 15. Within the black group, the 
percentage composition of 24: 1 n-9 was significantly increased. Also at day 15, the 
percentage compositions of n-6 FAs such as DGLA, AA, ADRA and DPA were significantly 
decreased whereas the percentage compositions of n-3 FAs such as EPA, DPA and DHA 
were significantly increased. In whites, the percentage composition of PTA was significantly 
decreased at day 15. The percentage compositions of DGLA and ADRA (n-6 FAs) were 
significantly decreased. In addition , the percentage compositions of n-3 FAs such as EPA, 
DPA and DHA were significantly increased compared to baseline. 
Intergroup comparisons 
There were no significant differences observed in the concentrations of FAs between groups 
during the supplementation period at both days 15 and 30 (Table 3.3). The lower MA, PTA 
and OA concentrations observed in blacks compared to whites at both days 15 and 30 were 
not attributed to the effect of supplementation since they were present at baseline. 
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The comparison of the percentage compositions of FAs in plasma total phospholipids 
between groups are shown in Table 3.5. At day 30, the percentage composition of MA was 
lower in blacks whereas the percentage composition of DHA (n-3 FA) was higher. The 
differences in the percentage compositions of PTA and OA observed at days 15 and 30 
were also present at baseline. 
Washout period 
The concentrations of FAs in plasma total phospholipids during the washout period within 
both groups are shown in Table 3.3. In the black population , the concentrations of OA and 
24:1 n-9 were significantly higher than baseline concentrations. In addition, the concentration 
of DPA (n-6 FA) in plasma phospholipids was significantly lower than baseline. With regards 
to n-3 FAs; EPA, DPA and DHA concentrations were significantly higher than baseline 
concentrations. Within the white group, the concentration of ADRA (n-6 FA) was significantly 
higher compared to baseline concentrations. As for EPA, DHA and DPA (n-3 FAs), the 
concentrations of these FAs were significantly higher compared to baseline. 
For both race groups, the percentage compositions of FAs in plasma total phospholipids 
during the washout period are shown in Table 3.5. In blacks, the percentage compositions of 
AA, ADRA and DPA (n-6 FAs) were significantly lower compared to baseline concentrations. 
On the other hand, the percentage compositions of EPA, DHA and DPA (n-3 FAs) were 
significantly higher than baseline values. In the white group, n-6 FAs such as AA and ADRA 
were significantly lower compared to baseline concentrations whereas n-3 FAs such as EPA, 
DPA and DHA were significantly higher than baseline. 
There were no significant differences in the concentrations of FAs between groups during 
the washout period . On the other hand, the percentage composition of DPA (n-3 FA) in 
plasma phospholipids was higher in blacks compared to whites. 
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Figure 3.1: Percentage composition of PUFAs in blacks after n-3 FA supplementation 
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Figure 3.2: Percentage composition of PUFAs in whites after n-3 FA supplementation 
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3.4.5 Urinary risk factors 
Baseline 
Comparisons of urinary parameters between groups at baseline are shown in Table 3.7. 
Raw data showing the urinary composition of each subject at each sampling point are 
presented in Appendix 3.11. Calcium, magnesium and phosphate were significantly lower in 
the black group compared to the white subjects at baseline. 
~able 3.7 
Comparison of urinary risk factors between groups 
at baseline- n-3 FA study 
Parameter Blacks Whites p-value 
pH 6.56 ± 0.15 6.23 ± 0.11 0.0821 
!Volume (ml/day) 1154 ± 102 1158 ± 184 0.9880 
Calcium (mmol/24h) 2.63 ± 0.21 3.23 ± 0.14 0.0278; 
Magnesium (mmol/24h) 2.19 ± 0.26 3.00 ± 0.17 0.0171; 
Phosphate (mmol/24h) 24.6 ± 2.02 32.5 ± 2.23 0.0147; 
Chloride (mmol/24h) 161 ± 14.6 123±21 .5 0.1441 
Citrate (mmol/24h) 2.12 ± 0.22 2.21 ± 0.35 0.8197 
Creatinine (mmol/24h) 17.1 ± 0.97 18.1 ± 1.00 0.4967 
Oxalate (mmol/24h) 0.24 ± 0.02 0.24 ± 0.03 0.9743 
Potassium (mmol/24h) 47.2 ± 5.16 43.8 ± 5.06 0.6459 
Sodium (mmol/24h) 147±13.2 126 ± 14.4 0.2925 
Urate (mmol/24h) 3.69 ± 0.29 3.80 ± 0.28 0.7908 
PGE2 (ng/24h) 507 ± 83.0 627 ± 71 .9 0.2925 
HYP (nmol/mg creatinine) 2.85 ± 1.65 0.94 ± 0.28 0.2859 
MSL (mM) 0.91 ± 0.07 0.83 ± 0.05 0.3468 
TRI 202 ± 29.6 244 ± 81 .2 0.6204 
SS CaOx 4.13 ± 0.75 5.75 ± 0.83 0.1589 
SS Brushite 1.73 ± 0.46 2.44 ± 0.47 0.3014 
SS Uric acid 0.94 ± 0.24 1.87 ± 0.42 0.0637 
; : p-value s; 0.05 intergroup comparison 
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Post-supplementation 
The changes in the urinary risk factors within groups during the supplementation period are 
shown in Table 3.8. In the black group, there were no significant changes observed in the 
urinary parameters after supplementation at both days 15 and 30. Within the white group, a 
significant increase in the urinary concentration of magnesium was observed at day 30. In 
addition, the relative supersaturation of brushite was significantly decreased at day 30 
compared to baseline. 
Intergroup comparison 
The differences in the urinary parameters between groups during the supplementation 
period are shown in Table 3.9. Comparison between groups showed that the relative 
supersaturation of brushite was significantly lower in the black group compared to whites at 
day 15. The other urinary parameters were not statistically different between the two groups 
at both days 15 and 30. However, it was noted that although the black subjects had lower 
urinary magnesium and phosphate compared to whites at days 15 and 30 and also lower 
urinary calcium at day 30; these differences were present at baseline. 
Washout period 
The urinary parameters of both groups during the washout period are shown in Table 3.8. In 
the black group, there were no significant differences observed in the urinary risk factors 
during the washout period compared to baseline. In whites, urinary magnesium and 
phosphate were significantly higher compared than baseline concentrations. There were no 
significant differences in the urinary risk factors between groups at day 35 (Table 3.8). The 
lower urinary calcium, magnesium and phosphate concentrations that were observed in the 
black group at baseline were also present during the washout period . 
3.4.6 CaOx MSL 
The average CaOx MSL for black and white subjects observed on days 15, 30 and 35 are 
shown in Table 3.10. The p-values are shown in Table 3.11 . In both groups, there were no 
significant differences observed in the CaOx MSL values during the supplementation and 
washout periods. 
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The p-values for the comparison of the CaOx MSL between groups at days 15, 30 and 35 
are shown in Table 3.11 . At each day of the experiment, there were no significant 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Average CaOx MSL within groups after n-3 FA supplementation 
Blacks Whites 
Parameter 
Day O Day 15 Day 30 Day 35 Day O Day 15 Day 30 Day 35 
MSL (mM) 0.91 ± 0.07 1.05 ± 0.08 1.08 ± 0.10 1.09 ± 0.08 0.83 ± 0.05 1.00 ± 0.07 1.02 ± 0.09 0.96 ± 0.07 
Table 3.11 
P-values for the comparison of CaOx MSL within and between groups after n-3 FA 
supplementation 
Blacks Whites BvsW 
Parameter 
Day 15 Day 30 Day 35 Day 15 Day 30 Day 35 Day 15 Day 30 Day 35 
MSL (mM) 0.2047 0.1795 0.1042 0.0541 0.0746 0.1640 0.6073 0.6961 0.2201 
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3.5 DISCUSSION 
In the present study, the effects of EPA and DHA supplementation on serum biomarkers, 
plasma total phospholipids and urinary risk factors were investigated in healthy black and 
white South African males. Several significant differences between blacks and whites in 
parameters related to stone formation were observed at baseline. The differences in the 
dietary intakes between the two groups will be discussed in Chapter 8. 
3.5.1 Serum biomarkers 
Baseline 
The lower serum 25(0H)D concentrations in blacks subjects compared to whites (Table 3.4) 
are suggested to be due to the inefficient ability of the darker skin pigment of blacks to 
absorb UV rays [32 - 34]. This difference has been discussed in Chapter 2 - page 100. 
Post supplementation 
Supplementation did not show any effect on serum 25(0H)D and TAG concentrations in 
both population groups (Table 3.3). The unchanged 25(0H)D concentrations after 
supplementation are in agreement with the results obtained by Baggio et al. [7]. Vitamin D, 
EPA and DHA are natural constituents of oily fish [35, 36]. An increase in 25(0H)D 
concentrations was expected in the present study since traces of vitamin D are usually found 
in EPA and DHA capsules [37]. The amounts of vitamin D in the EPA and DHA capsules 
used in the present study were not reported by the manufacturer (Solgar, UK). In addition, 
the vitamin D content in the capsules could not be determined experimentally due to 
financial constraints. Thus, the amounts of vitamin D in these capsules could not be 
confirmed. 
With regards to serum TAG concentrations (Table 3.3) , similar results have been reported by 
other investigators after supplementation with EPA and DHA in healthy subjects for 4 weeks 
[38, 39]. Fish oil supplementation has been shown to decrease triglyceride concentrations in 
hypertriglyceridemic patients [40 - 42]. 
1371 Page 
Chapter 3 Discussion 
The most likely reason for not observing a significant change in TAG concentrations in the 
present study may be due to the difference in the health status of subjects, i.e. healthy 
subjects in the present study but stone formers in other studies. 
3.5.2 Plasma total phospholipids 
Baseline 
The fatty acid composition in plasma total phospholipids of healthy subjects has been shown 
to reflect the normal dietary intake of fatty acids [43 - 45]. Thus, the differences in the 
concentrations and percentage compositions of fatty acids in plasma total phospholipids 
between the two groups observed at baseline (Table 3.4 and 3.5) are suggested to de due to 
the differences in the dietary habits of black and white populations. As previously described 
Chapter 2 - page 100, comparison of the fatty acid composition between blacks and whites 
with other studies was not possible because of absence of published data. In the present 
study, the concentrations and the percentage compositions of these fatty acids in plasma 
total phospholipids were found to be within the normal ranges for healthy individuals [46 -
49] . 
Post supplementation 
In both groups, the concentrations and the percentage compositions of PUFAs in plasma 
total phospholipids changed in a specific manner for each individual fatty acid during the 
supplementation period (Table 3.3 and 3.4). A significant decrease in the percentage 
compositions of DGLA and AA was observed at day 30. On the other hand, the 
concentrations and the percentage compositions of EPA and DHA were significantly 
increased after supplementation . The significant changes in the percentage compositions of 
these fatty acids are consistent with the results observed in other studies after EPA and DHA 
supplementation in healthy subjects [20, 25 and 50 - 53]. Thus, these findings meet the 
expectations of the present study and confirm good compliance by the subjects. 
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At day 15, certain significant changes occurred in the concentrations and percentage 
compositions of n-6 and n-3 FAs in both groups (Table 3.4 and 3.5). In the black group, the 
significant changes in the concentrations and percentage compositions of n-6 and n-3 FAs 
that were observed at day 15 were also significantly different at day 30 compared to 
baseline. In addition to the significant changes in the concentrations and percentage 
compositions of n-6 and n-3 FAs that occurred at day 15, a significant increase in the 
concentration and percentage composition of AA was observed in whites at day 30. 
These observations are consistent with the results from other n-3 FA supplementation 
studies where the percentage compositions of EPA and DHA in plasma total phospholipids 
were found to reach statistical significance compared to baseline with 1 week [54, 55] and 14 
days [56]. However, in all these studies, the amounts of AA in plasma total phospholipids 
were not significantly reduced. The findings of the present study suggest that EPA and DHA 
supplementation can significantly affect the fatty acid composition in membrane 
phospholipids within 15 days, and that the therapeutic effects of these FAs can be achieved 
within this time period. However, supplementation for longer periods may be required in 
order to achieve maximum levels of these FAs in total phospholipids and for additional 
effects in membrane phospholipids to occur. 
Supplementation with EPA and DHA has been shown to modulate the formation of PGE2 
from AA [57, 58]. After AA is incorporated into membrane phospholipids, the phospholipase 
A2 enzyme releases AA from the membrane phospholipids so that it can undergo 
metabolism to form PGE2. EPA has been shown to inhibit the release of AA from the 
membrane phospholipids, thus reducing the amounts of substrate available for the 
production of PGE2 [57, 58]. Because EPA and DHA are incorporated into membrane 
phospholipids just like AA, an increase in the percentage composition of these FAs in 
membrane phospholipids will result in a decrease in the incorporation of AA [59, 60], further 
reducing the metabolism of AA into PGE2. Another beneficial effect from increased EPA and 
DHA percentage compositions in membrane phospholipids is that the eicosanoids produced 
from the metabolism of these FAs have different biological activities from those of PGE2 [61 
- 63]. Thus, increased dietary intakes of EPA and DHA may be of importance as a strategy 
to alleviate the effects of PGE2 in CaOx stone formation. 
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Intergroup comparisons 
In both groups, a decreasing trend in the concentrations and percentage compositions of n-6 
FAs was observed during the supplementation period (Table 3.4 and 3.5). Although the 
concentrations of AA in plasma total phospholipids decreased during the supplementation 
period, statistical significance was achieved by the white group only at day 30. With regard 
to the percentage composition of AA in membrane phospholipids, statistical significance was 
observed at both days 15 and 30 in the black group, whereas in whites, AA was merely 
decreased significantly at day 30. In addition , it was observed that the black group had a 
significantly higher percentage composition of DHA at day 30 compared to whites (Table 
3.5). These findings imply that the incorporation rates of certain FAs in membrane 
phospholipids differed between the two groups. Comparison of these observations with other 
studies was not possible because of absence of data. Regarding n-3 FAs, the 
concentrations and percentage compositions of EPA and DHA were found to be increased in 
a similar manner in both groups after supplementation . 
Washout period 
Within both groups, the concentrations and percentage compositions of n-6 FAs appeared to 
increase during the washout period whereas a decreasing trend in n-3 FAs was observed. 
Nevertheless, certain FAs were still significantly different compared to baseline values after 
supplementation was discontinued (Table 3.4 and 3.5) . In the present study, a period of 5 
days was not sufficient for FAs in plasma phospholipids to return to pre-supplementation 
levels. Similar findings have been reported in other studies after observing washout periods 
of 7 days [55) , 8 weeks [25) and 24 weeks [51) . These results indicate that the effects of n-3 
FA supplementation on risk factors for kidney stone formation continue for long periods after 
cessation of supplementation . 
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3.5.3 Urinary risk factors 
Baseline 
Consistent with observations made previously in healthy black and white South African 
subjects, black subjects were found to have significantly lower urinary calcium, magnesium 
and phosphate concentrations compared to whites [64]. The discussion for the differences in 
CaOx risk factors between the two groups will be addressed in Chapter 8. 
Post supplementation 
In the present study, there were no statistically significant changes in urinary calcium and 
oxalate excretion in both groups following n-3 FA supplementation (Table 3.8). These 
findings are contrary to those reported by Baggio et al [7] who observed significant 
decreases in both parameters after giving hypercalciuric stone patients EPA and DHA 
capsules with doses similar to the ones used in the present study for the same period of 
time. The discrepancy between results from the present study and those of Baggio et al [7] 
might be explained by the different health status of the participants in the respective studies. 
Healthy subjects were investigated in the present study, while hypercalciuric stone patients 
were investigated in the other study. This implies that FA metabolism in healthy subjects 
might not be the same as in stone formers. Of particular interest is that there were no 
significant changes observed in urinary PGE2 excretion after supplementation in both 
groups (Table 3.8). These results are comparable to those reported by Siener et al [65] in 
the normal healthy male population on a similar dose of EPA and DHA supplementation for 
the same duration. n-3 FA supplementation has been shown to result in decreased 
production of PGE2 and increased formation of n-3 eicosanoids such as prostaglandin E3 
(PGE3) [61 , 66 - 68]. In the present study, it is speculated that a decrease in PGE2 might 
have occurred if the duration of the supplementation had been longer. Cao et al [25] showed 
that the incorporation of EPA and DHA in phospholipids of healthy subjects is a rapid 
process while decreases in the percentage compositions of AA proceed more slowly. The 
changes in the concentrations of AA in plasma phospholipids (Table 3.3) after 
supplementation demonstrate the slower incorporation of AA in membrane phospholipids 
very aptly and are suggested to account for the absence of a decrease in PGE2. 
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Intergroup comparisons 
As shown in Table 3.4, the response of the two groups to n-3 FA supplementation was not 
the same. This suggests that the metabolic pathways of FAs are sensitive to physiological 
features which are characteristic of each population. Regarding the lower SS brushite in 
blacks at day 15 (Table 3.9), this difference is suggested to be of little clinical significance 
since it is speculated that it may have been greatly influenced by the increase in phosphate 
concentration in the white group. 
Washout period 
Despite withdrawal of n-3 FA supplements, additional supplementation effects on urinary risk 
factors were observed within the white group at day 35 (Table 3.8) . These observations 
provide further evidence that a 5 day washout period is not sufficient for reducing the 
membrane phospholipids levels of EPA and DHA to baseline levels. 
Summary 
The present study has shown that ingestion of n-3 FAs did not elicit any changes in urinary 
calcium and oxalate in healthy subjects. This is in contrast to previous studies involving 
stone-forming patients, in whom n-3 FAs were found to regulate calcium and oxalate 
balance. Since the present study did not involve kidney stone patients, no conclusions can 
be drawn regarding the efficacy or mode of action of n-3 FA supplementation in managing 
stone disease. However, the conflicting results in healthy subjects and stone forming 
patients might be indicative of different handling mechanisms in the two groups. In addition, 
the study has demonstrated that although 30 days of supplementation may be adequate for 
altering the FA composition in membrane phospholipids, supplementation for longer periods 
may be beneficial for producing positive effects in urinary CaOx risk factors. Lastly, the 
findings of the present study have again demonstrated that blacks and whites differ in their 
response to supplemental challenges. 
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4.1 INTRODUCTION 
Previous studies have shown that supplementation with GLA results in an increase in the 
percentage composition of DGLA in plasma phospholipids [1 - 5] . High amounts of DGLA in 
membrane phospholipids may be beneficial for kidney stone formation because of two 
reasons. Firstly, a high percentage composition of DGLA will result in a decrease in the 
levels of AA in plasma phospholipids [6 - 8] ; which is favourable because it implies a 
reduction in the production of PGE2. Secondly, a high percentage composition of DGLA in 
membrane phospholipids is suggested to favour the formation of prostaglandin E1 (PGE1), 
which has anti-inflammatory properties that suppress those of PGE2 [9, 10]. 
The main concern with regard to increases in DGLA is that the metabolism of this FA may 
also lead to the formation of AA [11 - 13]. Johnson et al demonstrated that supplementation 
with 1.5, 3.0 and 6.0 g GLA per day for 3 weeks significantly increased the concentrations of 
AA in healthy subjects [14] . Therefore, supplementation with GLA for longer periods may 
possibly increase PGE2 production with subsequent elevations in the urinary concentrations 
of calcium and oxalate. 
Nonetheless, supplementation with EPA and DHA has been shown to replace the n-6 FAs 
content, especially AA, in membrane phospholipids with these FAs [15 - 18]. Thus, addition 
of EPA and DHA capsules to dietary intakes during GLA supplementation may complement 
the effects of DGLA by blocking the accumulation of AA in membrane phospholipids. 
In view of this , the present study was undertaken to investigate the influence of dietary 
supplementation with a combination of n-6 and n-3 FAs on the fatty acid composition in 
plasma total phospholipids of healthy black and white South African subjects. The effects of 
n-6 and n-3 FAs supplementation on serum and urinary risk factors for CaOx stone 
formation were also studied . Furthermore, the effects of supplementation in black and white 
South African subjects were investigated to determine whether this might lead to new 
insights as to why the incidence of stone disease is lower in the black group. 
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4.2 STUDY PROTOCOL 
Participants were recruited from students enrolled at the University of Cape Town - South 
Africa. The Human Research Ethics Committee of the University of Cape Town - South 
Africa , approved (HREC REF: 366/2011) the study (Appendix 4.1) and all volunteers gave 
informed consent before taking part in the study. Participants were excluded if they had 
metabolic disorders or medical conditions such as heart disease, diabetes and urinary tract 
diseases. During the course of the study, none of the participants were taking any 
medication including antibiotics, vitamins or fatty acid supplements. 
10 Black and 1 O white healthy South African males participated in the study. This samples 
size was chosen because it was sufficient to give a statistical power of 80 %, as described in 
Chapter 2 - page 69. Seven of the original 1 O subjects from the white group and 1 O subjects 
from the black group completed the study. Before the administration of n-6 and n-3 FAs 
capsules to subjects, blood and 24h urine samples were collected at baseline as control 
samples. Subjects recorded their food intakes in a food diary (Appendix 2.5) ; and while they 
were collecting samples, they were required to avoid foods that have high oxalate content 
(Appendix 2.6). 
Subjects were required to take a combination of n-3 FAs (1 .08 g EPA and 0.72 g DHA; 
Omega-3 Double strength) and n-6 FAs (0.30 g GLA; One-a-day GLA) supplements that 
were obtained from Solga, UK. Each n-3 FA capsule was reported to contain 0.36 g EPA, 
0.24 g DHA and mixed tocopherols as antioxidants. The n-6 FA capsule contained 225 mg 
LA, 150 mg GLA and 250 mg of other fatty acids. Specifically, subjects were required to 
consume a total of 3 n-3 FA capsules (i.e. one during breakfast, one during lunch and one 
during supper) and a total of 2 n-6 FAs capsules (one during breakfast and one during lunch) 
daily, over a period of 30 days. 
The dose for n-6 FA capsules was chosen in accordance with the findings described in 
Chapter 2. The capsules that contained the dose used in Chapter 3 for n-3 FA 
supplementation were no longer provided by the manufacturer (Solgar - UK). As a result , a 
dose (1 .80 g EPA and DHA) similar to the one (1 .92 g EPA and DHA) used in Chapter 3 was 
chosen because its effect on the fatty acid composition in plasma total phospholipids was 
anticipated to be similar to the latter. 
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Further, the chosen dosages for GLA, EPA and DHA were within the recommended daily 
intakes for healthy individuals [19, 20]. 
Additional blood samples were obtained at days O and 30 while 24h urine samples were 
collected during the supplementation period, at days 15 and 30; and at day 35 during the 
washout period. The food intakes recorded at baseline were consumed again by subjects on 
blood and 24h urine sample collecting days. 
4.3 EXPERIMENTAL ANALYSIS 
4.3.1 Nutrient intakes 
The energy and nutrient intakes of subjects at baseline were calculated using the Foodfinder 
II computer program as described in Chapter 2 - page 71 . 
4.3.2 Blood analysis 
The collected fasting blood samples were separated into different fractions as described in 
Chapter 2 - page 71 . Serum 25(0H)D and TAGs concentrations were measured at Pathcare 
Laboratories and South African Medical Research Council, respectively; using the procedure 
described in Chapter 2 - page 72. Plasma and RBCs samples were sent to South African 
Medical Research Council and the FA profile in each sample was determined using the 
method described in Chapter 2 - page 72. 
4.3.3 Urinary risk factors 
The urinary composition of each 24h urine samples was evaluated as described in Chapter 2 
- page 76. 
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4.3.4 Crystallization experiments 
The CaOx MSL and crystallization kinetics were determined in all urine samples using the 
spectrophotometer as described in Chapter 2 - page 80. 
4.3.5 Risk indices 
The TRI and SS values of CaOx, brushite and uric acid were calculated in all 24h urine 
samples as described in Chapter 2 - page 81 . 
4.3.6 Statistical analysis 
Data were analyzed using GraphPad lnstat and a p-value s 0.05 was regarded as 
statistically significant. All the results are reported as average values with standard error 
(SE). Graphs with standard error bars were prepared with Microsoft Excel 201 O. 
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4.4. RESULTS 
4.4.1 Subject's characteristics 
The mean age and BMI of subjects at baseline are shown in Table 4.1. Raw data for the 
subjects' characteristics recorded at baseline are presented in Appendix 4.2. Intergroup 
comparison showed that the subject's characteristics were not significantly different. 
Table 4.1 
Subject's characteristics at baseline - n-6 & n-3 FA study 
Parameter Blacks Whites p-value 
!Age (years) 21 .8 ± 0.51 21 .9 ± 0.91 0.9539 
BMI (kg/m2} 22.6 ± 1.24 23.1 ± 1.00 0.7881 
4.4.2 Nutrient intake assessment 
Raw data for each subject's nutrient intake recorded at baseline are presented on Appendix 
4.3. The results for the nutrient intakes for the two groups are going to be discussed in 
Chapter 8. 
4.4.3 Supplement compliance test 
Subject's adherence to the supplement protocol was determined using the two techniques 
described in Chapter 2 - page 83. Firstly, the number of capsules remaining after the 
supplementation period was counted to determine compliance. One participant from the 
white group missed taking the supplements for 2 days. The other remaining 16 subjects did 
not have leftover capsules at day 30, showing that they had adhered to the supplement 
protocol. 
Secondly, the changes in the concentration of EPA, DHA and GLA in RBC total 
phospholipids after supplementation compared to baseline were calculated as a measure of 
supplement compliance. These FAs were chosen because they were the major components 
of the n-6 and n-3 FA capsules given to subjects. 5 Black and 5 white subjects were 
randomly selected from the study participants for the compliance test. 
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The concentrations of EPA and DHA in RBCs total phospholipids of the selected subjects at 
days O and 30 are shown in Table 4.2. Raw data showing the FA composition (as 
concentration (µg/ml)) in RBC total phospholipids for each individual are presented in 
Appendix 4.4. The percentage changes of FAs after supplementation were calculated as 
shown in Chapter 2 - page 83. 
In both groups, supplementation significantly increased the concentrations of EPA in plasma 
total phospholipids at day 30. In blacks, the mean percentage change for EPA in plasma 
total phospholipids was 530 % (p-value < 0.0001), whereas in whites, a mean percentage 
change of 315 % (p-value <0.0001) was observed . The concentrations of DHA in plasma 
phospholipids increased to a lesser degree in comparison to those of EPA. The mean 
percentage change for DHA in plasma total phospholipids was 46 % (p-value = 0.0871) in 
blacks and 39 % (p-value = 0.0305) in whites. These results are in agreement with the 
changes observed in Chapter 3 - page 120 and with those in other studies where the n-3 FA 
dose similar to the one used in the present study was given to healthy subjects [15, 21 and 
22]. 
Concentrations of GLA in RBC total phospholipids after supplementation in the majority of 
subjects were extremely low (Table 4.2). As such, the percentage changes in GLA 
concentrations in plasma total phospholipids could not be determined as a measure of 
compliance for the n-6 FA capsules. 
As an alternative, the changes in the concentrations of DGLA in RBC phospholipids were 
calculated to determine whether the absence of an increase in GLA concentrations was due 
to the metabolism of GLA to DGLA [11 - 13]. The concentrations of DGLA in RBC total 
phospholipids for each subject at days O and 30 are shown in Table 4.2. The mean 
percentage change for DGLA was -11 .2 % (p-value = 0.5924) in blacks and -5.9 % (p-value 
= 0.4502) in whites. These values show that there was no increase in the concentration of 
DGLA after supplementation. It was therefore concluded that the concentrations of DGLA in 
RBC total phospholipids do not reflect the metabolism of GLA to DGLA. The explanations for 
the low GLA and DGLA concentrations in RBC total phospholipids after GLA 
supplementation are described in Chapter 2 - page 83. In the present study, the changes in 
the concentrations of GLA were not determined in other lipid fractions because of financial 
constraints. 
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As a result, n-6 FA capsule compliance by subjects could not be confirmed . However, since 
subjects were instructed to take the n-6 FA capsules together with n-3 FA capsules during 
meal times, it was reasonably assumed that they had complied. 
Overall , it was concluded that subjects had adhered to the supplement protocol since > 85 % 
of the fatty acid capsules given to subjects were consumed [23, 24]; and because of the 
changes in the concentrations of EPA and DHA in RBC total phospholipids that were 
observed. 















































































































































































































































































































Chapter 4 Results 
4.4.4 Serum biomarkers and FA composition in plasma total phospholipids 
Baseline 
The differences in the concentrations of serum biomarkers and fatty acids in plasma total 
phospholipids between the black and white subjects observed at baseline are shown in 
Table 4.3. Raw data showing the concentrations of 25(0H)D and TAGs for each subject are 
shown in Appendix 4.5 and 4.6 respectively. Raw data showing the concentrations of FAs in 
plasma phospholipids for each individual are presented in Appendix 4.7. Serum 25(0H)D 
concentrations were significantly lower in the black group compared to the white subjects. 
The differences in the concentrations of FAs between the two groups at baseline are 
summarized in Table 4.4. The comparison of the percentage composition of FAs in plasma 
phospholipids between the two groups at baseline are shown in Table 4.5. Raw data 
showing the percentage composition of FAs in plasma phospholipids for each individual are 
presented in Appendix 4.8. There were no significant differences observed in the percentage 
composition of FAs between the groups observed at baseline. 
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Table 4.4 
Summary of significant differences in concentrations of 
FAs (µg/mL) between groups at day O - n-6 & n-3 FA study 
FA class Type of FA BvsW 
SFA PA B<W* 
MUFA OA B<W* 
PUFA LA (n-6 FA) B<W* 
*: p-value s; 0.05 (intergroup comparison) 
Post-supplementation 
The concentrations of serum biomarkers and FAs in plasma phospholipids at day 30 are 
shown in Table 4.3. In both groups, the concentrations of serum 25(0H)D and TAGs at day 
30 were not statistically different to those observed at baseline. In the black group, 
significant decreases in the concentrations of n-6 FAs such as EDA, AA, ADRA and DPA 
were observed after supplementation. On the other hand, concentrations of n-3 FAs such as 
EPA, DPA and DHA were significantly increased at day 30 compared to baseline. Within the 
white group, the concentration of ADRA (n-6 FA) was significantly reduced at day 30 
whereas concentrations of EPA, DPA and DHA (n-3 FAs) were significantly increased. There 
were no significant changes in the concentrations of SFAs and MUFAs after 
supplementation in both groups. The differences in the concentrations of FAs in plasma total 
phospholipids between groups at day 30 are shown in Table 4.3. Comparison of the fatty 
acid concentrations in plasma total phospholipids between groups at day 30 showed VA 
(MUFA) , and SFAs such as MA, ARA and LGA to be significantly lower in the black group. 
Similar to the observations at baseline, the concentrations of 25(0H)D, PA (SFA) and OA 
(MUFA) were found to be significantly lower in the black group at day 30. 
The percentage compositions of FAs in plasma phospholipids at day 30 are shown in Table 
4.5. The changes in the percentage composition of PUFAs in blacks and whites relevant to 
the present study are illustrated in Figures 4.1 and 4.2, respectively. With in the black group, 
the percentage compositions of PA (SFA) and n-6 FAs such as EDA, AA, ADRA and DPA 
were significantly decreased at day 30. In contrast, significant increases in the percentage 
compositions of n-3 FAs such as EPA, DPA and DHA were observed after supplementation . 
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Chapter 4 Results 
In the white group, the percentage composition of ADRA (n-6 FA) was significantly 
decreased at day 30. On the other hand, the percentage compositions of EPA, DPA and 
DHA (n-3 FAs) in plasma total phospholipids were significantly increased after 
supplementation. 
The differences in the percentage composition of FAs in plasma TPL between groups at day 
30 are shown in Table 4.5. After supplementation, the percentage composition of MA (SFA) 
and GA (MUFA) were found to be significantly lower in blacks compared to whites, whereas 
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Figure 4.1: Percentage composition of PUFAs in blacks after n-6 & n-3 FA supplementation 
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Figure 4.2: Percentage composition of PUFAs in whites after n-6 & n-3 FA supplementation 
4.4.5 Urinary risk factors 
Baseline 
The differences in the urinary parameters between groups at baseline are shown in Table 
4.6. Raw data showing the urinary parameters of each subject are presented in Appendix 
4.9. The comparison of urinary composition between groups at baseline showed urinary 
calcium, magnesium and RS brushite to be significantly lower in blacks, whereas urinary 
sodium was significantly higher. Urinary calcium, magnesium and RS brushite remained 
significantly lower in blacks during the supplementation and washout periods. 
Post-supplementation 
The changes in the urinary risk factors within groups during the supplementation period are 
shown in Table 4.7. The p-values are presented in Appendix 4.10. In the black group at day 
30, urinary citrate was significantly increased compared to baseline whereas urinary oxalate 
and RS CaOx were significantly decreased. In whites, a significant increase in urinary 
magnesium was observed at day 30. 
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Table 4.6 
Comparison of urinary risk factors between groups at baseline 
- n-6 & n-3 FA study 
Parameter Blacks Whites p-value 
pH 6.34 ± 0.34 6.15 ± 0.16 0.6718 
Volume (ml/24h) 1397 ± 210 1361 ±281 0.9172 
Calcium (mmol/24h) 1.77 ± 0.20 2.46 ± 0.22 0.0358:; 
Magnesium (mmol/24h) 1.55 ± 0.20 2.29 ± 0.22 0.0260+ 
Phosphate (mmol/24h) 24.1 ± 2.56 30.5 ± 1.83 0.0821 
Chloride (mmol/24h) 136 ± 12.4 118 ± 20.0 0.4284 
Citrate (mmol/24h) 2.03 ± 0.38 1.78 ± 0.25 0.6272 
Creatinine (mmol/24h) 16.2 ± 0.96 17.4 ± 0.79 0.4020 
Oxalate (mmol/24h) 0.31 ± 0.03 0.32 ± 0.06 0.9184 
Potassium (mmol/24h) 33.2 ± 2.17 27.4 ± 3.30 0.1477 
Sodium (mmol/24h) 128 ± 9.96 90.0 ± 9.60 0.0193:; 
Urate (mmol/24h) 3.07 ± 0.29 3.83 ± 0.22 0.0729 
Ionized Ca,!+ (mmol/L) 0.37 ± 0.07 0.52 ± 0.16 0.3662 
PGE2 (ng/24h) 604 ± 88.4 509 ± 70.7 0.4460 
HYP (nmol/mg creatinine) 2.14±1.33 0.89 ± 0.24 0.3827 
MSL (mM) 1.12±0.14 0.99 ± 0.13 0.5145 
TRI 179±19.9 203 ± 43.1 0.5821 
SS CaOx 3.78 ± 0.68 5.48 ± 1.08 0.1808 
SS Brushite 0.52 ± 0.10 1.32 ± 0.44 0.0497:; 
SS Uric acid 1.91 ± 0.54 2.25 ± 0.72 0.7082 
:i: . . p-va/ue :5 0.05 (intergroup companson) 
The differences in the urinary parameters between groups during the supplementation 
period are shown in Table 4.8. The comparison of urinary parameters between groups at 
day 30 showed phosphate, creatinine, urate and SS CaOx to be significantly lower in the 
black group. At day 15, it was observed that n-6 & n-3 FA supplementation had an effect on 
the urinary parameters in both groups. Within the black group, creatinine, oxalate, potassium 
and urate were significantly decreased compared to baseline. In whites, magnesium was 
significantly increased at day 15 compared to baseline concentrations. 
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Similarly to the observations made at day 30, the comparison of urinary parameters between 
groups at day 15 showed phosphate, creatinine, urate and SS CaOx to be significantly lower 
in the black group (Table 4.8). 
Washout period 
The urinary compositions of the two groups during the washout period are shown in Table 
4.7. In the black group, urinary oxalate and sodium were significantly lower than baseline 
concentrations at day 35. In whites, phosphate, creatinine and urate were significantly lower 
than baseline during washout. There were no significant differences in the urinary 
parameters between groups during the washout period (Table 4.8). 
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Chapter 4 Results 
2.4.6 CaOx MSL and crystallization kinetics studies 
The average CaOx MSL for black and white subjects observed on days 15, 30 and 35 are 
shown in Table 4.9. The p-values are shown in Table 4.10. Within groups, there were no 
significant differences observed in the CaOx MSL during the supplementation and washout 
periods compared to baseline. 
The p-values for the CaOx MSL intergroup comparisons during the supplementation and 
washout period2 are shown in Table 4.10. The Ca Ox MSL between groups was not 
statistically significant on each day of the experiment. 
The average values for the rates of particle formation in each group at each sampling point 
are shown in Table 4.9 and illustrated in Figures 4.3 and 4.4 for blacks and whites, 
respectively. The p-values are shown in Table 4.10. Raw data for each individual are 
presented in Appendix 4.11 . Within groups, there was no significant change in the rates of 
particle formation during the supplementation and washout periods compared to baseline. 
However, it was noted that there was an increasing trend in the rates of particle formation in 
the black group during the supplementation and washout period compared to baseline 
values (Figure 4.3) . In contrast, a decreasing trend in the rates of CaOx crystallization was 
observed in whites at days 15, 30 and 35 compared to those observed at baseline (Figure 
4.4). 
Quantitative comparison of CaOx crystallization kinetics between groups was not determined 
because different instruments were used, and therefore different values were obtained 
(Table 4.9). 
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Figure 4.4: Rates of particle formation in whites after n-6 & n-3 FA supplementation 
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4.5 DISCUSSION 
As indicated in the preceding chapters , the discussion in the present study will focus on 
plasma and urinary risk factors for CaOx stone formation while dietary intakes of subjects 
recorded at baseline will be discussed in Chapter 8. 
4.5.1 Serum biomarkers 
Supplementation did not show any effect on the serum concentrations of 25(0H)D and 
TAGs in both groups (Table 4.3). Comparison of these results with those of other studies 
was not possible because the latter have not investigated the effects of a combination of n-6 
& n-3 FAs on these serum biomarkers as has been done in the present study. The lower 
serum 25(0H)D concentrations in blacks observed at baseline compared to whites in the 
present study are consistent with results obtained in Chapters 2 and 3 (Tables 2.3 and 3.3) 
and are associated with the differences in vitamin D synthesis between the groups. 
4.5.2 Plasma total phospholipids 
Baseline 
As previously described in Chapter 2 - page 100, the differences in the fatty acid 
composition in plasma total phospholipids between the two race groups at baseline are 
attributable to the differences in the dietary habits of the two populations. 
Post supplementation 
In the present study, it was speculated that supplementation with a combination of n-6 and 
n-3 FAs would result in an increase in the concentrations and percentage compositions of 
EPA, DHA, GLA and DGLA in plasma total phospholipids. Furthermore, supplementation 
was not expected to change the concentrations and percentage compositions of AA in 
plasma total phospholipids. 
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EPA and DHA - n-3 FAs 
Within groups, the concentrations and percentage compositions of EPA and DHA in plasma 
total phospholipids were significantly increased after supplementation (Table 4.3 and 4.5) . 
Thus, the n-3 FA content of the capsules given to subjects during supplementation period 
increased the proportions of these FAs in plasma phospholipids, as expected . These results 
are similar to those reported by other investigators after supplementation with a combination 
of n-3 and n-6 FAs for 3 to 6 weeks with doses of GLA, EPA and DHA comparable to those 
used in the present study [25 - 27]. 
GLA and DGLA - n-6 FAs 
In the present study, the amounts of GLA in plasma total phospholipids before and after 
supplementation were low for the majority of black and white subjects (Appendix 4.7 and 
4.8) . Considering that GLA supplementation is expected to increase the amounts of GLA in 
various lipid fractions, an increase in the fatty acid composition of this FA was also expected 
in this study. Haglund et al [26] reported similar observations with regards to the low GLA 
amounts in plasma total phospholipids after supplementation with n-6/n-3 FAs for 4 weeks. 
In contrast, significant increases in the percentage compositions of GLA in other lipid 
fractions such as serum phospholipids and plasma total lipids has been reported by other 
studies after n-6/n-3 FA supplementation [25, 27]. As previously described in Chapter 2 -
page 90, the low GLA amounts after supplementation in the present study are suggested to 
be due to the limited incorporation of GLA into plasma phospholipids compared to other lipid 
fractions. Due to financial constraints, the changes in the concentrations and percentage 
composition of GLA in these lipid fractions could not be determined. 
With regards to DGLA, a decreasing trend in the concentrations and percentage 
compositions of this FA in plasma total phospholipids was observed in both groups after 
supplementation (Table 4.3 and 4.5) . Similar observations were reported by other studies 
after supplementation with n-6 & n-3 FAs [25, 26] . Nonetheless, these findings are contrary 
to those reported by Laidlaw et al. [27] and Geppert et al [28] on the same supplement 
protocol. 
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Most importantly, it was shown in Chapter 2 (Table 2.3 and 2.5) that GLA supplementation 
with the same dose used in the present study results in an increase in the concentrations 
and percentage compositions of DGLA in plasma total phospholipids. Therefore, the 
absence of an increase in the amounts of DGLA in total phospholipids in the present study is 
suggested to be due to the action of EPA and DHA. 
In Chapter 3 (Table 3.3 and 3.5), it was demonstrated that EPA and DHA supplementation 
resulted in a significant decrease in the concentrations and percentage compositions of 
DGLA in plasma total phospholipids in both groups. The inclusion of EPA and DHA in the 
current supplement protocol is suggested to have prevented the incorporation of DGLA in 
membrane phospholipids since there is competition between these n-6 and n-3 FAs for 
PUFA metabolic synthesis which favours the n-3 FA pathway [28 - 31]. 
AA-n-6 FA 
In the present study, the concentrations and percentage compositions of AA in plasma total 
phospholipids decreased after supplementation (Table 4.3 and 4.5). Furthermore, this 
decrease was statistical significant in the black group. These observations are similar to 
those made by Laidlaw et al. [26] and Haglund et al [27] after supplementation with a 
combination of n-6 and n-3 FAs for 4 weeks. In Chapter 2 (Table 2.3 and 2.5), it was 
demonstrated that GLA supplementation with the same dosage used in the present study 
does not affect the fatty acid composition of AA in plasma total phospholipids. However, in 
Chapter 3 (Table 3.5) , the percentage composition of AA in plasma total phospholipids was 
significantly decreased in both groups after supplementation . Thus, it can be seen that in the 
present study, EPA and DHA competed with AA for incorporation into membrane 
phospholipids which decreased the amounts of AA in this lipid fraction . 
Intergroup comparisons 
The effects of supplementation with a combination of n-6/n-3 FAs on the fatty acid 
composition with in black and white subject were similar. In both groups, a decreasing trend 
in the amounts of n-6 FAs was observed , whereas n-3 FAs were significantly increased after 
supplementation (Table 4.3 and 4.5). However, the significantly reduced AA amo~nts that 
were observed in blacks only (Table 4.3 and 4.5) suggests that the incorporation rates of 
FAs in membrane phospholipids may be uniquely different for each population group. 
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This study shows that dietary supplementation with a combination of GLA, EPA and DHA in 
healthy subjects can be used to increase the amounts of EPA and DHA in plasma total 
phospholipids without increasing those of AA. These results may have favourable 
implications for CaOx stone formation since they imply a higher formation of anti-
inflammatory agents from EPA and DHA as opposed to the pro-inflammatory agents from 
AA which are known to increase calcium and oxalate excretion . 
4.5.3 Urinary risk factors 
In the present study, the urinary excretion of PGE2 within groups was not significantly 
affected by supplementation with n-6 & n-3 FAs. As such, urinary calcium and oxalate were 
expected to remain unchanged after supplementation. The unchanged concentrations of 
urinary calcium in both groups and urinary oxalate in whites are in line with the expectations 
of the study (Table 4.7) . The changes in urinary oxalate that were observed in the black 
group are not considered to be due to the significantly decreased amounts of AA in plasma 
total phospholipids since urinary PGE2 was not decreased after supplementation. However, 
it is speculated that the lower urinary oxalate and therefore, SS CaOx in blacks, may be due 
to the effects of the metabolic products of EPA and DHA on the urinary CaOx risk factors. An 
increased production of PGE3 has been demonstrated after increasing the fatty acid 
composition of EPA and DHA in membrane phospholipids; whereas lower PGE2 formation is 
associated with decreases in AA [32 - 34] . Although the n-3 FA metabolites were not 
determined in the present study, an increase was expected since significant increases in the 
fatty acid composition of EPA and DHA were observed. The comparison of the effects of the 
current supplement protocol on the CaOx urinary risk factors with literature could not be 
determined because of lack of data. 
Moreover, the increase in urinary citrate and magnesium that was observed in blacks and 
whites, respectively, is suggested to be due to the effects of both n-3 and n-6 FAs since 
these changes were also observed after supplementation with these fatty acids separately 
(Chapter 2 - Table 2.8 and Chapter 3 - Table 3.8) . Thus, the combination of n-6 & n-3 FA 
supplement protocol may be more effective than n-3 or n-6 FAs alone in reducing the risk 
factors for kidney stone disease. 
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Additionally, the current supplement protocol elicited some changes on the urinary risk 
factors in both groups at day 15 (Table 4.7). These findings suggest that supplementation for 
this period with these FAs may be sufficient for generating beneficial changes in urinary 
CaOx risk factors. With regards to the effects of supplementation within groups, the study 
has shown that the two groups responded differently to the supplement protocol as observed 
in the urinary risk factors after supplementation (Table 4.7) . These observations support the 
views of other investigators where these two groups have been observed to have different 
renal handling mechanisms with respect to dietary supplementation agents [35] . 
Despite supplement withdrawal , additional changes in the urinary risk factors within both 
were observed at day 35 (Table 4.7) . These findings support the hypothesis that a washout 
period of 5 days is insufficient for the fatty acid composition in plasma total phospholipids to 
return to baseline values in healthy subjects. Due to financial constraints , these observations 
could not be confirmed by determining the fatty acid composition in membrane phospholipids 
at day 35. 
Summary 
Combined supplementation produced conflicting favorable results within the 2 race groups. 
In the black group, a significant decrease in AA was observed after n-6 & n-3 FA 
supplementation . In addition , a significant decrease in urinary oxalate and SS CaOx was 
observed at day 30 while urinary citrate was significantly increased. Meanwhile, a significant 
increase in urinary magnesium was observed in whites after n-6 & n-3 FA supplementation. 
These results confirm the findings from other studies where blacks and whites responded 
differently to dietary supplement challenges. 
In plasma total phospholipids, common favorable changes were observed in both groups 
after supplementation. A significant increase in the percentage compositions of EPA and 
DHA were observed post-supplementation compared to baseline. This increase may be 
beneficial to CaOx stone formation since it implies that the EPA and DHA metabolites may 
be formed to a greater extent compared to PGE2. Overall , there were no significant 
decreases in AA concentrations and urinary calcium and oxalate after supplementation in 
both groups. Thus, n-6 & n-3 FA supplementation was not effective in reducing the blood 
and urinary risk factors associated with CaOx stone formation . 
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5.1 INTRODUCTION 
Urinary excretion of glycosaminoglycans (GAGs) in stone patients has been shown to be 
considerably lower than in healthy individuals [1 - 4]. As a result, the role of GAGs in kidney 
stone disease has been investigated in numerous studies [5 - 8]. When tested in in vitro 
experiments, various GAGs have been shown to have protective effects against stone 
formation by retarding the kinetic processes involved in crystal formation . For example, 
chondroitin sulfate (CS) [9-11 ], heparan sulfate [12, 13] and dermatan sulfate [14] have been 
found to inhibit nucleation , crystal growth and aggregation in synthetic and/or real urine 
samples. 
In view of this, it has been suggested that increasing the levels of urinary GAGs may be of 
great benefit to stone formers by preventing or reducing the risk of kidney stone formation [7, 
15]. The possibility of achieving the required levels of GAGs by ingesting GAG supplements 
needs to be investigated. 
The present study was therefore undertaken to investigate the role of GAG supplementation 
in kidney stone formation. The particular GAG selected was CS because it is the major GAG 
found in urine, and therefore its role in kidney stone disease is of great interest. The 
objectives of the study were to evaluate the urinary excretion of total GAGs in healthy black 
and white South African subjects before and after supplementation with CS. In addition, the 
effect of CS supplementation upon biochemical urinary risk factors in these subjects was 
also determined. Moreover, the effect of CS on CaOx crystallization in urine samples of 
subjects before and after supplementation was investigated to determine whether 
supplementation increases the inhibitory activity of urinary CS against crystallization. 
5.2 STUDY PROTOCOL 
The study protocol was approved (HREC Ref: 381/2013) by the University of Cape Town 
Human Research Ethics Committee (Appendix 5.1) and informed consent was obtained from 
all the subjects before the commencement of the study. Subjects had no history of renal 
disease, blood clotting disorders or bone diseases. 6 Black and 6 white healthy male 
subjects from the University of Cape Town were enrolled in the study. Prior to the 
supplementation protocol , subjects collected 24h urine samples that were used as control 
samples 
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Food intakes were recorded in a food diary (Appendix 2.5). Subjects were given a list of 
foods that have high oxalate content (Appendix 2.6), and they were required to avoid these 
foods while collecting urine samples. 
CS supplements were purchased from Biogen, SA (Glucosamine Chondroitin 1500/1200, 
Biogen Platinum Series). Each capsule contained 1500 mg glucosamine sulfate and 1200 
mg chondroitin sulfate. Subjects were instructed to ingest 1 capsule per day, during 
breakfast, for 7 days. 
CS in combination with glucosamine sulfate is often used as a health supplement for the 
treatment of arthritis [16 - 18]. Glucosamine sulfate and chondroitin sulfate (GLU-CS) 
supplementation has been reported to be beneficial for patients with arthritis because 
glucosamine sulfate is a substrate for GAG synthesis in humans [19, 20]. 
The GLU-CS supplement that was used in the present study was chosen because it 
contained the lowest number of other components compared to other such products. Other 
supplement capsules contained components such as magnesium, vitamin D and calcium 
which were deemed as being potentially conflicting. 
The chosen amounts of glucosamine sulfate and CS were within the recommended daily 
intakes in healthy subjects [21] . Dietary supplementation with 1500 mg glucosamine sulfate 
in combination with 1200 mg chondroitin sulfate per day, for periods ranging from 1 week to 
3 years, has not been associated with any side effects [16, 22 - 24]. Furthermore, it has 
been shown that supplementation with GLU-CS can increase the concentrations of the 
glucosamine sulfate and CS sulfate in serum samples of healthy subjects within 5 hours [25]. 
At day 7, subjects collected additional 24h urine samples while consuming the foods that 
were recorded at baseline. 
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5.3 EXPERIMENTAL ANALYSIS 
5.3.1 Nutrient intake analysis 
The nutrient intakes of the two groups at baseline were calculated using the Foodfinder II 
computer program as described in Chapter 2 - page 71 . 
5.3.2 Urinary risk factors 
Pooled urine sample preparation 
A 250 ml aliquot of the 24h urine sample from each subject was decanted to form a pooled 
urine sample for each race group. The pooled urine sample was prepared by mixing together 
six 250 ml of 24h urine samples from each group. Thus, each group had a pooled urine 
sample (1 .5 l) on days O and 7. Another 1.5 l pooled urine sample was prepared using the 
same procedure described above and was reserved for the total GAG assay. The pooling of 
urine samples was implemented to eliminate interracial urinary differences such as urine 
chemistry and crystallization parameters. 
Urine analyses 
24h and pooled urine samples were analyzed for biochemical urinary risk factors as 
described in Chapter 2 - page 76. 
5.3.3 Risk indices 
The urinary composition data of 24h and pooled urine samples were used to determine the 
TRI and the SS values of CaOx, brushite and uric acid as described in Chapter 2 - page 81 . 
5.3.4 CaOx crystallization experiments 
24h urine samples were filtered and prepared for crystallization experiments as described in 
Chapter 2 - page 80. 
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CaOx metastable limit 
The CaOx metastable limit of each 24h urine sample was determined using the procedure 
described in Chapter 2 - page 80. The optical density of was measured at 620 nm using a 
spectrophotometer. 
CaOx crystallization kinetics 
The rates of CaOx particle formation in each 24h urine sample were determined according to 
the method described in Chapter 2 - page 81 . 
5.3.5 Effect of CS on CaOx crystallization experiments 
In the present study, the effects of exogenous CS upon CaOx crystall ization experiments 
were investigated in synthetic, 24h and pooled urine samples. CS was chosen because it is 
the major GAG found in human urine [26] , and therefore, its contribution to kidney stone 
disease is of greater importance compared to other urinary GAGs. The concentration of CS 
in urine of healthy subjects has been reported to be 0.16 µg/ml of urine [27] . CS normally 
exists either as chondroitin-4-sulfate (CSA) or chondroitin-6-sulfate (CSC), depending on the 
position of the ester sulfate group on the galactose ring of the disaccharide unit [28, 29]. 
When the ester sulfate group is in the 4th position, CS exists as CSA and as CSC when the 
sulfate group is in the 6th position. Thus, in the present study, the effects of the two isomers 
will be investigated on CaOx crystallization to determine whether they will be different from 
each other. The chemical structures of CSA and CSC are shown in Figure 5.1. 
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Synthetic urine preparation 
In an attempt to find the effect of CS in vitro, crystallization experiments were conducted in 
synthetic urine samples containing specific amounts of ions that are usually found in real 
urine. Synthetic urine was prepared using the procedure described by Walton et al. [30]. 
Various salts, NaCl (18.7 g), NaH2P04 (6.90 g) , MgCb (1 .33 g), KCI (12.2 g), K3C6H50 7 (1.41 
g), (NH4)2S04 (5.79 g) and NH4CI (0.37 g), were dissolved in 1 L distilled water. Care was 
taken to ensure that each salt was dissolved completely before mixing the next one. The pH 
of the solution was adjusted to 6.0 by the addition of 5 M NaOH. 
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Thereafter, the synthetic urine was kept in a refrigerator at 4 °C and was used within 4 days. 
0.12 M CaCl2 and 0.05 M Na20x were prepared separately and stored at 4 °C. On the day of 
analysis, the stored solutions were warmed in a waterbath at 37 °C and filtered through a 
0.22 µm filter paper (Whatman No 1, Germany) just before use. 
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500 ml distilled water, 50 ml CaCl2 and 20 ml Na20x solutions were added to 430 ml of 
the synthetic urine to give a molar calcium and oxalate ratio of 6: 1. 
Preparation of CS solutions 
Chondroitin sulfate sodium salts, CSA from bovine trachea (C-8529, Lot # 84H0127) and 
CSC from shark cartilage (C-4384, Lot # 1426300V), were obtained from Sigma Aldrich, 
South Africa. CSA and CSC standard solutions of 150 µg/ml were prepared separately in 
distilled water. 
Effect of CS on CaOx MSL 
Seven 100 ml aliquots of synthetic urine samples were used to determine the effect of CS 
on the CaOx metastable limit [31]. One of the aliquots was treated as a control sample in 
which no CSA or CSC was added. The other six aliquots were dosed with different volumes 
of CSA or CSC standard solutions to give various final concentrations as shown in Table 5.1 . 
Thus, CS was tested in synthetic urine at physiological concentrations and at 2, 10 and 100 
times higher than physiological concentrations. 
rrable 5.1 
Concentrations of CS in urine samples 
Amounts added Concentration 
Sample 
{mL) {µg/mL) 
CSA/C-0 0 0 
CSA-1 0.1 0.15 
CSA-2 0.2 0.30 
CSA-10 1.0 1.50 
CSC-1 0.1 0.15 
CSC-2 0.2 0.30 
CSC-10 1.0 1.50 
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5 mls of each synthetic urine sample were transferred into 13 coulter cups and warmed at 
37 °C in an oven for 10 minutes. CaOx precipitation was instigated by adding 50 µl Na20x 
standard solutions to each cup at increasing concentrations from 15 to 195 mM (in 
increments of 15 mM) to give final concentrations of 0.15 to 1.95 mM. The samples were 
further warmed at 37 °C. After 30 minutes, optical density was measured with an 
ultraviolet/visible (UV) spectrophotometer (Specord 40 Analytik Jena, UK) at a wavelength of 
620 nm. The measured absorbance was plotted against the final concentrations of the dosed 
urine samples, and the metastable limit was defined as lowest Na20x concentration that 
gave a sharp increase in optical density. 
24h and pooled urine samples were filtered as described in Chapter 2 - page 80. The effect 
of CS on the CaOx MSl was determined in each 24 and pooled urine sample after dosing 
with CSA or CSC using the procedure described for synthetic urine. 
Effect of CS on CaOx crystallization kinetics 
The effect of CS on CaOx crystallization kinetics was determined according to the method 
described by Ryall et al [31] . For each sample, 25 ml aliquot of the dosed artificial , 24h and 
pooled urine sample was transferred into a soda lime bottle and dosed with 25 µl Na20x at 
a concentration 15 mM above the previously determined MSl. The samples were then 
incubated for 90 minutes in a shaking waterbath at 37°C. Absorbance at 620 nm for each 
sample was measured at 15 min intervals using a spectrophotometer. The CaOx 
crystallization experiment was repeated twice for each urine sample. Plots of absorbance 
versus time were constructed ; and the slope of the linear portion was taken as the rate of 
CaOx crystal growth. 
5.3.6 Total GAG assay 
Total GAGs were extracted from the pooled urine samples according to a method described 
by Gohel et al. [32] . A 1.5 l aliquot of the pooled 24h urine samples was filtered on a plastic 
collapsible strainer to remove sediments. 4.5 l of 0.025 M acetate buffer (pH 5.8) and 150 
ml of cetylpyridium chloride (5 % in acetate buffer) were added to the filtered pooled urine 
samples. After mixing , the mixture was refrigerated overnight at 4 °C. The supernatant was 
decanted and the precipitate was centrifuged at 10 000 rpm for 20 minutes at 4 °C using a 
Model J2-21 
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Centrifuge (Beckman Coulter, USA) with a J14 rotor. The formed pellet was washed three 
times by adding cooled distilled water (4 °C), centrifugating for 10 minutes at 4 °C and 
afterwards discarding the supernatant. The pellet was then dissolved in 1 ml propan-1-
ol/water (2: 1, v/v) . 4 ml of sodium-acetate-saturated ethanol was added to the dissolved 
pellet mixture and refrigerated overnight at 4 °C to re-precipitate the pellet as sodium salt. 
Thereafter, the precipitate was washed twice with cooled ethanol (4 °C) by centrifuging at 
1 O 000 rpm for 1 O min and discarding the supernatant. The final pellet, which represents 
total urinary GAGs, was dried at 60 °C and weighed . 
5.3.7 Statistical analysis 
Statistical comparison of data was carried out using GraphPad lnstat 3 program. All data are 
reported as mean±SE. The results were considered statistically significant if p-value ~ 0.05. 
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5.4 RESULTS 
5.4.1 Subject's characteristics 
The man age and BMI of subjects at baseline are shown in Table 5.2. Raw data for each 
individual's age, height, weight and BMI are presented in Appendix 5.2. There were no 
significant differences observed with regards to age and BMI between the two groups. 
Table 5.2 
Subject's characteristics at baseline - CS study 
Parameter Blacks Whites p-value 
Age {years) 20.8 ± 0.70 20.7 ± 0.92 0.8883 
BMI {kg/m2) 23.6 ± 1.49 24.4 ± 0.76 0.6222 
5.4.2 Nutrient intakes 
Raw data showing the dietary intakes of subjects recorded at baseline are presented in 
Appendix 5.3. Results for the comparison of nutrient intakes between groups are going to be 
discussed in Chapter 8. 
5.4.3 Compliance test 
In the present study, supplement compliance was determined by counting the number of 
capsules remaining at the end of the supplementation period [33, 34] . None of the subjects 
returned GLU-CS supplements at day 7. As a result, it was concluded that the subjects had 
adhered to the supplement protocol. 
5.4.4 Urinary risk factors 
24h urine samples 
Mean urinary parameters of the two groups at baseline and on day 7 are shown in Table 5.3. 
Raw data showing the urinary composition of each subject at days O and 7 are presented in 
Appendix 5.4. Urinary creatinine, oxalate and phosphate were observed to be significantly 
lower in the black group compared to the white subjects at baseline. 
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Within groups, there were no significant differences in any of the measured parameters at 
day 7 compared to baseline. 
Comparison of urinary parameters between groups at day 7 showed that the RS brushite 
was significantly lower in the black group compared to whites. The differences in urinary 
oxalate and phosphate between groups that were observed at day 7 were not attributed to 
the effect of supplementation since they were present at baseline. 
Table 5.3 
Urinary risk factors in 24h urine samples of blacks and whte subjects - CS study 
Blacks Whites B vs W (p-values) 
Parameter 
Day O Day7 DayO Day7 Day O Day 7 
pH 6.41 ± 0.21 6.03 ± 0.09 6.20 ± 0.11 6.21 ±0.12 0.3832 0.2599 
Volume (ml/24h) 1213±167 1408±151 1372±124 1383 ± 207 0.4649 0.9241 
Calcium (mmol/24h) 4.03 ± 0.29 3.21 ± 0.27 3.38 ± 0.56 4.08 ± 0.94 0.3229 0.3944 
Chloride (mmol/24h) 170 ± 15.1 161 ± 20.6 174±27.1 159±24.1 0.9083 0.9428 
Citrate (mmol/24h) 2.45 ± 0.25 2.29 ± 0.24 3.26 ± 0.53 2.22 ± 0.31 0.1970 0.8546 
Creatinine (mmol/24h) 14.8 ± 0.95 14.7±1 .17 20.0 ± 1.55 18.5±1.92 0.0165* 0.1167 
Magnesium (mmol/24h) 3.00 ± 0.42 2.76 ± 0.28 3.83 ± 0.55 3.80 ± 0.55 0.2568 0.1210 
Oxalate (mmol/24h) 0.21 ± 0.02 0.22 ± 0.01 0.36 ± 0.04 0.28 ± 0.02 0.0097* 0.0413* 
Phosphate (mmol/24h) 23.0 ± 1.55 21.7 ± 2.25 41 .6 ± 6.00 37.5±5.41 0.0131* 0.0225* 
Potassium (mmol/24h) 35.4 ± 3.72 33.8 ± 4.29 38.2 ± 5.84 34.7 ± 5.54 0.6962 0.8949 
Sodium (mmol/24h) 144 ± 11 .5 131 ±21.4 154 ± 20.8 137 ± 17.1 0.6902 0.8326 
Urate (mmol/24h) 3.03 ± 0.27 3.27 ± 0.32 3.92 ± 0.33 4.08 ± 0.41 0.0657 0.1494 
TRI 221 ± 19.0 180±15.7 192 ± 20.5 210 ± 28.2 0.3161 0.3772 
SS CaOx 5.04 ± 0.76 3.62 ± 0.48 5.23 ± 1.03 6.08 ± 1.58 0.8860 0.1675 
SS Brushite 1.51 ± 0.43 0.61 ± 0.09 1.44 ± 0.30 2.03 ± 0.60 0.8932 0.0411 * 
SS Uric acid 1.31 ± 0.74 1.73±0.41 1.55 ± 0.40 1.81 ± 0.59 0.7809 0.9099 
*: p-va/ue :5 0.05 (intergroup comparison) 
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Pooled urine samples 
The urinary composition of the pooled urine samples for blacks and whites at days O and 7 
are shown in Table 5.4. Intra- and inter-group statistical comparison of the urinary 
compositions in pooled urine samples at days O and 7 could not be determined because of 
insufficient data. For each group, there was one pooled urine sample at each day of the 
experiment. A minimum of three sets of data are required for statistical analysis. As a result, 
statistical analysis in pooled urine samples was not performed in the present study. 
!Table 5.4 
Urinary risk factors in pooled urine samples of black and 
~hite subjects - CS study 
Parameter 
Blacks (n=6) Whites (n=6) 
Day O Day7 DayO Day7 
pH 6.33 6.1 6.18 6.13 
[Volume (L) 1.50 1.50 1.50 1.50 
Calcium (mmol/L) 3.37 3.53 2.87 4.47 
Chloride (mmol/L) 182 125 121 120 
Citrate (mmol/L) 1.44 1.31 1.37 2.47 
Creatinine (mmol/L) 14.7 11 .1 15.1 14.7 
Magnesium (mmol/L) 2.65 1.85 2.90 3.10 
Oxalate (mmol/L) 0.19 0.17 0.29 0.24 
Phosphate (mmol/L) 24.2 14.2 31 .8 30.2 
Potassium (mmol/L) 42.1 13.3 25.2 26.4 
Sodium (mmol/L) 146 102 103 96 
Urate (mmol/L) 3.07 2.40 3.07 3.40 
TRI 190 282 245 267 
SS CaOx 5.04 6.67 7.42 8.25 
SS Brushite 2.23 1.26 2.01 2.54 
SS Uric acid 0.98 1.33 1.42 1.76 
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5.4.5 CaOx MSL in 24h and pooled urine samples 
Table 5.5 shows the values for CaOx MSL in 24h and pooled urine samples of black and 
white subjects at days O and 7. Raw data for the experiments are presented in Appendix 5.5. 
In 24h urine samples, the average CaOx MSL in each group was not significantly different at 
day 7 compared to baseline. Intergroup comparisons at both days O and 7 showed that the 
CaOx MSL between groups were not statistically significant.The changes in CaOx MSL of 
pooled urine samples (Table 5.5) could not be determined because of insufficient data 
(Explanation in Chapter 5 - page 190). 
~able 5.5 
CaOx MSL in 24h and pooled urine samples at days O and 7 - CS study 
Blacks Whites B vs W (p-values) 
Urine sample 
DayO Day7 DayO Day 7 DayO Day 7 
24h 1.13±0.08 1.32 ± 0.06 0.95 ± 0.09 1.17±0.06 0.1918 0.0955 
Pooled<!> 1.20 0.90 0.75 0.60 ND ND 
<I> : No statistical analysis in pooled urine samples 
5.4.6 Effect of CS on the CaOx MSL 
Synthetic urine 
The concentrations of Na20x required to induce crystallization in synthetic urine after dosing 
with increasing concentrations of CSA and CSC are shown in Table 5.6. Raw data for each 
experiment are presented in Appendix 5.6. In both experiments, the CaOx MSL was not 
significantly affected by the addition of CSA or CSC. 
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!Table 5.6 
Effect of CS on CaOx MSL in 
isvnthetic urine 
Sample Expt<ti 1 Expt<ti 2 
CSA/C-0 1.20 1.20 
CSA-1 1.20 1.20 
CSA-2 1.20 1.20 
CSA-10 1.20 1.05 
CSC-1 1.05 1.20 
CSC-2 1.20 1.20 
CSC-10 1.20 1.20 
<I> : Expt - experiment 
24h urine samples 
Table 5.7 shows the CaOx MSL in 24h urine samples of black and white subjects at days O 
and 7. Raw data for the experiments are presented in Appendix 5.7. In each group, the 
effect of CS dosing was investigated in 3 subjects because the total urine volume in other 
subjects was not sufficient to conduct a greater number of determinations. Within groups, the 
CaOx MSL was found to be unaltered in all the urine samples after the addition of CSA and 
CSC. The shift in the CaOx MSL in subject 2 at day O in the black group was not considered 
to be statistically significant. 
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Pooled urine samples 
The CaOx MSL for the pooled urine samples in each group at days O and 7 are shown in 
Table 5.8. Raw data for the experiments are presented in Appendix 5.8. In both groups, the 
CaOx MSL was not affected by the addition of CSA or CSC at both days O and 7. The shift 
in the MSL that was observed after dosing with CSA-1 at day O and CSC-1 and CSC-10 at 
day 7 in blacks; and CSA-2 and CSC-10 at day 7 in whites, was not attributed to the effect of 
CS dosing since these shifts were not statistically significant. 
Table 5.8 
Effect of CS on CaOx MSL in pooled urine samples 
Blacks Whites 
Sample 
DayO Day 7 DayO Day 7 
CSA/C-0 1.20 0.90 0.75 0.60 
CSA-1 1.05 0.90 0.75 0.60 
CSA-2 1.20 0.90 0.75 0.75 
CSA-10 1.20 0.90 0.75 0.60 
CSC-1 1.20 0.75 0.75 0.60 
CSC-2 1.20 0.90 0.75 0.60 
CSC-10 1.20 0.75 0.75 0.45 
5.4.7 CaOx crystallization kinetics in 24h and pooled urine samples - days O and 7 
The average rates of CaOx crystallization kinetics in 24h urine samples at days O and day 7 
within groups are shown in Table 5.9 and illustrated in Figures 5.2 and 5.3 for blacks and 
whites, respectively. Raw data for the experiment are presented in Appendix 5.9. There were 
no significant differences observed within groups at day 7 compared to baseline in both two 
groups. 
Intergroup comparison showed that there were no significant differences in the rates of 
particle formation between groups at days O and 7. The p-values at day O and 7 were 0.6348 
and 0.0988, respectively. 
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rTable 5.9 
!Average rates of particle formation (particle/min) in 
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Figure 5.2: Rates of particle formation in 24h urine samples of black subjects 
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Figure 5.3: Rates of particle formation in 24h urine samples of white subjects 
Results 
The rates of CaOx crystallization kinetics in pooled urine samples of black and white 
subjects at days O and day 7 are shown in Table 5.10 and illustrated in Figures 5.4 and 5.5 
for blacks and whites, respectively. Raw data for the experiment are presented in Appendix 
5.10. Statistical analysis on the rates of kinetics was not done as explained in Chapter -
page 190. 
Table 5.10 
Average rates of particle formation (particle/min) 
in pooled urines of blacks and whites at days O & 7 
Subjects Day O Day 7 p-value 
Blacks 0.0004 0.0002 0.9853 
Whites 0.0002 0.0009 0.1641 
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Figure 5.4: Rates of particle formation in pooled urine samples of black subjects 
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Figure 5.5: Rates of particle formation in pooled urine samples of white subjects 
5.4.8 Effect of CS on the CaOx crystallization kinetics 
Synthetic urine 
The rates of CaOx particle formation in synthetic urine after CS dosing are shown in Table 
5.11 . The effects of CS on the CaOx crystallization kinetics in synthetic urine are illustrated 
in Figure 5.6. Raw data for the experiment is presented in Appendix 5.11 . 
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The average rates of particle formation in synthetic urine were found to be CSA/C-0 = CSA-1 
= CSA-2 = CSC-2 = CSC-10 > CSA-10 = CSC-1, but there were no significant differences 
observed in the rates of CaOx particle formation in urines dosed with CSA or CSC compared 
to the control synthetic urine sample. 
rTable 5.11 
Rates of CaOx particle 





































0 15 30 45 60 75 90 105 
Time (min) 
Figure 5.6 - Rates of CaOx crystallization in synthetic urine after CS dosing 
24h urine samples 
The average rates of particle formation in each group at days O and 7 are shown in Table 
5.12. The effects of CS on the rates of CaOx particle formation in 24h urine samples of black 
and white subjects are illustrated in Figure 5.5 and 5.6, respectively. Raw data for each 
experiment is presented in Appendix 5.12. 
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Table 5.12 
Rates of CaOx crystallization in 24h urine samples 
Sample 
Blacks Whites 
Day O Day7 Day O Day 7 
CSA/C-0 0.0026 0.0003 0.001 0.0004 
CSA-1 0.0021 0.0003 0.001 0.0003 
CSA-2 0.0027 0.0002 0.001 0.0003 
CSA-10 0.0019 0.0002 0.0017 0.0004 
CSC-1 0.0028 0.0002 0.0016 0.0004 
CSC-2 0.0021 0.0003 0.001 0.0004 
CSC-10 0.0024 0.0002 0.001 0.0005 
The trends in the rates of particle formation in both groups at days O and 7 are summarized 
below. 
Blacks 
Day 0: CSC-1 > CSA-2 > CSA/C-0 > CSC-10 > CSA-1 = CSC-2 > CSA-10 
Day 7: CSA/C-0 = CSA-1 = CSC-2 > CSA-2 = CSA=10 = CSC-1 = CSC-10 
Whites 
Day 0: CSA-10 > CSC-1 > CSA/C-0 = CSA-1 = CSA-2 = CSC-2 = CSC-10 
Day 7: CSC-10 > CSA/C-0 = CSA-10 = CSC-1 = CSC-2 > CSA-1 = CSA-2 
In both groups, the average rates of particle formation in dosed urine samples were not 
significantly different from those in which CSA or CSC was not added. 
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Pooled urine samples 
The rates of particle formation in pooled urine samples at days O and 7 are shown in Table 
5.13. The effects of CS on the CaOx crystallization kinetics in pooled urine samples of black 
and white subjects are illustrated in Figures 5.7 and 5.8, respectively. Raw data for the 
experiment is presented in Appendix 5.13. 
Table 5.13 
Rates of CaOx crystallization in pooled urine samples 
Blacks Whites 
Sample 
Day O Day 7 Day O Day7 
CSA/C-0 0.0015 0.0001 0.0002 0.0012 
CSA-1 0.0012 0.0002 0.0003 0.0012 
CSA-2 0.0011 0.0002 0.0004 0.0015 
CSA-10 0.0018 0.0001 0.0004 0.0018 
CSC-1 0.0014 0.0001 0.0004 0.0015 
CSC-2 0.002 0.0001 0.0002 0.0013 
CSC-10 0.0015 0.0001 0.0005 0.0015 
The trends in the rates of particle formation in pooled urine samples of both groups are 
summarized below. In both groups, the rates in particle formation within groups were not 
significantly different between dosed and un-dosed urine samples. 
Blacks 
Day 0: CSC-2 > CSA-10 > CSC-10 > CSC-1 > > CSA-1 > CSA-2 > CSA/C-0 
Day 7: CSA-1 > CSA-2 > CSA/C-0 = CSA=10 = CSC-1 = CSC-2 = CSC-10 
Whites 
Day 0: CSC-10 > CSA-2 = CSA10 = CSC-1 > CSA-1 > CSA/C-0 = CSC-2 
Day 7: CSA-10 > CSA-2 = CSC-1 = CSC-10 > CSC-2 > CSA/C-0 = CSA-1 
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5.4.9 Total GAG assay 
The amounts of total GAGs extracted in the pooled urine samples from before and after 
supplementation in each group are shown in Table 5.12. The percentage difference in the 
amounts of total GAGs at day 7 compared to baseline was 11 % in blacks and 3 % in whites. 
Since total urinary GAGs were extracted from pooled urine samples, statistical analysis on the 
differences in the excretion of total urinary GAGs could not be performed. 
n-able 5.14 
n-otal GAGs (mg/1500 ml pooled urines) 
from black and white subjects 
Subjects Day O Day 7 
Blacks 0.140 0.155 
Whites 0.129 0.133 
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5.5 DISCUSSION 
Intergroup comparisons at baseline showed that there were several significant differences in the 
urinary composition of the two groups. These differences will be discussed in Chapter 8. 
There was no significant increase in the amounts of total GAGs extracted in pooled urine 
samples after supplementation compared to baseline in both groups. This finding does not 
reflect the urinary concentrations of CS, which was one of the major components in the 
supplement capsules given to subjects. As mentioned earlier, due to financial constraints, the 
isolation of CS from the total GAGs was not feasible. Nonetheless, it has been shown that more 
than 50 % of the CS administered to healthy subjects is excreted in urine as high and low 
molecular weight derivatives of CS [35] . Thus, an increase in CS derivatives was expected in 
the present study as well. 
The present study demonstrated that the CaOx MSL and the rates of particle formation in 
synthetic, 24h and pooled urine samples dosed with different concentrations of CSA or CSC 
(0.15, 0.30 and 1.5 µg/ml) were not significantly different from control samples in which no 
CSA or CSC were added. These findings are similar to the observations made by Ryal! et al 
[36] where the physiological concentrations of CSA had no significant effect on the CaOx MSL 
and crystal growth in 24h urine samples. Since CSA or CSC concentrations 1 O times greater 
than physiological concentrations were used in the present study with no effect, previously 
reported growth inhibition may be due to total GAGs. Other studies have reported that GAGs, 
heparan sulfate and dermatan sulfate [37] , CSC and hyaluronic acid [38] and chondroitin sulfate 
[39] inhibit crystal growth and aggregation by adsorbing to the surface of crystals , preventing 
the development of large crystals. 
However, it should be noted that in the present study, a low molecular weight CS sodium salt 
(503.34 g/mol, Sigma Aldrich - South Africa) with one disaccharide unit was used in these 
crystallization experiments; whereas in urine CS exists as a polymer consisting of about 50 
disaccharide units with a molecular weight of about 20-25 kDa and 50-80 kDa for CSA and 
CSC, respectively [43] . Thus, the mode of action of commercial CS salts on CaOx 
crystallization may be different from that of CS extracted from urine samples. The extraction of 
CS from real urine samples could not be undertaken in the present study due to financial 
constraints; as such , the effect of human CS on CaOx crystallization could not be investigated. 
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Supplementation with CS in healthy black and white South African subjects for 7 days did not 
significantly change any of the urinary risk factors associated with CaOx stone formation which 
were investigated. These findings are in contrast to those made by Baggio et al [44] who 
observed a significant decrease in urinary oxalate after supplementation with a mixture of GAGs 
such as heparin and dermatan sulfate. Thus, it is suggested that CS did not interfere with any of 
the mechanisms responsible for calcium and oxalate excretion in the present study. 
Furthermore, there were no significant changes observed in CaOx MSL (Table 5. 3) and 
crystallization kinetics (Table 5.4) after supplementation compared to baseline in both groups. 
Summary 
Since the excretion of urinary GAGs in stone formers is lower than in healthy subjects, the 
present study was undertaken to determine the effects of higher urinary CS concentrations on 
the urinary risk factors for CaOx stone formation and on CaOx crystallization kinetics. Firstly, 
the effects of exogeneous CS concentrations on the CaOx MSL and crystallization kinetics were 
investigated in synthetic, 24h and pooled urine samples. The effects of CS at physiological 
concentrations on the MSL and crystallization kinetics were compared to those above 
physiological concentrations (2, 10- and 100-fold). The CaOx MSL and the rates of particle 
formation at higher CS concentrations were not significantly different from those at physiological 
concentrations. Secondly, the effect of oral administration of CS supplements was investigated 
in healthy black and white subjects to determine whether the urinary CaOx risk factors and 
crystallization kinetics will be affected. There were no significant changes on the urinary risk 
factors and crystallization kinetics experiments post-supplementation compared to baseline in 
both groups. 
Thus, increasing the concentrations of CS by dosing or by supplementation provided no new 
insights as to the mechanisms by which higher urinary CS concentrations may influence CaOx 
crystallization. Therefore, the role of CS in kidney stone formation may be further investigated 
by studying other mechanisms by which GAGs have been reported to inhibit stone formation 
[40 - 42] . It has been suggested that CS inhibits CaOx crystallizations through mechanisms 
other than preventing the growth of crystals such as complexation with ions such as Ca2+ [40 -
42] . 
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6.1 INTRODUCTION 
Urinary GAGs such as CS are negatively charged [1 - 4] . As such, they have the ability to bind 
and form complexes with cations such as calcium. This implies that GAGs can reduce the 
saturation of CaOx salts in urine by reducing the amounts of ionized calcium available to 
combine with oxalate. 
The binding of CS with calcium has been previously investigated using different techniques 
such as equilibrium dialysis [5, 6], frog heart perfusion, murexide, ultrafiltration, and calcium 
selective electrodes [7] . These studies have shown that calcium binds to a disaccharide unit of 
CSA or CSC to form a Ca-CSA or Ca-CSC complex. In all previous studies, the equilibrium 
binding constant for the formation of Ca-CSA or Ca-CSC complex was reported to be between 
14.9 - 43.4 M-1 [5 - 7]. 
However, in all these studies, the mechanisms by which CSA or CSC bind calcium have not 
been fully investigated. Since these GAGs are potential inhibitors of kidney stone disease, it is 
of great interest to investigate the manner in which they bind calcium. 
The purpose of the present study, therefore, is to investigate the mechanisms by which CSA 
and CSC bind calcium using isothermal titration calorimetry (ITC) [8 - 13]. The advantage of 
this technique over the previously mentioned techniques is that, in addition to measuring the 
binding constant, ITC also provides information on the stoichiometry (n) and the binding 
enthalpy (b.H) of each experiment. Furthermore, the Gibb's free energy (b.G) and entropy {b.S) 
can be calculated from the determined binding constant (K) . With ITC, for a given reaction, 
these thermodynamic parameters are all obtained from a single experiment. 
Because urine contains other cations that might compete with calcium for binding to CSA and 
CSC, it is the aim of the present study to measure the thermodynamic parameters associated 
with the binding of CSA and CSC to magnesium, and to compare them with those determined 
for calcium. The role of magnesium in kidney stone disease has been previously described in 
Chapter 1 - pages 9 and 11 . 
Lastly, it was shown in the study described in Chapter 1 - page 9 that an increase in the 
precipitation of CaOx salts is observed at urinary pH values < 5.5 and > 6.4. Therefore, the 
effect of pH on the binding of CSA or CSC with calcium and magnesium was investigated as 
well. 
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6.2 ITC PRINCIPLE 
When two components in solution are mixed together at constant temperature and pressure, 
there is a change in heat energy [8 , 9]. ITC is a technique that measures and records the 
amounts of heat released or absorbed during the interaction of two reactants [1 O - 13]. A typical 
ITC instrument consists of two identical cells made from Hastelloy™ alloy. ITC monitors these 
heat changes by measuring the differential power, applied to the cell heaters, required to 
maintain zero temperature difference between the reference and sample cells as the reactants 
are mixed [14 - 16]. A schematic diagram of an ITC calorimeter is shown in Figure 6.1 [17]. 
The sample cell in which the titration occurs, usually contains one of the reactants, known as 
the ligand (L) . The reference cell acts as a thermal reference and normally contains distilled 
water or a buffer solution. The syringe, which also acts as a stirrer to ensure proper mixing of 
the sample cell components, is usually filled with the metal solution (M) , the second reactant. 
The M and L solutions are always prepared in the same buffer. Situated between the two cells 
is a calorimeter which monitors the temperature of the sample and reference cells. This 
calorimeter is controlled by a power feedback system whose purpose is to maintain the 
temperature difference between the two cells as low as possible. In the absence of any 
reaction , this feedback power is taken as the baseline level. 
During an ITC experiment, the M solution is injected into the sample cell in small quantities 
using a syringe. The resulting chemical reaction caused by the interaction of the ligand and the 
metal in the sample cell either releases or absorbs a certain amount of heat. This heat is 
proportional to the amount of metal bound to the ligand. Thus, the power feedback system will 
adjust the power applied to the sample cell , depending on the type of reaction that is taking 
place in the sample cell. If heat is released (exothermic reaction) , the power system will 
decrease the amounts of power supplied to the sample cell. Alternatively, the power applied to 
the sample cell will increase during an endothermic reaction where heat is absorbed. Thus, the 
temperature of the two cells is controlled in such a way that they will remain the same during 
the entire experiment. 
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Figure 6.1 : A schematic diagram of an isothermal calorimeter [17] 
Introduction 
The difference in power (µcal/sec) that is supplied to each cell is recorded by a computer linked 
to the calorimeter as a function of time and corresponds to the signal seen in the form of a 
peak. The area under each peak corresponds to the heat released or absorbed during the 
reaction after each injection . The heat evolved or absorbed by the reaction is then obtained by 
integration of these deflections from baseline, with respect to time. 
At the beginning of the titration , large amounts of heat are released or absorbed on each 
addition of the metal solution , refleeting substantial increases in complex formation at each 
step. Further additions of the metal solution will result in decreased peak signals. When the 
ligand in the sample cell becomes saturated with the metal , the heat signals remain constant. 
The heat changes registered by the calorimeter after saturation (called heats of dilution) are 
caused by mixing the contents of the cell and by the dilution of the ligand. These heats of 
dilution are subtracted from each peak during data analysis. 
A binding curve is then obtained from the plots of heats against the ratio of metal and ligand 
inside the ITC cell from each titration . The binding curve is analysed with an appropriate binding 
model to determine the stoichiometry (n) , the binding enthalpy (l::,.H) and the binding constant 
(K) [10 - 16]. 
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Determination of the heats of dilution 
The changes in heat energy due to mixing are usually small ; therefore they are ignored during 
data analysis [17, 18]. The heats resulting from the dilution of the ligand are determined in two 
ways [17 - 20]. Firstly, control experiments are performed separately to determine the amounts 
of heat produced by the titration of the ligand into solvent and also the solvent into the ligand. 
These experiments are conducted in a similar manner as when performing the actual M-L 
titration experiments. The observed heats of dilution are then subtracted from the overall heat 
effects measured during the M-L titration . Secondly, the heat effects are automatically 
subtracted from the overall heat effects when correcting the baseline level during data analysis 
[17 - 20]. 
6.3 EXPERIMENTAL ANALYSIS 
6.3.1 Solution preparation 
Chondroitin sulphate sodium salts (CSA from bovine trachea and CSC from shark cartilage) , 
molecular weight of 503 g/mol were obtained from Sigma Aldrich , South Africa. NaCl , CaCl2 and 
MgCl2.6H20 were purchased from Merck, South Africa. A solution of 0.137 M NaCl was 
prepared with deionized water from MilliQ Millipore system (Millipore Direct-03, France) with a 
resistivity of 18 O cm which had been boiled to remove C02 and kept in a container protected 
by a C02 trap. Solutions of 335.05 mM calcium and 67.05 mM magnesium were used as metal 
solutions and were prepared by dissolving CaCl2 and MgCl2 .6H20 salts, respectively, in NaCl. 
Three solutions were prepared for each metal, and the pH was adjusted to 5.8, 6.4 and 7.0, 
respectively, by the addition of NaOH and HCI. Three ligand solutions of 18.425 mM CSA or 
CSC were prepared separately by dissolving CSA or CSC sodium salts in NaCl. For each 
ligand, the pH of each solution was adjusted to 5.8, 6.4 and 7 .0 with Na OH or HCI. 
6.3.2 ITC titration experiments 
Titration experiments were conducted using an isothermal titration calorimeter (ITC200 Microcal , 
GE Healthcare - UK). For each titration, 300 µL of the ligand sample (18.425 mM CSA or CSC 
solution) was loaded into the sample cell after filling the reference cell with deionized water. The 
metal solution (calcium or magnesium) was placed in the injection-stirrer syringe. Experiments 
were carried out at 37 °C. 
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The metal solution was injected stepwise into the sample cell using a syringe. Each titration 
consisted of 19 injections with an interval of 120 seconds between injections to ensure that the 
titration peak had returned to baseline before the next injection. The time taken for each 
injection was 5s. Because the needle of the syringe is usually not full before the first injection 
due to the long equilibration time, the first volume of the injection is made to be less than the 
other injections. In the present study, the volume of the first injection was 1 µL. The other 18 
ligand injection volumes were 2 µL. The contents of sample cell were stirred continuously at a 
rate of 1000 rpm. The heat of each injection was recorded by a calorimeter that was part of the 
ITC instrument. Each experiment was done three times. 
6.3.3 Heats of dilution experiments 
Blank titration experiments were conducted to measure the effects of dilution of the ligand. 
These were done by titrating CSA or CSC (in the syringe) into deionized water (in the sample 
cell). Secondly, deionized water was placed in the syringe, and it was titrated into the CSA or 
CSC solution which was placed in the sample cells. The procedure for these heats of dilution 
experiments was similar to the one described in section 6.3.2 - page 217. 
There were no heat signals detected during each heat of dilution titration experiment, indicating 
that the heat signals observed during the actual M-L titration were only due to the binding of the 
metal to the ligand. Therefore, the heats of dilution were neglected during data analysis. 
6.3.4 Data analysis 
The heat signal corresponding to the first injection of the metal (1 µL) was removed before the 
analysis of data. Origin 7.0 software program (MicroCal , GE Healthcare, UK) was used to 
analyze the ITC data from each titration using a one-site binding model. A one-site model was 
chosen because it is the simplest binding model and it assumes that the metal binds to the 
ligand at a single site [18] . 
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n, Kand .b.H were calculated by integration of the thermograms. The free energy change (LIG) 
associated with calcium and magnesium binding to a single site in CSA or CSC was calculated 
from the K values according to the following "Gibbs Free Energy" equation: 
~G=-RTlnK 
where R is the gas constant (1.9872 cal/mol/K) and Tis the absolute temperature (Kelvin). 
The entropy change (.b.S) was then calculated from the LIG and LIH and T (KJ according to the 
following equation: 
.1G = .1H - T.1S 
where rearrangement of the above equation gave entropy change as: 
.1H - .1G 
.1S=---
T 
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6.4 RESULTS 
6.4.1 ITC data for the titration experiments 
Raw data obtained for the titration of CSA or CSC repeat units with calcium or magnesium at 
pH values 5.8, 6.4 and 7.0 are illustrated in Figures 6.2 - 6.13 
The upper part of the left panel in the ITC output in each figure represents the individual heat 
signals plotted against time (µcal/sec) for each titration. The lower part represents the ITC 
binding isotherm obtained by plotting heat versus the molar ratio. The right panel shows the 
thermodynamic data for each experiment as calculated by the ORIGIN 7.0 software. 
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Figure 6.2: ITC output for the titration of CSA with calcium at pH 5.8 
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Figure 6.3: ITC output for the titration of CSA with calcium at pH 6.4 
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Figure 6.4: ITC output for the titration of CSA with calcium at pH 7.0 
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Figure 6.5: ITC output for the titration of CSC with calcium at pH 5.8 
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Figure 6.8: ITC output for the titration of CSA with magnesium at pH 5.8 
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Figure 6.9: ITC output for the titration of CSA with magnesium at pH 6.4 
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Figure 6.10: ITC output for the titration of CSA with magnesium at pH 7.0 
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Figure 6.11: ITC output for the titration of CSC with magnesium at pH 5.8 
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Figure 6.12: ITC output for the titration of CSC with magnesium at pH 6.4 
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Figure 6.13: ITC output for the titration of CSC with magnesium at pH 7.0 
226 I Page 
Chapter 6 Results 
Summary of ITC results 
The thermodynamic parameters obtained from the titration of CSA or CSC with calcium and 
magnesium at different pH values are summarized in Table 6.1 . All data are reported as an 
average of 3 experiments. 
Table 6.1 
Thermodynamic parameters for the binding of CSA or CSC with calcium 
and magnesium 
Complex pH K l:t.H l:t.G l:t.S n (M.1) (cal/mol) (cal/mol) ( cal/mol/K) 
5.8 1 29.2 ± 3.08 106 ± 5.69 -2078 ± 8.95 7.05 ± 0.02 
Ca-CSA 6.4 1 23.0 ± 0.99 125 ± 2.84 -1930 ± 12.5 6.63 ± 0.04 
7.0 1 84.4 ± 15.7 58 ± 3.52 -2731 ± 32.1 8.99 ± 0.09 
5.8 1 24.4 ± 3.31 131 ±9.19 -1969 ± 17.9 6.77 ± 0.05 
Ca-CSC 6.4 1 18.9±1 .96 167 ± 9.79 -1811 ± 15.5 6.37 ± 0.04 
7.0 1 14.9 ± 1.96 176±11 .0 -1663±7.11 5.95 ± 0.03 
5.8 0.26 230 ± 97.1 267 ± 92.0 -3345 ± 55.2 11 .7±0.10 
Mg-CSA 6.4 0.20 171 ±51.4 510 ± 1352 -3137 ± 139 11 .9±0.31 
7.0 0.18 247 ± 87.3 321±133 -3396 ± 17.5 12.0 ± 0.03 
5.8 0.15 108 ± 51 .3 695 ± 822 -2881 ± 8.95 11 .6 ± 0.02 
Mg-CSC 6.4 0.14 99 ± 79.5 1328 ± 4822 -2813 ± 96.8 13.4 ± 1.30 
7.0 0.20 102 ± 65.4 609 ± 775 -2848 ± 41 .5 11 .2 ± 0.06 
6.4.2 Effect of pH on the thermodynamic parameters for the formation of M-L complexes 
Ca-CSA complex formation 
Comparison of the thermodynamic parameters at various pH showed that the values of K, !:,.H, 
!:,.G and !:,.S were not quantitatively different at pH 5.8 and 6.4. The values of K, !:,.G and !:,.S at 
pH 7.0 were observed to be higher than those at pH 5.8 and 6.4 whereas the value for l:,.H was 
lower. 
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Ca-CSC complex formation 
Comparison of the data at various pH values showed that K, l::::..G and l::::..S values decreased with 
increasing pH while an increasing trend in the l::::..H values was observed. 
Mg-CSA complex formation 
The n-values were found to decrease with increasing pH. The K value at pH 7.0 was higher 
than at pH 5.8 and 6.4, with the lowest K value observed at pH 6.4. The l::::..H value at pH 6.4 was 
greater than at pH 7.0, with the least l::::..H value observed at pH 5.8. At all pH values, the l::::..G and 
l::::..S values were not quantitatively different. 
Mg-CSC complex formation 
Comparison of thermodynamic parameters at various pH values showed the n value to be 
higher at pH 7.0. At pH 5.8 and 6.4, the n values were similar. With regards to Kand l::::..G values, 
no differences were observed at various pH values. The l::::..H and l::::..S values were higher at pH 
6.4 than pH 5.8; with the least l::::..H and l::::..S values observed at pH 6.4. 
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6.5 DISCUSSION 
The formation of complexes by the binding of Mand Lis represented by the following reaction: 
M + L H ML, 
where M is calcium or magnesium, L is CSA or CSC and ML is the Ca-CSA or Ca-CSC 
complex or the Mg-CSA or Mg-CSC complex. 
The binding constant (K) for the calcium and magnesium complexes is described by the 
following equation: 
[ML] 
Keq = [M][L] 
where K eq is the equilibrium constant for the reaction , [ML] is the equilibrium concentration of 
the metal-ligand complex, [M] is the equilibrium concentration of the metal and [L] is the 
concentration of the ligand. The K value is a measure of the extent to which reactants are 
converted to products in a reaction [7 - 9] . 
In the present study, the K vaues for the binding of CSA and CSC with calcium were found to 
be between 14.9 - 84.4 M-1 and between 99 - 247 M-1 for magnesium. The effect of pH on the 
binding of calcium and magnesium was small as depicted by the agreement of K values for the 
formation of each complex by each isomer (Table 6.1 ). The K values for the calcium complexes 
obtained in the present study are comparable to those reported by Urist et al [7] who found log 
K values between 1.04 and 1.64 for CSC. This lends a measure of credibility to the present 
results. 
The binding constants for the calcium complexes were found to be lower than those observed 
for the magnesium complexes (Table 6.1). These results imply that magnesium binds to both 
CSA and CSC to a greater extent than calcium. 
In the present study, it was expected that calcium and magnesium would bind CSA and CSC in 
a 1:1 ratio (one-single site model). Then values (Table 6.1) show that this expectation was 
realized for the calcium complexes. 
Non-integer values for n are normally attributed to experimental errors such as high 
experimental uncertainty of the data set, unspecific binding and degradation of ligand [12, 21] . 
Therefore, the observed n values for magnesium are suggested to be due to such errors. 
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In the present study, data analysis for the binding of calcium and magnesium with CSA and 
CSC was evaluated adopting a single binding site model (section 6.3.4 - page 218). As shown 
in Chapter 5 - Figure 1, the isomers of CS contain both sulfate and carboxyl groups, which are 
potential sites for complex formation with calcium and magnesium. It has been suggested 
however, that calcium preferentially binds with the sulfate group [6] . 
In the present study, the average log K values for calcium complexes ranged between 1.17 and 
1.93 for both Ca-CSA and Ca-CSC complexes over the pH range studied . These log K values 
are lower than those reported for the formation of the calcium sulfate complex at 25 °C (log K 
value 2.31) [22] . Log K values for calcium acetate (carboxyl group) are not available in the 
equilibrium constant database (SC-Database [22]) used in the present study. Thus, it was not 
possible to deduce whether calcium was bound to the sulfate or carboxyl group in the present 
study. 
The general behaviour for the binding of calcium and magnesium with CSA and CSC was 
observed to be qualitatively similar as shown by the ITC outputs (Figures 6.1 to 6.13). The b..G 
values were all negative, indicating that the binding of calcium and magnesium with CSA and 
CSC occurs spontaneously [8 , 9] . In addition, the calculated b..S values were positive for all the 
reactions and were observed to be higher for the magnesium complexes compared to the 
calcium complexes (Table 6.1 ). b..S is associated with the disorder of a system [8, 9] . A positive 
b..S is favourable and is an indication that the reaction is driven towards the products (calcium 
and magnesium complexes) . For all the complex formation reactions, the b..H values were 
positive, indicating that the reactions were endothermic. Endothermic reactions are 
unfavourable because the energy required for the reaction to occur is obtained from the 
surroundings [8 , 9] . 
These results are typical for hard metals like calcium (II) and magnesium (II) where the 
reactions are entropy driven rather than enthalpy driven. In these reactions the entropy change 
of the solvent, H20 , is critical and results from solvent reorganization upon charge neutralization 
which occurs during complexation. 
Since CSA and CSC are negatively charged and the metal positively charged, these are heavily 
solvated. This salvation is released upon complexation and hence the increase in entropy. 
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Summary 
In conclusion , the present study has demonstrated that calcium binds both CSA and CSC to 
form a calcium complex, as expected (see section 6.1 - page 214). In addition, it was shown 
that the binding capacity of this cation was lower in magnitude compared to that of magnesium. 
Since magnesium plays a role in kidney stone disease, these results imply that the magnesium 
complexes might influence the formation of calcium complexes in real urine samples by 
competing for binding with CSA and CSC. Furthermore, pH was shown to have minimal effects 
on calcium and magnesium complex formation . Thus, the formation of these complexes were 
not pH dependent in the range studied. 
The binding of calcium and magnesium to CSA and CSC was shown to be spontaneous, 
enthalphy unfavourable and entropically favourable. 
Determination of these thermodynamic parameters allowed the next phase of the project to be 
conducted . This involved modelling the effects of the formation of these complexes on urinary 
ionized calcium and the saturation of calcium salts, followed by a mini-trial in which CS was 
ingested by human subjects and the effects of complexation in urine was investigated. These 
experiments are described in the following chapter. 
While the results for Mg binding are not as good as the results obtained for Ca the use of the 
derived binding constant in the speciation calculations in JESS is justified by the obtained 
standard deviations. In addition , the Mg binding constants are as expected given the Ca results 
and the normal linear free energy relationship between Ca and Mg binding. 
Despite the non integer values, use of the derived binding constant in the speciation 
calculations in JESS is justified by the obtained standard deviations. 
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7.1 INTRODUCTION 
In kidney stone formation , the precipitation of CaOx salt is largely influenced by the amount of 
ionized calcium available to bind with oxalate [1 - 4]. Thus, CaOx stone formation preventative 
measures are mostly directed at reducing ionized calcium in urine. 
In Chapter 6, it was demonstrated that CSA and CSC effectively bind calcium. As a result, there 
exists the possibility that the formed Ca-CSA and Ca-CSC complexes may function as inhibitors 
of stone formation by reducing the supersaturation of CaOx in urine. 
The present study was undertaken in order to determine theoretically the extent to which CSA 
and CSC bind with calcium and magnesium in urines of healthy subjects, using chemical 
speciation computer modelling . In particular, the effect of varying the concentrations of both 
these GAGs on the chemical speciation of calcium, oxalate, phosphate and magnesium was 
modelled. In addition, the effectiveness of CS supplementation (described in Chapter 5) on 
calcium species and on saturation levels was investigated in the urines of black and white 
subjects. 
7.2 CHEMICAL SPECIATION COMPUTER MODELING 
Experimental determination of speciation 
Chemical speciation analysis of an element in a biological or environmental system is defined 
as the determination of the concentrations of the different physico-chemical forms of the 
element which together make up its total concentration in a sample [5 - 8]. Chemical speciation 
of elements can be determined experimentally by measuring the individual concentrations of 
species in a particular sample. 
Analytical techniques such as gas chromatography [9] , reversed phase liquid chromatography-
inductively coupled plasma mass spectrometry [1 O] , anodic stripping voltammetry [11] and 
atomic absorption spectrometry [12] can be used to measure speciation in various samples. 
Due to the number of species that might be present in a single sample, using these techniques 
tends to be complicated and time consuming . 
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Theoretical determination of speciation 
Computer modeling offers an alternative approach for determining chemical speciation in a 
variety of samples. It involves the application of theoretical chemical concepts to predict the 
distribution and transformations of chemical species in various systems by calculating the 
concentrations of species in equilibrium (13 -16]. These computer models use the Laws of Mass 
Action and Mass Balance and thermodynamic formation constants for all of the possible metal-
ligand species, in conjunction with defined parameters such as pH and total metal and total 
ligand concentrations (13 - 16]. 
7.3 JESS DATABASE COMPUTER PROGRAM 
In the present study, chemical speciation in 24h urine samples was evaluated using the Joint 
Expert Speciation System (JESS) database computer program. The JESS database system 
provides a powerful and versatile means of storing and retrieving the thermodynamic data 
associated with chemical reactions (17, 18]. Currently, it contains over 202 000 thermodynamic 
constants associated with more than 76 000 chemical reactions (19]. Furthermore, it has been 
shown to be capable of modelling chemical speciation of various elements in blood (20] and 
urine [21 - 23] . The JESS computer program uses the equilibrium binding constants (log K 
values) for known chemical reactions, pH and concentrations of the reactants to calculate the 
chemical speciation of an element in a sample, and therefore the saturation state of dissolved 
species. 
7.4 EXPERIMENTAL ANALYSIS 
7.4.1 Inputs for JESS modeling 
The JESS database does not contain the equilibrium constants for the formation of the Ca or 
Mg complexes with either CSA or CSC. Therefore, the binding constants for these complexes 
that were experimentally measured at pH 6.4 in Chapter 6 were incorporated into the JESS 
database. The chemical reaction and log K value for each complex as determined in the 
previous study is shown in Table 7.1. These values were chosen because the pH at which they 
were measured is relatively close to the pH values observed in the urinary composition of 
subjects used in the present study (Table 7.2) . 
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!Table 7.1 
~hemical equations and log K values of 
~SA and CSC complexes 
Chemical equation log Kvalue 
Ca2+ + [CSAr +--+ Ca-CSA 1.36 
Ca2+ + [Cser +--+ Ca-CSC 1.28 
Mg2+ + [CSAr +--+ Mg-CSA 2.23 
Mg2+ + [CSAr +--+ Mg-CSA 2.00 
Five different urine models were used for the JESS calculations. These are given in Table 7.2 
Urine data from a study by Hesse et al [24] constituted Model 1. This model was included to 
compare speciation results with those obtained from black and white subjects who participated 
in the CS study described in Chapter 5. 
Table 7.2 
Urinary composition of healthy subjects 
Parameter Hesse (Model 1) 
Day O Day 7 
Blacks (Model 2) Whites (Model 3) Blacks (Model 4) Whites (Model 5) 
pH 6.10 6.41 6.20 6.03 6.21 
Calcium (mol/L) 3.11 E-03 3.32E-03 2.46E-03 2.28E-03 2.95E-03 
Magnesium (mol/L) 3.37E-03 2.47E-03 2.79E-03 1.96E-03 2.75E-03 
Potassium (mol/L) 4.47E-02 2.92E-02 2.78E-02 2.40E-02 2.51E-02 
Sod ium (mol/L) 1.26E-01 1.19E-01 1.12E-01 9.30E-02 9.91E-02 
Chloride (mol/L) 9.94E-02 1.40E-01 1.27E-01 1.14E-01 1.1 5E-01 
Phosphate (mol/L) 1.61 E-02 1.90E-02 3.03E-02 1.54E-02 2.71E-02 
Sulfate (mol/L) 1.39E-02 1.00E-15 1.00E-15 1.00E-15 1.00E-15 
Urate (mol/L) 2.38E-03 2.50E-03 2.86E-03 2.32E-03 2.95E-03 
Oxalate (mol/L) 2.99E-04 1.73E-04 2.62E-04 1.56E-04 2.02E-04 
Citrate (mol/L) 9.22E-04 2.02E-03 2.38E-03 1.63E-03 1.61 E-03 
Ammonium (mol/L) 3.04E-02 1.00E-15 1.00E-15 1.00E-15 1.00E-15 
CSA (mol/L) 8.60E-05 8.60E-05 8.60E-05 1.72E-0441 1.72E-0441 
CSC (mol/L) 8.60E-05 8.60E-05 8.60E-05 1.72E-0441 1.72E-0441 
. . .. 
Note: mtra-group compans,on showed no statistical difference at days O and 7 for any of these parameters 
41 : See section 7.4.3- page 239 for explanation of these concentration values 
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The concentration of the disaccharide unit of CS in urines of healthy subjects has been reported 
to be 0.15 µg uronic acid/ml [25). However, in urine, CS exists as a polymer with a molecular 
weight of about 100 000 g/mol [26) . Therefore, the concentration of CS was calculated to be 





I 17 g mo 
= 0.86 x 10-7M 
where 175 g/mol is the molecular weight of uronic acid. 
Therefore, the concentration of CS was calculated as 
= (0.86x 10-6M) x 100 
= 0.86 xto-s M 
where 100 is the average number of CS repeat units in one chain of CS [26) . 
Thus, in the present study, the physiological CSA concentration in urines of healthy subjects 
was estimated to be 0.086 mM. The CSA isomer was chosen because the binding constant for 
both CSA and CSC were comparable (Chapter 6 - page 227). 
7.4.2 Effect of CS on the chemical speciation of calcium, oxalate, magnesium and 
phosphate 
The urinary compositions of healthy subjects (Models 1, 2 & 3 - Table 7.2) were used as inputs 
in the JESS modeling to determine the chemical speciation of calcium , oxalate, magnesium and 
phosphate as a function of CS concentrations. For each isomer, a 2-, 10- and 100-fold increase 
of the physiological concentration of CS (0.086 mM) was modelled . In addition , the effect of 
CSA and CSC concentrations on the supersaturation (SS) of calcium salts was investigated 
(page 241). 
7.4.3 Effect of CS supplementation on speciation 
The actual in vivo effect of CS supplementation on calcium speciation and SS of calcium salts 
in 24 urine samples was calculated using the urinary composition of black and white subjects on 
days O and 7 (Table 7.2). 
As described in Chapter 5 - page 207, the urinary concentrations of CS before and after 
supplementation were not measured in the present study due to financial constraints. 
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Thus, the concentration of CS that was used as input for speciation modelling at day O was that 
which has been previously reported elsewhere as physiological CS concentration (0.086 mM) 
[25] . At day 7, the concentration of CS that was used for speciation calculations was 2x 
physiological CS concentration to ensure that any increase in the concentration of urinary CS 
which might have occurred as a consequence of supplementation would be adequately covered 
in the speciation calculations. 
7.4.4 JESS CALCULATIONS 
After the pH and urinary composition of subjects had been entered into the JESS database, 
concentrations and percentages of calcium, oxalate, phosphate and magnesium species in 
urine were computed. The supersaturations of calcium salts were also calculated as part of the 
output from the speciation modelling. 
7.4.5 DATA ANALYSIS 
For the modeling calculations, statistical significance was not determined for the different 
species, as this would have required an extremely labour-intesive exercise for Models 2 and 3. 
Mean urinary compositions (as opposed to individual compositions) were used in these 
calculations. For Model 1, only mean values were available anyway, so these were used too. 
When these results were interrogated, a change in SS of ~ 10 % was arbitrarily selected as a 
threshold for potential clinical significance. 
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7.5 RESULTS AND COMMENTS 
The names and symbols for the common calcium salts species given as outputs from JESS 
calculations are shown in Table 7.3. In the following discussion, the description of calcium 
phosphate salts refers to a combination of OCP, HAP, triCaP and Brushite whereas CaOx is the 
same as COM (Chapter 1 - page 2). 
Table 7.3 
Names of calcium salts and their abbreviations 
Calcium salts Abbreviation 
Calcium oxalate monohydrate COM 
Brushite Brushite 
Calcium phosphate, tribasic triCaP 
Hydroxylapatite HAP 
Octacalcium phosphate OCP 
It should be noted that the amounts of calcium, oxalate, magnesium and phosphate species in 
the following discussion are reported as concentration (mol/L). The amounts of these species 
as percentage composition of the total species are presented in appendices together with raw 
data for the concentrations of species. Furthermore, it should be noted that 1x [CSA] and 1x 
[CSC] refers to the physiological concentration of CSA and CSC in healthy subjects. Thus, 2x, 
10x and 100x represents multiples of the physiological concentration. 
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7 .5.1 Theoretical modelling 
Effect of CS concentration on the supersaturation (SS) of calcium salts 
The SS values for calcium salts after varying the concentration of CSA and CSC in the urinary 
composition of healthy subjects (Models 1, 2 and 3) are shown in Tables 7.4 and 7.5, 
respectively. 
Table 7.4 
Urinary supersaturation of calcium salts in healthy subjects - CSA concentrations 
Salt 
[CSA] in Model 1 [CSA] in Model 2 [CSA] in Model 3 
1x 2x 10x 100x 1x 2x 10x 100x 1x 2x 10x 100x 
COM 4.55 4.55 4.56 4.56 3.20 3.20 3.21 3.26 3.40 3.40 3.40 3.44 
Brushite 1.53 1.53 1.53 1.45 1.95 1.95 1.95 1.86 1.60 1.60 1.60 1.52 
triCaP 1.85 1.85 1.82 1.53 8.04$ 8.02 7.91 6.84 1.36 1.36 1.34 1.16 
HAP (x 106) 1.60 1.60 1.56 1.17 24.2$ 24.1 23.5 18.4 0.85 0.85 0.82 0.64 
OCP 41.4 41 .3 40.6 32.5 226$ 225 221 183 31 .3 31.2 30.5 25.2 
Table 7.5 
Urinary supersaturation of calcium salts in healthy subjects - CSC concentrations 
Salt 
[CSCJ in Model 1 [CSC] in Model 2 [CSCJ in Model 3 
1x 2x 10x 100x 1x 2x 10x 100x 1x 2x 10x 100x 
COM 4.55 4.55 4.55 4.52 3.20 3.20 3.21 3.23 3.40 3.40 3.40 3.41 
Brushite 1.53 1.53 1.53 1.46 1.95 1.95 1.95 1.88 1.60 1.60 1.60 1.54 
riCaP 1.85 1.85 1.82 1.58 8.04cj, 8.02 7.94 7.06 1.36 1.36 1.34 1.20 
HAP (x 106) 1.61 1.60 1.57 1.23 24.2cj, 24.0 23.7 19.4 0.85 0.85 0.83 0.68 
OCP 41.5 41.3 40.6 33.7 226$ 225 222 191 31.3 31.2 30.8 26.4 
~Footnote: SS values for triCaP, HAP and OCP at 1x [CSA] in Model 2 were considerably higher compared to those 
in Models 1 and 3. The speciation of calcium phosphate salts has been shown to be pH dependent [22]. Since the 
pH in urinary composition of Model 2 was higher than that in the other models (Table 7.2), these SS values are 
attributed to the effect of pH on speciation calculations. 
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It is noted that subjects in all 3 models responded qualitatively and quantitatively in the same 
way to theoretical increases in CSA and CSC thereby predicting that there would not be any 
difference in their respective effects on urinary saturation levels in clinical situations in which 
they are independently administered . This is not surprising given that the binding constants for 
calcium as well as for magnesium have the same order of magnitude (Table 7.1). Thus, both 
CSA and CSC concentrations achieved the same effects. 
Regarding the effects themselves, decreases in SS values >10 % occurred only at 1 OOx 
physiological values, and only for OCP, HAP and triCaP. SS values for brushite and COM were 
unchanged. Irrespective of whether these decreases are clinically significant or not, the 
modelling in the present study has predicted that they will occur only if the urinary 
concentrations of CSA and CSC are raised to levels which are 1 OOx greater than physiological 
concentrations. Since concentrations such as these cannot be achieved with dietary or 
pharmacological interventions at this time, investigators need to make strategic decisions about 
pursuing this line of research . The key question would be whether it is worth attempting to 
develop pharmaceutical preparations designed to raize the urinary concentrations of CSA and 
CSC, given that SS COM and SS brushite would be unaffected anyway. 
From the inter-race perspective (Model 2 vs Model 3) , there was no difference in the response 
of the groups with respect of varying CSA and CSC. This is not regarded as being clinically 
important, but is noted with interest. 
Effect of CS concentration on speciation 
Although the absolute concentrations of the different species were different in Models 1 - 3 
(because component concentrations at baseline were different} , the same qualitative trends 
were observed for all of the models. As such, it is not necessary to present speciation plots for 
all three models here. Only those for Model 2 are presented. Furthermore, only plots for the 
speciation calculations using CSA concentrations are reported since similar results were also 
observed for CSC concentrations. 
Calcium, oxalate, magnesium and phosphate speciation plots for Model 2 are given in Figures 
7.1 to 7.4, respectively. Identical trends were observed in Models 1 and 3 (Appendices 7.1 and 
7.2, respectively). Raw data for these calculations are given in Appendices 7.3, 7.4 and 7.5 for 
Models 1, 2 and 3, respectively. 
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The concentration of [Cat2 in all 3 models decreased only when [CS) was 1 OOx its physiological 
value (Figure 7.1 ). This effect can be clearly attributed to the formation of the [Ca-CSA] complex 
which utilizes [Cat2 as shown in calcium speciation plots. 
The speciation of oxalate showed an interesting feature in all 3 models , namely an increase in 
[Oxr2 at 100x physiological concentration of CSA (Figure 7.2). This can be attributed to the 
decrease in the concentration of the [MgOx] complex which releases ox-2 , thereby increasing 
the concentration of the latter. This is demonstrated in the plot of Ox speciation (Figure 7.2). 
The decrease in the concentration of [Mg Ox] itself can be accounted for by the formation of the 
complex [Mg-CSA] which utilizes Mg2+ thereby decreasing its availability for binding with ox-2 
(Figure 7.3) . Despite this increase in [Oxr2• the supersaturation of COM was unaffected (Tables 
7.4 and 7.5), possibly because of the opposite effect due to the accompanying decrease in 
[Cat2. 
The phosphate speciation (Figure 7.4) does not show any special features which might explain 
the decreases in the supersaturation of OCP, HAP and triCaP at 1 OOx physiological 
concentrations (Tables 7.4 and 7.5) . This can be attributed to the stoichiometry of the different 
compounds with respect to the molar content of calcium [27) . In calcium oxalate (CaC20 4) and 
brushite (CaHP04.2H20) there is only one mole of calcium. However, in triCaP (CaJ(P04)z), 
HAP (Ca50H(P04h) and OCP (Ca8H(P04h there are 3. 5 and 8 moles of calcium, respectively 
[27) . 
Since SS is dependent on the ionic products of these salts (Chapter 1 - page 12), small 
changes in the concentration of [car2• brought about by complexation with CS at 1 OOx 
physiological values, will affect the SS of triCaP, HAP and OCP far more than those for COM 
and brushite. Thus, the decreases in SS of triCaP, HAP and OCP that were observed at 100x 
physiological concentrations of CS are attributed to the decrease in [Cat2 (Figure 7 .1) at this 
concentration. 
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Figure 7.2: Effect of CSA concentrations on oxalate speciation in Model 2 
•1x (CSA] 
• 2x (CSA] 
• 1ox [CSA] 
• 100x[CSA] 
•1x[CSA] 
• 2x [CSA] 







244 I Page 
12 
10 
















Figure 7.3: Effect of CSA concentrations on magnesium speciation in Model 2 
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Summary of speciation concentrations 
Summaries of the speciation concentrations corresponding to the formation of calcium and 
magnesium complexes with CSA and CSC are given in Tables 7.6 and 7.7, respectively. 
It is seen that substantial changes occurred only at 1 OOx physiological concentration of CS, and 
that these changes were not always >1 O %. It is also noted that the concentrations of the Mg-
CS complexes are approximately 1 Ox greater than those of the Ca-CS complexes. This is 
consistent with the binding constant values (Table 6.1 - page 227) which are approximately 1 Ox 
greater for magnesium complexes. 






















































































































































































































































































































Chapter 7 Results 
7.5.2 CS supplementation 
Urine composition 
Urine parameters before and after supplementation in both race groups have been 
previously presented (Table 7.2). There were no statistically significant intra-group changes 
in any of the parameters following CS supplementation . 
Effect of CS supplementation on the saturation of calcium salts 
The SS values for calcium salts in black and white subjects at days O and 7 are shown in 
Table 7.8. Raw data for the speciation calculations are shown in Appendices 7.6 and 7.7 for 
blacks and whites, respectively. 
Within groups, CS supplementation had no effect on the SS values of COM. However, in the 
black group, supplementation significantly decreased the SS values of calcium phosphate 
salts whereas in whites, the SS HAP value was significantly higher at day 7 than baseline. 
With respect to intragroup comparisons, SS brushite values were significantly lower in black 
subjects compared to white subjects on day 7. Other significantly different values at day 7 
were also present at baseline; as such they can be ignored. 
rTable 7.8 
Effect of CS supplementation on the SS values for calcium salts in black and white subjects 
Blacks 
Parameter 
Day O Day 7 p-values Day O 
COM 3.20 ± 0.84 3.51 ± 0.50 0.7677 3.40 ± 0.71 
Brushite 1.95 ± 0.23 1.09 ± 0.10 0.0094* 1.60 ± 0.23 
~riCaP 8.04 ± 0.93 0.43 ± 0.08 0.0142* 1.36 ± 0.39 
HAP (x 106) 24.2 ± 1.73 0.13 ± 0.04 0.0214* 0.85 ± 0.09 
OCP 226 ± 6.87 6.60 ± 1.21 0.0354* 31 .3 ± 4.72 
: p-va/ue :S 0.05 comapred to baseline (intragroup comparison) 
*: p-va/ue :S 0.05 (intergroup comparison) 
Whites BvsW 
Day 7 p-values Day O Day 7 
3.54 ± 0.84 0.8096 0.9054 0.4884 
1.99 ± 0.39 0.4567 0.6085 0.0331 * 
2.83 ± 0.43 0.0719 0.0476* 0.0324* 
3.01 ± 0.47 0.0351 * 0.0269* 0.0436* 
79.6 ± 5.82 0.0547 0.0397* 0.0438* 
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Effect of CS supplementation on speciation 
The distribution of calcium species in the black and white groups at days O and 7 are 
presented in Figures 7.5 and 7.6 and for phosphate speciation in Figures 7.7 and 7.8, 
respectively. Raw data for the speciation calculations are shown in Appendix 7.6 and 7.7 for 
blacks and whites, respectively. The concentrations of species before and after 
supplementation are summarized in Table 7.9. 
The decrease in the SS values of CaP salts in black subjects can be attributed to the 
decrease in the concentration of [Car2 and [HPo/-] (Table 7.9) albeit that neither of these 
was statistically significant. These effects can probably be attributed to the decrease in pH 
which occurred post CS supplementation. Since there were no statistically significant 
differences in dietary intake at baseline and at day 7, these differences are not diet related . It 
is not possible to deduce whether the decrease in pH itself can be attributed to the ingestion 
of CS. 
In white subjects, the increase in the SS of HAP can be attributed to the increase in the 
concentration of [Car2 at day 7, despite the decrease in [HPo/-] (Table7.9) . As noted in the 
white group, these changes were not statistically significant. Unlike the black group, pH did 
not change. 
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Figure 7.6: Calcium speciation in white subjects pre- and post- supplementation with CS 
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Figure 7.7: Phosphate speciation in black subjects pre- and post- supplementation with CS 
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Figure 7.8: Phosphate speciation in white subjects pre- and post- supplementation with CS 
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Chapter 7 Discussion 
7.6 DISCUSSION 
In the present study, the theoretical calculations showed that the reduction in the 
concentration of ionized calcium, and therefore risk in CaOx stone formation , is largely 
dependent on the concentrations of CSA and CSC. Although favourable results were 
observed at 1 OOx for both CSA and CSC, the required CSA and CSC concentrations are 
unrealistic in humans since they are not clinically feasible. In addition , the binding capacity of 
CSA and CSC with magnesium in real urines was shown to be higher than that for calcium. 
These findings are potentially unfavourable for CaOx stone formation in two ways. Firstly, 
urinary magnesium may compete successfully with calcium for binding CSA and CSC in 
urine, and thereby compromising the capacity of CSA and CSC to reduce the saturation of 
CaOx. Secondly, a reduction in the concentration of [Mgr2 (caused by complexation with 
CS) is unfavourable since this will reduce the concentration of [MgOx], thereby releasing 
more ox-2 which can potentially bind with calcium and form CaOx crystals . 
Although the concentration of the [Ca-CSA] complex was increased in both groups at day 7 
compared to baseline, the concentrations of ionized calcium were not significantly different 
to those at baseline (Table 7.9). Furthermore, the SS values of COM were unaffected by 
supplementation (Table 7.8). Although SS values of the CaP salts decreased in the black 
group, this effect could not be attributed to the ingestion of CS per se. The increase in SS of 
HAP in whites is also an anomaly. 
It is recognized that an important limitation of this study is that urinary CS concentrations 
were not measured on days O and 7 (Chapter 5 - page 208). Nevertheless, the CS 
concentrations that were used for speciation calculations were considered appropriate to 
reflect the CS concentrations that might be expected in healthy subjects before and after 
supplementation . 
Summary 
The results of this study show that the formation of the Ca-CSA and Ca-CSC complexes was 
not effective in reducing the saturation levels of urinary CaOx in healthy subjects. Moreover, 
the presence of competing cations with calcium such as magnesium might have an influence 
on the role of these GAGs in real urine samples. The results also demonstrate that black and 
white subjects respond differently to CS supplementation. 
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8.1 INTRODUCTION 
As previously described in Chapter 1 - page 24, the incidence of kidney stone disease in 
South Africa is lower in the black population than in whites. The influences of factors such as 
nutrition, metabolic disorders and genetics on the ethnic difference in the prevalence of 
kidney stone disease in these populations have been investigated [1 - 5] . 
In Chapters 2 - 4, several differences in the dietary and urinary risk factors were observed 
between the two groups at baseline. These differences are not part of the objectives of this 
thesis, but since they are contributing to the motivation for conducting the present 
investigation, they need to be discussed. 
8.2 DIETARY RISK FACTORS 
Mean nutrient intakes in black and white subjects observed at baseline in studies described 
in Chapter 2 to 5 are shown in Table 8.1. Compared with whites, black subjects had a lower 
intake total sugars and calcium. 
8.3 URINARY RISK FACTORS 
The differences in the urinary parameters associated with CaOx stone formation between 
blacks and whites observed at baseline during studies described in Chapters 2 - 5 are 
shown in Table 8.2. Urinary pH was significantly higher in blacks compared to the white 
subjects while magnesium, phosphate, SS CaOx and SS brushite were significantly higher in 
whites. 
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!Table 8.1 
Mean nutrient intake in black and white subjects 
Nutrient Blacks (n= 38) Whites (n=34) p-values 
Moisture [g] 1929 ± 139 1886 ± 147 0.8342 
Energy [kJ] 10101 ± 654 10494 ± 577 0.6564 
Total protein [g] 97.9 ± 8.26 99.6 ± 5.63 0.8653 
Animal protein [g] 60.4 ± 7.27 59.3 ± 5.05 0.9019 
Total fat [g] 82.4 ± 7.90 91.4 ± 8.14 0.4306 
Carbohydrate [g] 294±18.9 286±16.1 0.7744 
Total sugars [g] 43.0 ± 6.02 67.1 ±9.59 0.0333* 
Total dietary fibre [g] 23.4 ± 1.91 30.9 ± 3.85 0.0754 
Ca [mg] 439 ± 57.2 759 ± 73.3 0.0009* 
Mg [mg] 316 ± 22.8 365 ± 28.4 0.1841 
P[mg] 1255 ± 89.6 1446 ± 85.9 0.1307 
K[mg] 2935 ± 222 3067 ± 200 0.6622 
Na [mg] 2527 ± 262 2788 ± 273 0.4928 
Cl[mg] 1875 ± 302 1937 ± 330 0.8892 
Phytate [mg] 287±47.1 194 ± 32.7 0.1155 
Malic acid [mg] 469 ± 86.4 973 ± 253 0.0526 
Citric acid [mg] 969 ± 201 1645 ± 304 0.0629 
Oxalic acid [mg] 27.5 ± 5.70 64.0 ± 21 .0 0.0816 
Vitamin 86 [mg] 1.89±0.17 2.26 ± 0.20 0.1602 
Vitamin C [mg] 207 ± 44.6 117±20.7 0.0800 
Vitamin D [µg] 3.05 ± 0.61 2.73 ± 0.56 0.7073 
Vitamin E [mg] 10.1 ± 1.97 14.6 ± 2.06 0.1182 
Hydroxyproline [g] 0.49±0.10 0.33 ± 0.07 0.2190 
C18:2 n-6 LA (g) 24.4 ± 2.94 20.3 ± 2.31 0.2831 
18:3 n-3 ALA (g) 0.53 ± 0.06 0.66 ± 0.05 0.1108 
C18:3 n-6 GLA (g) 0.53 ± 0.06 0.66 ± 0.05 1.1108 
20:3 n-6 DGLA (g) 0.02 ± 0.004 0.02 ± 0.01 0.3786 
C20:4 n-6 AA (g) 0.13 ± 0.02 0.11 ± 0.02 0.3842 
C20:5 n-3 EPA (g) 0.05 ± 0.01 0.07 ± 0.02 0.4609 
C22:6 n-3 DHA (g) 0.11±0.03 0.12 ± 0.03 0.8541 
* : p-value ::;; 0. 05 (intergroup comparison) 
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rrable 8.2 
Mean urine parameters in black and white subjects 
Parameter Blacks (n=38) Whites (n=34) p-value 
pH 6.45 ± 0.11 6.20 ± 0.05 0.0478* 
~olume (ml/24h) 1284 ± 78.2 1186 ± 92.4 0.4149 
Calcium (mmol/24h) 2.38 ± 0.17 2.74 ± 0.1 6 0.1269 
Chloride (mmol/24h) 149 ± 7.22 128±10.8 0.1071 
Citrate (mmol/24h) 2.16±0.15 2.20 ± 0.18 0.8895 
Creatinine (mmol/24h) 16.8 ± 0.53 18.0 ± 0.61 0.1445 
Magnesium (mmol/24h) 1.93±0.15 2.68 ± 0.18 0.0020* 
Oxalate (mmol/24h) 0.26 ± 0.01 0.27 ± 0.02 0.7716 
Phosphate (mmol/24h) 23.7 ± 1.01 33.7 ± 1.61 <0.0001 * 
Potassium (mmol/24h) 36.3 ± 2.23 34.6 ± 2.39 0.5994 
Sodium (mmol/24h) 129 ± 6.24 115 ± 7.34 0.1400 
Urate (mmol/24h) 3.37 ± 0.14 3.68 ± 0.14 0.1212 
Ionized Ca2+ (mmol/L) 0.72 ± 0.12 0.50 ± 0.08 0.1269 
PGE2 (ng/24h) 601 ± 50.0 582 ± 42.3 0.7936 
HYP (nmol/mg creatinine) 1.26 ± 0.45 0.98 ± 0.13 0.6035 
MSL (MmM) 1.19 ± 0.22 0.90 ± 0.05 0.1960 
rTRI 178 ± 12.5 188 ± 28.7 0.7213 
SS CaOx 3.83 ± 0.34 4.98 ± 0.41 0.0331 * 
SS Brushite 1.12 ± 0.18 1.73 ± 0.21 0.0304* 
SS Uric acid 1.28 ± 0.22 1.88 ± 0.23 0.0618 
:i: : p-value s; 0.05 (intergroup comparison) 
8.4 COMMENTS 
The higher dietary intake of calcium and sugar in the white subjects who participated in the 
various studies described in this thesis might have been expected to cause significantly 
higher excretion of urinary calcium in this group [1 - 4] . However, this did not occur (Table 
8.2). 
The significantly lower excretion of magnesium in black subjects is counterintuitive as lower 
concentrations of this component have been attributed to a higher risk of stone formation by 
some workers [1, 9]. 
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The most important difference in the urinary composition of the two groups is the significantly 
higher pH in black subjects which manifests itself in lower values for the supersaturation of 
CaOx and brushite. 
The dietary and urinary similarities, differences and anomalies between blacks and white 
subjects which were observed in the present study have been reported in numerous 
previous investigations [1-9]. The findings in this regard are therefore not new. Of 
importance is whether the mean diets and urine chemistries observed in the present study 
might be conflicting factors in interpreting the results which have been recorded. Thus, the 
lower supersaturation values for CaOx and brushite in blacks need to be taken into account 
in the present studies. Since these parameters did not undergo any changes as a result of 
FA or CS supplementation , it can be concluded that there was no conflict. 
The dietary and urinary similarities, differences and anomalies between blacks and white 
subjects which were observed in the present study have been reported in numerous 
previous investigations [1-9]. The findings in this regard are therefore not new. Of 
importance is whether the mean diets and urine chemistries observed in the present study 
might be conflicting factors in interpreting the results which have been recorded. Thus, the 
lower supersaturation values for CaOx and brushite in blacks need to be taken into account 
in the present studies. Since these parameters did not undergo any changes as a result of 
FA or CS supplementation , conflicting factors need not be considered. 
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In drawing conclusions about the various studies described in this thesis, it is helpful to 
consider the extent to which the objectives were met and what they revealed. 
The first main aim was to investigate potential beneficial effects of supplemental PUFAs and 
CS on the risk of CaOx stone formation . Although several changes in various blood and 
urine parameters were observed , ingestion of n-6 and n-3 fatty acids independently and in 
combination did not significantly reduce blood and urinary risk factors for CaOx urolithiasis. 
Taken together, these findings indicate that at the tested doses, FA supplementation in 
healthy subjects were not effective in reducing the risk factors associated with CaOx stone 
formation . It is not yet possible to draw conclusions on the role of FAs as therapeutic agents 
for CaOx stone disease since only healthy subjects were studied. Whether the reduction of 
urinary calcium and oxalate will be associated with FA supplementation still needs to be 
investigated, perhaps in a follow up study with stone formers. Nevertheless, the findings of 
the present studies are important since they form a foundation for evaluating the effects of 
both n-6 and n-3 FAs on CaOx risk factors in human subjects. 
Theoretical modeling and in vitro crystallization experiments demonstrated that chondroitin 
sulfates A and C would not have an effect on the supersaturation of urinary calcium salts 
when present at normal physiological concentrations. This was confirmed by an in vivo study 
in which subjects ingested CS supplements. Overall , findings from these studies suggest 
that CS does not reduce supersaturation of CaOx stone formation in healthy subjects. 
Therefore, the use of CS as a therapeutic agent for CaOx stone disease remains doubtful. 
It is acknowledged that there were limitations to these studies. The use of commercial salts 
instead of CS extracted from human urine might have influenced the outcome. The mode of 
action of commercial CS and human GAGs could not be compared in the present work. 
Further studies, involving CS obtained from humans, are needed to confirm the present 
findings. It could also be intriguing to investigate the effect of other urinary GAGs (besides 
CSA and CSC) binding to calcium as well. The protocol outlined in the present thesis could 
be used as a template for studies aimed at investigating the role of these GAGs in CaOx 
stone formation . Another limitation of the present study was the use of estimated urinary CS 
concentrations as opposed to empirically measured values in human subjects. 
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Thus, the results of the studies in this thesis do not support the hypothesis that supplemental 
fatty acids or chondroitin sulfate have beneficial effects for reducing blood and urinary risk 
factors for CaOx stone formation . 
The second main aim of the project was to investigate whether black and white South 
Africans respond differently to FA and CS supplements and if so, whether such differences 
provide insights into understanding the anomaly of the different stone incidence rates in the 
two race groups, and whether these in turn, help us understand stone pathogenesis, and 
thereby leading to insights for improved therapeutic management. 
In the present study, the blood (FA studies) and urinary outcomes after FA and CS 
supplementation were found to be different between the two groups. Thus, supplementation 
yielded different results within groups. Other studies have also reported different renal 
handling mechanisms in blacks and whites after various supplement challenges. However, 
the present (and previous) studies have not been able to provide new information to explain 
the difference in the incidence of CaOx stone disease in the two population groups. 
Thus, the inter-group results of the studies in this thesis do not support the hypothesis that 
different renal handling of fatty acids and chondroitin sulfate will shed light on the different 
stone occurrences in the two groups. However, the observation that such differences exist is 
likely to be important in the eventual resolution of this phenomenon. 
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